<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:st1="urn:schemas-microsoft-com:office:smarttags"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 11">
<meta name=Originator content="Microsoft Word 11">
<!--<link rel=File-List href="index_files/filelist.xml">
<link rel=Edit-Time-Data href="index_files/editdata.mso">
[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>Buspirone and aggression | Pacific Neuropsychiatric Institute</title>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="country-region"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="PostalCode"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="Street"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="State"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="PlaceType"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="PlaceName"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="address"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="City"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="place"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>VERNON M NEPPE MD, PHD</o:Author>
  <o:LastAuthor></o:LastAuthor>
  <o:Revision>4</o:Revision>
  <o:TotalTime>17</o:TotalTime>
  <o:Created>2005-11-22T21:55:00Z</o:Created>
  <o:LastSaved>2006-02-06T01:39:00Z</o:LastSaved>
  <o:Pages>13</o:Pages>
  <o:Words>14124</o:Words>
  <o:Characters>80507</o:Characters>
  <o:Company>PNI</o:Company>
  <o:Lines>670</o:Lines>
  <o:Paragraphs>188</o:Paragraphs>
  <o:CharactersWithSpaces>94443</o:CharactersWithSpaces>
  <o:Version>11.5606</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:GrammarState>Clean</w:GrammarState>
  <w:FormsDesign/>
  <w:DoNotHyphenateCaps/>
  <w:DrawingGridHorizontalSpacing>6 pt</w:DrawingGridHorizontalSpacing>
  <w:DrawingGridVerticalSpacing>6 pt</w:DrawingGridVerticalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery>
  <w:DisplayVerticalDrawingGridEvery>0</w:DisplayVerticalDrawingGridEvery>
  <w:UseMarginsForDrawingGridOrigin/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:Compatibility>
   <w:SpaceForUL/>
   <w:BalanceSingleByteDoubleByteWidth/>
   <w:DoNotLeaveBackslashAlone/>
   <w:ULTrailSpace/>
   <w:DoNotExpandShiftReturn/>
   <w:UsePrinterMetrics/>
   <w:WW6BorderRules/>
   <w:FootnoteLayoutLikeWW8/>
   <w:ShapeLayoutLikeWW8/>
   <w:AlignTablesRowByRow/>
   <w:ForgetLastTabAlignment/>
   <w:AutoSpaceLikeWord95/>
   <w:LayoutRawTableWidth/>
   <w:LayoutTableRowsApart/>
   <w:UseWord97LineBreakingRules/>
   <w:SelectEntireFieldWithStartOrEnd/>
   <w:UseWord2002TableStyleRules/>
  </w:Compatibility>
  <w:DocumentVariables>
   <w:EN_Lib_Name_List_Name>26ser bu sz acd ms pa td use</w:EN_Lib_Name_List_Name>
   <w:EN_Main_Body_Style_Name>J of Clinical Psychiatry</w:EN_Main_Body_Style_Name>
  </w:DocumentVariables>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" LatentStyleCount="156">
 </w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
 classid="clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=ieooui></object>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<link rel=Stylesheet type="text/css" media=all
href="http://www.pni.org/styles.css">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536902279 -2147483648 8 0 511 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:536902279 -2147483648 8 0 511 0;}
@font-face
	{font-family:ArenaCondensed;
	mso-font-alt:Times;
	mso-font-charset:77;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:50331648 0 0 0 1 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Times;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	color:black;}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Helvetica;
	mso-bidi-font-family:"Times New Roman";
	color:black;
	mso-font-kerning:0pt;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Times;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:#990000;
	mso-text-animation:none;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;}
a:visited, span.MsoHyperlinkFollowed
	{color:#990000;
	mso-text-animation:none;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;}
p
	{mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	mso-fareast-font-family:"Times New Roman";}
p.HEADERSYTLE, li.HEADERSYTLE, div.HEADERSYTLE
	{mso-style-name:"HEADER SYTLE";
	margin-top:0in;
	margin-right:4.6pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-alt:solid windowtext .75pt;
	padding:0in;
	mso-padding-alt:0in 0in 0in 0in;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Times;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.MAJORHEADER, li.MAJORHEADER, div.MAJORHEADER
	{mso-style-name:"MAJOR HEADER";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-alt:solid windowtext .75pt;
	padding:0in;
	mso-padding-alt:0in 0in 0in 0in;
	font-size:18.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Times;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;
	text-decoration:underline;
	text-underline:single;}
p.Affiliations, li.Affiliations, div.Affiliations
	{mso-style-name:Affiliations;
	mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:8.5pt;
	mso-pagination:widow-orphan;
	tab-stops:12.0pt;
	font-size:8.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:ArenaCondensed;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:ArenaCondensed;
	mso-bidi-font-family:"Times New Roman";
	font-style:italic;
	mso-bidi-font-style:normal;}
p.Bodytext, li.Bodytext, div.Bodytext
	{mso-style-name:"Body text";
	mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:12.0pt;
	mso-pagination:widow-orphan;
	tab-stops:12.0pt;
	font-size:10.0pt;
	font-family:ArenaCondensed;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:ArenaCondensed;
	mso-bidi-font-family:"Times New Roman";}
p.Tableftnote1stline, li.Tableftnote1stline, div.Tableftnote1stline
	{mso-style-name:"Table ftnote 1st line";
	mso-style-parent:"Body text";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:8.5pt;
	mso-pagination:widow-orphan;
	tab-stops:12.0pt;
	border:none;
	mso-border-top-alt:solid windowtext .75pt;
	padding:0in;
	mso-padding-alt:0in 0in 0in 0in;
	font-size:8.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:ArenaCondensed;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:ArenaCondensed;
	mso-bidi-font-family:"Times New Roman";}
p.Tableftnotemiddle, li.Tableftnotemiddle, div.Tableftnotemiddle
	{mso-style-name:"Table ftnote middle";
	mso-style-parent:"Table ftnote 1st line";
	mso-style-next:"Table ftnote 1st line";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:8.5pt;
	mso-pagination:widow-orphan;
	tab-stops:12.0pt;
	font-size:8.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:ArenaCondensed;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:ArenaCondensed;
	mso-bidi-font-family:"Times New Roman";}
p.notice, li.notice, div.notice
	{mso-style-name:notice;
	mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:8.5pt;
	mso-fareast-font-family:"Times New Roman";}
p.copyright, li.copyright, div.copyright
	{mso-style-name:copyright;
	font-size:9.0pt;
	mso-fareast-font-family:"Times New Roman";}
p.header, li.header, div.header
	{mso-style-name:header;
	font-size:9.0pt;
	mso-fareast-font-family:"Times New Roman";}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
.style1 {font-size: 10px}
.style2 {font-size: 10}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:#0400;
	mso-fareast-language:#0400;
	mso-bidi-language:#0400;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1029"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body bgcolor="#FFCC66" lang=EN-US link="#990000" vlink="#990000"
style='tab-interval:.5in' alink="#990000"
onload="MM_displayStatusMsg('PNI.org | Pacific Neuropsychiatric Institute');return document.MM_returnValue">

<div class=Section1>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=700
 style='width:525.0pt;mso-cellspacing:0in;border:outset black 1.0pt;mso-border-alt:
 outset black .75pt;mso-padding-alt:0in 0in 0in 0in'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'>
  <td style='border:inset black 1.0pt;mso-border-alt:inset black .75pt;
  padding:0in 0in 0in 0in'>
  <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
   style='width:100.0%;mso-cellspacing:0in;background:#C4D2FF;mso-padding-alt:
   0in 0in 0in 0in'>
   <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
    <td style='padding:0in 0in 0in 0in'>
    <p class=MsoNormal><script language="JavaScript"  type="text/JavaScript">
<!--
function MM_displayStatusMsg(msgStr) { //v1.0
  status=msgStr;
  document.MM_returnValue = true;
}
//-->
    </script><a name=top></a><span style='font-size:10.0pt;font-family:Arial'><a
    href="../../../../"><!-- InstanceBeginEditable name="head" --><!-- InstanceEndEditable --><img
    border=0 width=700 height=127 id="_x0000_i1026" src="../../../../header.jpg"></a><o:p></o:p></span></p>    </td>
   </tr>
  
   <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes'>
    
    <td style='padding:0in 0in 0in 0in'>
	<script>
						  (function() {
							var cx = '009175660163571863627:du9tocqgd6q';
							var gcse = document.createElement('script');
							gcse.type = 'text/javascript';
							gcse.async = true;
							gcse.src = 'https://cse.google.com/cse.js?cx=' + cx;
							var s = document.getElementsByTagName('script')[0];
							
							s.parentNode.insertBefore(gcse, s);
						  })();
						</script>
						<gcse:search></gcse:search>
						
						<div class="search-div"></div> 
    <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
     width="100%" style='width:100.0%;mso-cellspacing:0in;mso-padding-alt:11.25pt 11.25pt 11.25pt 11.25pt'>
     <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'>
      <td width="73%" style='width:73.0%;padding:11.25pt 11.25pt 11.25pt 11.25pt'>
      <p><span style='font-size:12.0pt'><a href="../../../../clinical/"><strong><span
      style='font-family:Arial'>CLINICAL</span></strong></a><strong><span
      style='font-family:Arial'> | <a href="../../../../neuropsychiatry/">NEUROPSYCHIATRY</a>
      | <a href="../../../../psychopharmacology/">PSYCHOPHARMACOLOGY</a> </span></strong><b><br>
      <strong><span style='font-family:Arial'><a href="../../../../forensics/">FORENSICS</a>
      | <a href="../../../../research/">RESEARCH</a> | <a
      href="../../../../research/anomalous/">ANOMALOUS EXPERIENCES</a> </span></strong><br>
      <strong><span style='font-family:Arial'><a href="../../../../philosophy/">PHILOSOPHY</a>
      | <a href="http://www.brainvoyage.com/ctbm/">CRY THE BELOVED MIND</a> | <a
      href="../../../../research/anomalous/deja/">DÉJÀ VU<br>
      </a><a href="../../../../neuropsychiatry/chit/">HEAD INJURY</a> | <a
      href="../../../../perspective.html">PERSPECTIVES</a> | <a
      href="../../../../books/">LITERATURE<br>
      </a><a href="../../../../interesting/">INTERESTING AREAS</a> | <a
      href="../../../../philosophy/ethics/">ETHICS</a><a
      href="../../../../philosophy/ethics/"></a> | <a
      href="http://pni.org/about_pni.html">CONTACT</a> | <a href="../../../../">HOME</a></span></strong></b></span></p>      </td>
      <td width="27%" style='width:27.0%;padding:11.25pt 11.25pt 11.25pt 11.25pt'>
      <form action="http://www.pni.org/cgi-local/fmsearch/fmsearch.cgi"
      method=POST enctype="application/x-www-form-urlencoded">
      <p align=right style='text-align:right'><!--<INPUT TYPE="text" SIZE="20" NAME="keywords"><INPUT TYPE="submit" ACTION="http://www.pni.org/cgi-local/fmsearch/fmsearch.cgi" VALUE="Search" METHOD="POST" NAME="B1">--></p>
      <!--</form>-->     </td>
	  
     </tr>
    </table>
    <p class=MsoNormal style='margin-top:0in;margin-right:-14.2pt;margin-bottom:
    0in;margin-left:.25in;margin-bottom:.0001pt'><span class=GramE><b
    style='mso-bidi-font-weight:normal'>Ref:</b><b style='mso-bidi-font-weight:
    normal'><span style='font-size:18.0pt;mso-bidi-font-size:10.0pt'> </span></b>Neppe
    VM.</span> The serotonin <span class=GramE>1A<span
    style='mso-spacerun:yes'>  </span>neuromodulation</span> of aggression :
    Bimodal buspirone dosage as a prototype anti-irritability agent in
    adults.<span style='mso-spacerun:yes'>  </span>Australian J of
    Psychopharmacology. <span class=GramE>1999, January; 9: 8-25.</span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:-14.2pt;margin-bottom:
    0in;margin-left:.25in;margin-bottom:.0001pt'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:-14.2pt;margin-bottom:
    0in;margin-left:.25in;margin-bottom:.0001pt'>This is a pioneering article on the use of buspirone use in anger and irritability in adults.<br><br> 
 Based on the data available, buspirone appears  an extremely safe medication in adults. Of course, all patients should be evaluated by a physician. We gratefully acknowledge the opportunity to publish a minor adaptation<br>of  this article which originally appeared in the Australian Journal of Psychopharmacology in 2003. This article<br>was published in the Australian J of Psychopharmacology—the final draft may not necessarily be identical. 
<span
    style='mso-spacerun:yes'>  </span></p>
	<p>	</p>
	
    <p>See Also: <a
    href="http://www.pni.org/neuropsychiatry/aggression/buspirone/">the pioneering article on the use of buspirone use as adjunct to methylphenidate (Ritalin) predominanlty in attention deficit disorder.</a><br><br>Buspirone is a major medication discussed in Dr Vernon Neppe's classic sciction book, <a href="http://www.brainvoyage.com/ctbm">Cry the Beloved Mind: A Voyage of Hope</a>  Of course, all patients should be evaluated by a physician.
<b style='mso-bidi-font-weight:normal'><span
    style='font-size:18.0pt;mso-bidi-font-size:10.0pt;font-family:Times;
    mso-bidi-font-family:"Times New Roman"'><br clear=all style='mso-special-character:
    line-break;page-break-before:always'>
    </span></b></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><span style='font-size:18.0pt;
    mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></b></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><span style='font-size:18.0pt;
    mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></b></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><span style='font-size:18.0pt;
    mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></b></p>
    <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><span style='font-size:18.0pt;
    mso-bidi-font-size:10.0pt'>Buspirone and aggression</span><o:p></o:p></b></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>
    <h1 style='margin-right:-49.5pt'><st1:City w:st="on"><st1:place w:st="on"><span
      style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>Vernon</span></st1:place></st1:City><span
    style='font-family:Times;mso-bidi-font-family:"Times New Roman"'> M Neppe <o:p></o:p></span></h1>
    <p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
    0in;margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify'><span
    style='font-size:11.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal style='text-indent:14.2pt'><span style='font-size:11.0pt;
    mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>SUMMARY :</b></p>
    <p class=MsoNormal>Exploration of aggression spectrum concepts <span
    class=GramE>are compromised</span> by inadequate terminology, diagnostic,
    measuring, classification and therapeutic difficulties in research. </p>
    <p class=MsoNormal style='margin-right:9.0pt;tab-stops:508.0pt'>Evidence
    exists for serotonin and specifically the 1A receptor involvement in the
    aggression spectrum using animal and human models. High dose beta
    2-adrenergic blockers, lithium and eltoprazine all act non-specifically on
    serotonin 1A and are apparently anti-aggressive. </p>
    <p class=MsoNormal style='margin-right:9.0pt;tab-stops:508.0pt'><span
    style='mso-spacerun:yes'> </span>Animal models of <span class=GramE>aggression<span
    style='mso-spacerun:yes'>  </span>suggest</span> the azapirones are potent
    anti-aggressive agents hypothetically through its specific serotonin
    1A<span style='mso-spacerun:yes'>  </span>partial agonist effects<span
    style='mso-spacerun:yes'>  </span>. Irritability is an early target symptom
    of response with buspirone in generalized anxiety disorder and scattered
    case reports suggest and anti-aggressive effect for buspirone.</p>
    <p class=MsoNormal>4 clinical open study cohorts using buspirone in
    aggression are described: Experience suggests a biphasic dose effect for <span
    class=GramE>buspirone :</span> Low doses of buspirone ( 15-25 mg per day )
    were effective after a few days in alleviating irritability (N=9
    inpatients) without associated significant anxiety. Higher doses such as
    60-90 mg per <span class=GramE>day<span style='mso-spacerun:yes'> 
    </span>within</span> a day greatly relieved manic irritability,<span
    style='mso-spacerun:yes'>  </span>agitation,<span
    style='mso-spacerun:yes'>  </span>restlessness and mood lability in 12 in-
    and out-patients. Two cohorts of outpatients (thirteen without coarse
    organicity and twenty (initially. later twelve) with carbamazepine adjunct)
    showed impressive results generally over a prolonged <span class=GramE>period(</span>18/18
    {15-25mg buspirone daily}, 3/3 {30-45mg}, 9-10/12 {&#8805;60mg}. Eight
    stopped the carbamazepine. </p>
    <p class=MsoNormal>There are major limitations to this study including
    selected sample, retrospective review, rankings<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>milieu</span>, patient motivation,
    assessment methods, clinical presentations and polytherapy but the results
    are encouraging and require adequate controlled studies. If real<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>these</span> effects
    can be explained in a unified serotonin 1 A pre- and post-synaptic theory. </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>
    <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>AGGRESSION<o:p></o:p></b></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>Concept of Aggression </u><o:p></o:p></b></p>
    <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span>There is no current diagnostic
    framework for aggression.<span style='mso-spacerun:yes'>  </span>The
    Diagnostic and Statistical Manual III <span class=GramE>Revision<span
    style='mso-spacerun:yes'>  </span>and</span> DSM-IV and 1V-R<span
    style='mso-spacerun:yes'>  </span><span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>1, 2</span></sup><!--[if gte mso 9]><xml>
     <w:data>E725A6F50096A3685610000832CF656E726600ACD9296A0001717802000000040000017902000000715B416D65726963616E205073796368696174726963204173736F63696174696F6E20436F6D6D69747465652C20203139383720233338333B20416D65726963616E205073796368696174726963204173736F63696174696F6E20436F6D6D69747465652C20203139393420233338345D000000</w:data>
    </xml><![endif]--></span>,<span style='mso-spacerun:yes'> 
    </span>recognizes a variety of different syndrome criteria,<span
    style='mso-spacerun:yes'>  </span>making up subgroups of psychosis,<span
    style='mso-spacerun:yes'>  </span>anxiety and depression.<span
    style='mso-spacerun:yes'>  </span>However<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>the</span> fourth potential system
    cluster in that quartet,<span style='mso-spacerun:yes'> 
    </span>aggression,<span style='mso-spacerun:yes'>  </span>is represented
    only by the condition of intermittent explosive disorder<span
    style='mso-spacerun:yes'>  </span>(IED).<span style='mso-spacerun:yes'> 
    </span>IED is limiting in that one cannot diagnose it in the face of a
    major contribution from common diagnostic conditions such as depression<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>substance</span>
    use,<span style='mso-spacerun:yes'>  </span>anxiety and psychosis and
    mania. <span class=GramE>Moreover,<span style='mso-spacerun:yes'> 
    </span>the aggressive episodes are not better accounted for by another
    mental disorder (e<span style='mso-spacerun:yes'>  </span>.g<span
    style='mso-spacerun:yes'>  </span>.,<span style='mso-spacerun:yes'> 
    </span>Antisocial Personality Disorder,<span style='mso-spacerun:yes'> 
    </span>Borderline Personality Disorder,<span style='mso-spacerun:yes'> 
    </span>Head injury,<span style='mso-spacerun:yes'>  </span>Alzheimer’s
    disease,<span style='mso-spacerun:yes'>  </span>Conduct Disorder,<span
    style='mso-spacerun:yes'>  </span>or Attention-Deficit / Hyperactivity
    Disorder) and are not due to the direct physiological effects of a
    substance (e<span style='mso-spacerun:yes'>  </span>.g. a drug of abuse or
    a medication) or a general medical condition (e<span
    style='mso-spacerun:yes'>  </span>.g<span style='mso-spacerun:yes'> 
    </span>.,<span style='mso-spacerun:yes'>  </span>head trauma or Alzheimer's
    disease).</span> In DSM 111 <span class=GramE>R<span
    style='mso-spacerun:yes'>  </span>it</span> implied phases of normality
    between episodes,<span style='mso-spacerun:yes'>  </span>something which is
    almost contradictory to the condition,<span style='mso-spacerun:yes'> 
    </span>and fortunately this has been eliminated in DSM 1V. Nevertheless<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>it</span> remains a
    rare condition,<span style='mso-spacerun:yes'>  </span>requiring
    disproportionate dyscontrol. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>2</span></sup><!--[if gte mso 9]><xml>
     <w:data>3453829E005EA3685610000832CF656E726600ACD9296A0001719202000000010000003202000000395B416D65726963616E205073796368696174726963204173736F63696174696F6E20436F6D6D69747465652C20203139393420233338345D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>Empirically,<span
    style='mso-spacerun:yes'>   </span>by far the most common form of
    aggression relates to frustration leading to outbursts of anger : many of
    these people have mainly controlled aggression directed towards others
    without amnesia of any kind,<span style='mso-spacerun:yes'>  </span>and may
    be experiencing a relatively chronic high basal level of stress.<span
    style='mso-spacerun:yes'>  </span><span class=GramE>Thus,<span
    style='mso-spacerun:yes'>  </span>one could argue that there are two
    dichotomous poles in relation to aggression,<span
    style='mso-spacerun:yes'>  </span>what Dieter Blumer and I<span
    style='mso-spacerun:yes'>  </span>have called “paroxysmal behavioral
    disorder” <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>3</span></sup><!--[if gte mso 9]><xml>
     <w:data>2764A7F0003AA3685610000832CF656E726600ACD9296B000171A402000000010000003302000000155B4E657070652C2020313939322023383234395D000000</w:data>
    </xml><![endif]--></span>,<span style='mso-spacerun:yes'>  </span><span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>4</span></sup><!--[if gte mso 9]><xml>
     <w:data>0674EEAE0045A3685610000832CF656E726600ACD9296B000171B702000000010000003402000000205B426C756D65722C2020313939352D20696E2070726573732023313234345D000000</w:data>
    </xml><![endif]--></span>-<span style='mso-spacerun:yes'>  </span>the
    explosive loss of control disorder possibly associated with firing in the
    brain<span style='mso-spacerun:yes'>  </span>possibly in relation to
    epilepsy-related behavioral changes <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>5</span></sup><!--[if gte mso 9]><xml>
     <w:data>EFF8EF41003BA3685610000832CF656E726600ACD9296B000171CC02000000010000003502000000165B426C756D65722C2020313939302023313234335D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>and the
    frustration -aggression component which is chemically linked to
    norepinephrine and serotonin but has no overt organic (coarse
    neurobehavioral ) elements.</span><span style='mso-spacerun:yes'>  </span>.
    Aggression is by its nature <span class=GramE>episodic :</span> Even if
    those episodic elements persist almost continuously over time,<span
    style='mso-spacerun:yes'>  </span>they are perceived as chronic episodic
    elements. Even planned aggressive elements have episodic <span class=GramE>expression<span
    style='mso-spacerun:yes'>  </span>.</span></p>
    <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-spacerun:yes'> </span><span style='mso-tab-count:1'>           </span>A
    further complicating <span class=GramE>element<span
    style='mso-spacerun:yes'>  </span>relates</span> to terminology.<span
    style='mso-spacerun:yes'>  </span>In <span class=GramE>aggression<span
    style='mso-spacerun:yes'>  </span>research</span> we come across a variety
    of terms which if not synonymous are very similar.<span
    style='mso-spacerun:yes'>  </span><span class=GramE>Rage<span
    style='mso-spacerun:yes'>  </span>is</span> used to imply profound
    outbursts of anger which are not controlled<span style='mso-spacerun:yes'> 
    </span>.In the medical context, this frequently implies a<span
    style='mso-spacerun:yes'>  </span>coarse neurobehavioral component<span
    style='mso-spacerun:yes'>  </span>with high levels of aggression.<span
    style='mso-spacerun:yes'>  </span><span class=GramE>Dyscontrol<span
    style='mso-spacerun:yes'>  </span>is</span> similar but has an impulsive
    component to it,<span style='mso-spacerun:yes'>  </span>with elements of
    loss of control,<span style='mso-spacerun:yes'> 
    </span>non-directedness,<span style='mso-spacerun:yes'>  </span>and,<span
    style='mso-spacerun:yes'>  </span>at times,<span style='mso-spacerun:yes'> 
    </span>amnesia.<span style='mso-spacerun:yes'>  </span>Anger implies
    outbursts which are under control<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>which</span> are generally directed,<span
    style='mso-spacerun:yes'>  </span>and usually have verbal components or
    components expressing themselves somatically. <span class=GramE>Irritability<span
    style='mso-spacerun:yes'>  </span>is</span> generally used to imply high
    basal levels of anger and agitation - a simmering over time. <span
    class=GramE>Hostility<span style='mso-spacerun:yes'>  </span>is</span>
    further along this continuum,<span style='mso-spacerun:yes'>  </span>in
    that it does not necessarily even imply the expression of anger:
    passive-aggressive components in<span style='mso-spacerun:yes'> 
    </span>hostility may be state or trait related. <span class=GramE>Violence<span
    style='mso-spacerun:yes'>  </span>is</span> perceived as physical force
    exerted for the purpose of violating,<span style='mso-spacerun:yes'> 
    </span>damaging,<span style='mso-spacerun:yes'>  </span>or abusing implying
    elements of some premeditation.<span style='mso-spacerun:yes'>  </span>Even
    <span class=GramE>assertiveness<span style='mso-spacerun:yes'>  </span>has</span>
    elements of aggression which are perceived as socially appropriate. Finally<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>impulsivity</span><span
    style='mso-spacerun:yes'>  </span>relates to many of the above,<span
    style='mso-spacerun:yes'>  </span>because of the inherent nature of
    aggressive behavior having episodic elements but impulsivity goes beyond
    aggression alone. Moreover<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>impulsivity</span> also relates to any
    kind of symptom,<span style='mso-spacerun:yes'>  </span>so that it will
    include such a major phenomenon as episodic lability<span
    style='mso-spacerun:yes'>  </span>as well. It also covers behavior which is
    non-motivated<span class=GramE>,<span style='mso-spacerun:yes'>  </span>not</span>
    well thought out and acted out generally to the detriment of the patient.
    These variations in terminology reflect one of the difficulties of
    quantifying aggression. Operationally<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>probably</span> the easiest measure of
    entry into pathologic aggression research is the recognition that the anger
    is impairing functioning at any of the biopsychofamiliosociocultural
    levels. Given the lack of aggression classification in </p>
    <p class=MsoNormal style='tab-stops:508.0pt'><span class=GramE>in</span>
    the Diagnostic and Statistical Manual III revision or DSM-IV,<span
    style='mso-spacerun:yes'>  </span>there are no FDA approved drugs for
    aggression.<span style='mso-spacerun:yes'>  </span><span class=GramE>Thus</span>
    all drug discussion is necessarily Innovative Psychopharmacotherapy.<span
    style='mso-spacerun:yes'>  </span>This is a cogent reason for developing a
    classification <span class=GramE>into<span style='mso-spacerun:yes'> 
    </span>DSM</span> V and Figure 1 represents my preliminary<span
    style='mso-spacerun:yes'>  </span>proposal presented without further
    comments<span style='mso-spacerun:yes'>  </span>.</p>
    <p class=MsoNormal style='margin-right:-49.5pt;tab-stops:508.0pt'><o:p>&nbsp;</o:p></p>
    <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
    mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
    margin-left:0in;margin-right:4.5pt'>
    <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in center 463.5pt;
    border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
    1.0pt 1.0pt 1.0pt 1.0pt'>FIGURE 1</p>
    <p class=MsoNormal style='tab-stops:center 463.5pt;border:none;mso-border-alt:
    solid windowtext .75pt;padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><b
    style='mso-bidi-font-weight:normal'>Proposed Multi-axial Classification of <span
    class=GramE>Aggression<span style='mso-spacerun:yes'>  </span>.</span></b></p>
    <p class=MsoNormal style='tab-stops:center 463.5pt;border:none;mso-border-alt:
    solid windowtext .75pt;padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='tab-stops:center 463.5pt;border:none;mso-border-alt:
    solid windowtext .75pt;padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><b
    style='mso-bidi-font-weight:normal'>Axis 1 : Irritability,<span
    style='mso-spacerun:yes'>  </span>Aggression and Psychopathology</b><span
    style='mso-spacerun:yes'>  </span>e<span style='mso-spacerun:yes'> 
    </span>.g. psychosis,<span style='mso-spacerun:yes'>  </span></p>
    <p class=MsoNormal style='tab-stops:center 463.5pt;border:none;mso-border-alt:
    solid windowtext .75pt;padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'>mood
    disorder,<span style='mso-spacerun:yes'>  </span>anxiety,<span
    style='mso-spacerun:yes'>  </span>attention deficit hyperactivity disorder</p>
    <p class=MsoNormal style='tab-stops:center 463.5pt;border:none;mso-border-alt:
    solid windowtext .75pt;padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><b
    style='mso-bidi-font-weight:normal'>Axis 2 : Irritability,<span
    style='mso-spacerun:yes'>  </span>Aggression and Personality disorder </b>e<span
    style='mso-spacerun:yes'>  </span>.g. borderline,<span
    style='mso-spacerun:yes'>  </span>antisocial,<span
    style='mso-spacerun:yes'>  </span>developmental problems,<span
    style='mso-spacerun:yes'>  </span>sexual deviation</p>
    <p class=MsoNormal style='tab-stops:center 463.5pt;border:none;mso-border-alt:
    solid windowtext .75pt;padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><b
    style='mso-bidi-font-weight:normal'>Axis 3: Irritability,<span
    style='mso-spacerun:yes'>  </span>Aggression and Medical Condition Causes</b>
    - intracranial e<span style='mso-spacerun:yes'>  </span>.g. Alzheimer’s
    disease,<span style='mso-spacerun:yes'>  </span>paroxysmal cerebral firing
    or<span style='mso-spacerun:yes'>  </span>extracranial e<span
    style='mso-spacerun:yes'>  </span>.g. thyroid</p>
    <p class=MsoNormal style='tab-stops:center 463.5pt;border:none;mso-border-alt:
    solid windowtext .75pt;padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><b
    style='mso-bidi-font-weight:normal'>Axis 4:<span style='mso-spacerun:yes'> 
    </span>Irritability<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>Aggression</span> and Psychosocial Stressors </b>-e<span
    style='mso-spacerun:yes'>  </span>.g.<span style='mso-spacerun:yes'> 
    </span>stress - frustration - irritability,<span style='mso-spacerun:yes'> 
    </span>dynamic elements</p>
    <p class=MsoNormal style='tab-stops:center 463.5pt;border:none;mso-border-alt:
    solid windowtext .75pt;padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><b
    style='mso-bidi-font-weight:normal'>Axis <span class=GramE>5 :</span>
    Irritability,<span style='mso-spacerun:yes'>  </span>Aggression and
    Functionality Impairment</b> - ab initio e<span style='mso-spacerun:yes'> 
    </span>.g. mental retardation ; developed e<span style='mso-spacerun:yes'> 
    </span>.g. dementia. Subgroup : organic rage,<span
    style='mso-spacerun:yes'>  </span>catastrophic reactions</p>
    <p class=MsoNormal style='tab-stops:center 463.5pt;border:none;mso-border-alt:
    solid windowtext .75pt;padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><b
    style='mso-bidi-font-weight:normal'>Axis 6 : Irritability,<span
    style='mso-spacerun:yes'>  </span>Aggression and Psychopharmacologic
    Involvement </b>e<span style='mso-spacerun:yes'>  </span>.g. alcohol,<span
    style='mso-spacerun:yes'>  </span>sedative hypnotics,<span
    style='mso-spacerun:yes'>  </span>serotonin modulating drugs,<span
    style='mso-spacerun:yes'>  </span>pleasure drugs</p>
    <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in center 463.5pt;
    border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
    1.0pt 1.0pt 1.0pt 1.0pt'>© Vernon M<span style='mso-spacerun:yes'> 
    </span>Neppe<b style='mso-bidi-font-weight:normal'><o:p></o:p></b></p>
    </div>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>Measurement of aggression </u></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span>Aggression and irritability are
    extremely difficult to measure. A variety of different scales have been
    developed<span class=GramE>,<span style='mso-spacerun:yes'>  </span>some</span>
    relating to patient subjective rankings,<span style='mso-spacerun:yes'> 
    </span>others to objective rankings by researchers.<span
    style='mso-spacerun:yes'>  </span>Subjective rankings such as the
    Buss-Durkee<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>Monroe</span> Dyscontrol Scales,<span style='mso-spacerun:yes'> 
    </span><st1:place w:st="on"><st1:PlaceName w:st="on">Spielberger</st1:PlaceName>
     <st1:PlaceType w:st="on">State</st1:PlaceType></st1:place> and Trait
    Aggression Scales,<span style='mso-spacerun:yes'>  </span>and a variety of
    Short Aggression Questionnaires,<span style='mso-spacerun:yes'> 
    </span>have value in a<span style='mso-spacerun:yes'>  </span>population
    that is cooperative,<span style='mso-spacerun:yes'>  </span>motivated,<span
    style='mso-spacerun:yes'>  </span>non-psychotic and of normal intelligence.<span
    style='mso-spacerun:yes'>  </span>However<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>subjective</span> rankings cannot easily
    be used in a psychotic or demented population,<span
    style='mso-spacerun:yes'>  </span>both of whom,<span
    style='mso-spacerun:yes'>  </span>at times,<span style='mso-spacerun:yes'> 
    </span>have complications pertaining to aggression and irritability. </p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-spacerun:yes'> </span><span style='mso-tab-count:1'>           </span>Objective
    rating scales have the advantage of being quantifiable.<span
    style='mso-spacerun:yes'>  </span>The earliest modern one of these is the
    Yudofsky Overt Aggression Scale <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>6</span></sup><!--[if gte mso 9]><xml>
     <w:data>237D24FE003EA3685610000832CF656E726600ACD9296C000171DF02000000010000003602000000195B5975646F66736B792C202031393836202331323330305D000000</w:data>
    </xml><![endif]--></span> which however is nominal and not ordinal<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>and</span> evaluates
    outbursts of verbal and physical aggression.<span
    style='mso-spacerun:yes'>  </span>This <span class=GramE>was<span
    style='mso-spacerun:yes'>  </span>made</span> ordinal by Kay's
    modification,<span style='mso-spacerun:yes'>  </span>The Modified Overt
    Aggression Scale <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>7</span></sup><!--[if gte mso 9]><xml>
     <w:data>69CE91D60038A3685610000832CF656E726600ACD9296C000171F302000000010000003702000000135B4B61792C2020313938382023353633345D000000</w:data>
    </xml><![endif]--></span>.<span style='mso-spacerun:yes'>  </span>In
    practice<span class=GramE>,<span style='mso-spacerun:yes'>  </span>these</span>
    scales are difficult to use because patients in an inpatient situation will
    commonly not exhibit episodes of aggression.<span
    style='mso-spacerun:yes'>  </span>Monitoring episodes of aggression is
    difficult and measurement is problematic in practice. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>6</span></sup><!--[if gte mso 9]><xml>
     <w:data>D562DB01003EA3685610000832CF656E726600ACD9296C0001720602000000010000003602000000195B5975646F66736B792C202031393836202331323330305D000000</w:data>
    </xml><![endif]--></span><span class=GramE>,<span
    style='mso-spacerun:yes'>  </span></span><span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>7</span></sup><!--[if gte mso 9]><xml>
     <w:data>93156E290038A3685610000832CF656E726600ACD9296D0001721902000000010000003702000000135B4B61792C2020313938382023353633345D000000</w:data>
    </xml><![endif]--></span>,<span style='mso-spacerun:yes'>  </span><span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>8, 9</span></sup><!--[if gte mso 9]><xml>
     <w:data>0ADE3862005AA3685610000832CF656E726600ACD9296D0001722D02000000040000012802000000355B50616C6D73746965726E612C2020313938372023383632373B2050616C6D73746965726E612C2020313938392023383632385D000000</w:data>
    </xml><![endif]--></span>. If the patient is an inpatient<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>he</span> is not under the same kind of
    stressors <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>10</span></sup><!--[if gte mso 9]><xml>
     <w:data>C1F5433E003AA3685610000832CF656E726600ACD9296D0001724202000000020000005102000000155B527964656E2C2020313939312023393830375D000000</w:data>
    </xml><![endif]--></span> and is less likely to have anger outbursts. </p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span>Consequently<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>measures</span> of hostility such as
    those found in the Brief Psychiatric Rating Scale <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>11</span></sup><!--[if gte mso 9]><xml>
     <w:data>BC4ED0D2003CA3685610000832CF656E726600ACD9296E0001725402000000020000005302000000175B4F766572616C6C2C2020313936322023383536335D000000</w:data>
    </xml><![endif]--></span> and quantified by Kay<span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>12,
    13, 14</span></sup><!--[if gte mso 9]><xml>
     <w:data>DCDACDE8005CA3685610000832CF656E726600ACD9296E00017268020000000A0000469502000000375B4B61792C2020313938362023353633313B204B61792C2020313938372023353633323B204B61792C2020313938382023353633335D000000</w:data>
    </xml><![endif]--></span>,<span style='mso-spacerun:yes'>  </span>may be
    useful at this point,<span style='mso-spacerun:yes'>  </span>and in fact
    has been used in Cohort 1 of the research below. Additionally<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>monitoring</span>
    specific episodes allows the patient or members of family to monitor
    outpatient aggression. This I have found has been most suitable<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>and</span> the patient
    or responsible other generally monitors episodes such that instrument
    sensitivity becomes adequate.<span style='mso-spacerun:yes'>  </span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'>THE BIOCHEMICAL LINKS<o:p></o:p></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'>Chemistry: The role of serotonin<o:p></o:p></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>Serotonin<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>chemically</span> 5
    hydroxy tryptamine (5HT),<span style='mso-spacerun:yes'>   </span>was
    isolated in platelets in 1947,<span style='mso-spacerun:yes'> 
    </span>almost a century after its initial discovery as a substance that
    contracted smooth muscle.<span style='mso-spacerun:yes'>  </span>The
    serotonin receptors apparently modulate a variety of basic functions at a
    large number of levels. Serotonin has physiologic effects on the
    hypothalamo-pituitary axis impacting neuroendocrine functions and circadian
    rhythms<span class=GramE>,<span style='mso-spacerun:yes'>  </span>and</span>
    it regulates temperature and even blood pressure. It has <span class=GramE>psychological<span
    style='mso-spacerun:yes'>  </span>effects</span> on memory,<span
    style='mso-spacerun:yes'>  </span>irritability,<span
    style='mso-spacerun:yes'>  </span>stress,<span style='mso-spacerun:yes'> 
    </span>mood lability,<span style='mso-spacerun:yes'>  </span>anxiety,<span
    style='mso-spacerun:yes'>  </span>depression and obsessionality. It
    also<span style='mso-spacerun:yes'>  </span>has behavioral effects on
    sleep,<span style='mso-spacerun:yes'>  </span>sex,<span
    style='mso-spacerun:yes'>  </span>appetite and weight and it<span
    style='mso-spacerun:yes'>  </span>modulates aggression <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>15, 16, 17, 18</span></sup><!--[if gte mso 9]><xml>
     <w:data>4F6CFDA40080A3685610000832CF656E726600ACD9296E0001727B020000000E0005E03B020000005B5B416272616D6574732C20203139393020233138303B205065726F75746B612C2020313938372023383830383B205065726F75746B612C2020313937392023383830353B2046696C6C696F6E2C2020313938332023333338345D000000</w:data>
    </xml><![endif]--></span>,<span style='mso-spacerun:yes'>  </span><span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>19, 20</span></sup><!--[if gte mso 9]><xml>
     <w:data>196FDE31004EA3685610000832CF656E726600ACD9296E0001728D0200000006000004D302000000295B4E657070652C2020313939302023383233313B204E657070652C2020313939332023383235385D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>The
    serotonin syndrome is a syndrome of serotonin overload in experimental
    animals associated with a variety of hyperactivity features. [<span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>19, 21</span></sup><!--[if gte mso 9]><xml>
     <w:data>A5C9D0810051A3685610000832CF656E726600ACD9296F0001729F0200000006000004F3020000002C5B4E657070652C2020313939302023383233313B205065726F75746B612C2020313939302023383831325D000000</w:data>
    </xml><![endif]--></span> A significant pharmacologic measure<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>namely</span> partial
    agonism,<span style='mso-spacerun:yes'>  </span>can be demonstrated most
    easily by inducing and blocking such a syndrome. Partial agonism implies
    that in the presence of an agonist these drugs<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>by</span> occupying the receptor,<span
    style='mso-spacerun:yes'>  </span>act as functional antagonists. However<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>in</span> the absence
    of agonists,<span style='mso-spacerun:yes'>  </span>there will be no
    functional antagonism.<span style='mso-spacerun:yes'>  </span>In contrast<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>given</span> an
    adequate dose,<span style='mso-spacerun:yes'>  </span>there will be an
    incomplete agonist action producing a weak serotonin syndrome.<span
    style='mso-spacerun:yes'>  </span>Partial agonism is a post-synaptic
    phenomenon which can be perceived <span class=GramE>clinically<span
    style='mso-spacerun:yes'>  </span>as</span> potentially
    neuromodulating<span style='mso-spacerun:yes'>  </span>a condition back to
    normal. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>22</span></sup><!--[if gte mso 9]><xml>
     <w:data>BFE0B202003AA3685610000832CF656E726600ACD9296F000172B202000000020000005602000000155B4569736F6E2C2020313939302023333034325D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>Serotonin
    receptorology<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>however</span>,<span style='mso-spacerun:yes'>  </span>is complicated
    by numerous different actions. Today<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>we</span> know of at least fifteen
    different serotonin receptor subtypes all with specific anatomy,<span
    style='mso-spacerun:yes'>  </span>physiology,<span
    style='mso-spacerun:yes'>  </span>pharmacology,<span
    style='mso-spacerun:yes'>  </span>receptor responsiveness and probably even
    genetic predisposition based on cloning.<span style='mso-spacerun:yes'> 
    </span>*</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>The
    promise of a breakthrough in brain receptorology led to the rapid
    delineation of serotonin receptor subtypes<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>beginning</span> in 1979 <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>17</span></sup><!--[if gte mso 9]><xml>
     <w:data>19DA4C9A003DA3685610000832CF656E726600ACD9296F000172C402000000020000005F02000000185B5065726F75746B612C2020313937392023383830355D000000</w:data>
    </xml><![endif]--></span>. The 1980's saw the further subtyping of
    receptors into types 1 and 2. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>23, 24</span></sup><!--[if gte mso 9]><xml>
     <w:data>4803412D004EA3685610000832CF656E726600ACD92970000172D802000000060000044402000000295B486F7965722C2020313938352023343935363B20486F7965722C2020313938392023343935385D000000</w:data>
    </xml><![endif]--></span> The serotonin 3 receptor was a third class <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>25</span></sup><!--[if gte mso 9]><xml>
     <w:data>D624DBE8003CA3685610000832CF656E726600ACD92970000172EB02000000020000005802000000175B426F6C616E6F732C2020313939302023313238365D000000</w:data>
    </xml><![endif]--></span> then came serotonin 4 <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>26</span></sup><!--[if gte mso 9]><xml>
     <w:data>51074339003AA3685610000832CF656E726600ACD929700001730002000000020000005E02000000155B4661676E692C2020313939322023333231345D000000</w:data>
    </xml><![endif]--></span>,<span style='mso-spacerun:yes'>  </span>5,<span
    style='mso-spacerun:yes'>  </span>6 and 7 as well as<span
    style='mso-spacerun:yes'>  </span>several receptor subtypes like 1F <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>27</span></sup><!--[if gte mso 9]><xml>
     <w:data>3D71416E0039A3685610000832CF656E726600ACD929710001731302000000020000005C02000000145B416468616D2C20203139393320233231345D000000</w:data>
    </xml><![endif]--></span> (Serotonin 1A in 1981 through to current
    discoveries in 1995) <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>28, 29</span></sup><!--[if gte mso 9]><xml>
     <w:data>701588140053A3685610000832CF656E726600ACD92971000173250200000006000005F2020000002E5B426572656E6473656E2C2020313939352023313031383B2050616E6465792C2020313939352023383633385D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'>Serotonin<span
    style='mso-spacerun:yes'>  </span>and aggression </b></p>
    <p class=MsoNormal style='margin-right:2.6pt'><span style='mso-tab-count:
    1'>            </span>There is substantial research suggesting a link of
    aggression and serotonin. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>20, 30, 31, 32, 33, 34,
    35, 36, 37, 38, 39, 40, 41, 42, 43</span></sup><!--[if gte mso 9]><xml>
     <w:data>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</w:data>
    </xml><![endif]--></span> For example,<span style='mso-spacerun:yes'> 
    </span>in several studies of aggression,<span style='mso-spacerun:yes'> 
    </span>the CSF<span style='mso-spacerun:yes'>  </span>5-hydroxy-indole
    acetic acid level is inversely related to the extent of aggression. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>44</span></sup><!--[if gte mso 9]><xml>
     <w:data>9045E1CA003BA3685610000832CF656E726600ACD929720001734B02000000020000005C02000000165B4D69637A656B2C2020313938392023373438325D000000</w:data>
    </xml><![endif]--></span> As 5-HIAA is a metabolite of serotonin<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>and</span> deficiency
    would imply possible serotonin two excess states with long term down
    regulation,<span style='mso-spacerun:yes'>  </span>this result may have
    some relevance. Animal models support <span class=GramE>this :</span>
    decreased serotonergic activity increases predatory behavior. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>38, 40, 44, 45, 46</span></sup><!--[if gte mso 9]><xml>
     <w:data>1700047F008FA3685610000832CF656E726600ACD929720001735D0200000012004713B3020000006A5B4D634D696C6C656E2C2020313938372023373239353B204D69637A656B2C2020313938392023373438323B204F6C69766965722C2020313938392023383531363B204D6F6C696E612C2020313938372023373634333B204D616A2C2020313938322023363838375D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt'>There are difficulties in
    interpreting <span class=GramE>serotonin<span style='mso-spacerun:yes'> 
    </span>and</span> aggression states. For example<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>fluoxetine</span>,<span
    style='mso-spacerun:yes'>  </span>an inhibitor of serotonin uptake and
    other serotonin-mimetics inhibit mouse killing behavior without apparent
    secondary effects and when these compounds were tested on killer rats,<span
    style='mso-spacerun:yes'>  </span>a stronger antimuricidal effect was
    observed in rats having altered serotonin neurotransmission. These results
    support a role for the serotonergic supersensitivity in a model of
    aggressive behavior. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>40</span></sup><!--[if gte mso 9]><xml>
     <w:data>9EFDB7CE003BA3685610000832CF656E726600ACD929720001736F02000000020000005402000000165B4D6F6C696E612C2020313938372023373634335D000000</w:data>
    </xml><![endif]--></span>. Yet<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>in</span> delta 9-Tetrahydrocannabinol
    (THC) induced aggressive behavior in rats previously deprived of REM
    sleep,<span style='mso-spacerun:yes'>  </span>aggressiveness was
    significantly potentiated by tryptophan and fluoxetine. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>42</span></sup><!--[if gte mso 9]><xml>
     <w:data>D01D6CAC003CA3685610000832CF656E726600ACD929730001738102000000020000005002000000175B4361726C696E692C2020313938322023313738395D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>Further
    complicating animal interpretations is the use of the overlapping paradigms
    for aggression and anxiety. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>20, 33, 36, 47</span></sup><!--[if gte mso 9]><xml>
     <w:data>F870497A007EA3685610000832CF656E726600ACD9297300017394020000000E000450B202000000595B426172726574742C20203139393320233738373B204D6F6E74676F6D6572792C2020313938392023373637363B204E657070652C2020313939332023383235383B204C656F6E6172642C2020313939322023363434365D000000</w:data>
    </xml><![endif]--></span>,<span style='mso-spacerun:yes'>  </span><span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>45</span></sup><!--[if gte mso 9]><xml>
     <w:data>9E53DFDA003DA3685610000832CF656E726600ACD92973000173A702000000020000005E02000000185B4D634D696C6C656E2C2020313938372023373239355D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'>Serotonin 2 and aggression <o:p></o:p></b></p>
    <p class=MsoNormal style='margin-right:2.6pt'>Several drugs which have been
    noted empirically but not in double blind studies to have anti-aggressive
    effects act on the serotonin 2 receptor (now the 5-HT 2A Receptor subtype).
    The phenothiazines and other neuroleptics may have 5 % to 30 % of their
    total receptor profile as serotonin 2 blockade. <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>48,
    49</span></sup><!--[if gte mso 9]><xml>
     <w:data>F336CBF7004CA3685610000832CF656E726600ACD92974000173BB02000000060000059402000000275B4E657070652C20313938392023383232343B204E657070652C20313938392023383232335D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>For many
    years<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>phenothiazines</span> were used as anti-agitation drugs<span
    style='mso-spacerun:yes'>  </span>and their effects in taming animals are
    well-known. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>50, 51, 52</span></sup><!--[if gte mso 9]><xml>
     <w:data>9739A4E6005CA3685610000832CF656E726600ACD92974000173CD020000000A00004E9502000000375B4974696C2C20313937352023353134393B204974696C2C20313937382023353135313B204C696F6E2C20313937352023363634355D000000</w:data>
    </xml><![endif]--></span> Trazodone has serotonin 2 blocking effects and in
    case reports has anti-aggressive effects. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>53, 54, 55, 56, 57, 58,
    59</span></sup><!--[if gte mso 9]><xml>
     <w:data>97B5C22D00BAA3685610000832CF656E726600ACD92974000173E0020000001A59A4603302000000955B4265726E737465696E2C20313939322023313035333B2047656479652C20313939312023333836343B204F274E65696C2C20313938362023383432353B2050696E6E65722C20313938382023383935383B2053696D70736F6E2C2031393836202331303439303B2057696C636F636B2C2031393837202331323032313B205A7562696574612C2031393932202331323430305D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt'>The relevance of these
    effects in the context of the data below is the apparent inverse control
    with serotonin 1A drugs:<span style='mso-spacerun:yes'>  </span>1A agonism
    seems to have similar effects or controlling effects <span class=GramE>to<span
    style='mso-spacerun:yes'>  </span>2A</span> antagonism using several
    pharmacologic models. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>22, 60</span></sup><!--[if gte mso 9]><xml>
     <w:data>0F8559B2004CA3685610000832CF656E726600ACD92974000173F202000000060000048602000000275B4569736F6E2C20313939322023333034353B204569736F6E2C20313939302023333034325D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>This is
    also seen clinically with anti-aggressive<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>anti</span>-anxiety and anti-depressant
    parallels but not with other areas,<span style='mso-spacerun:yes'> 
    </span>some controversial,<span style='mso-spacerun:yes'>  </span>such as
    sedation and psychosis with 5HT 2A not 1A,<span style='mso-spacerun:yes'> 
    </span>and anti-impulsivity aspects and neuroregulation with 1A not 2A. </p>
    <p class=MsoNormal style='margin-right:2.6pt'><b style='mso-bidi-font-weight:
    normal'><o:p>&nbsp;</o:p></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'>Serotonin 1A receptors</b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span>The serotonin 1 receptors<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>particularly</span>
    serotonin 1A,<span style='mso-spacerun:yes'>   </span>are relevant in aggression.<span
    style='mso-spacerun:yes'>  </span>The serotonin 1A receptor was discovered
    in the early 1980's<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>and</span> serotonin 1 and then serotonin 1A was differentiated at
    that point,<span style='mso-spacerun:yes'>  </span>relating to their
    specific interactions with guanasyl nucleotides, adenylyl cyclase<span
    style='mso-spacerun:yes'>  </span>and differential effects with
    different<span style='mso-spacerun:yes'>  </span>ligands. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>61</span></sup><!--[if gte mso 9]><xml>
     <w:data>0D1F41D80038A3685610000832CF656E726600ACD929750001740502000000020000005402000000135B50617A6F732C313938372023383732385D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>62</span></sup><!--[if gte mso 9]><xml>
     <w:data>11AD92150037A3685610000832CF656E726600ACD929750001741802000000020000005202000000125B57752C2031393838202331323138355D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>63, 64, 65, 66</span></sup><!--[if gte mso 9]><xml>
     <w:data>B99B24700074A3685610000832CF656E726600ACD929750001742C020000000E00045300020000004F5B49656E692C20313938382023353035353B2044756D7569732C20313938382023323932303B2047696C6C69732C20313938392023333936383B204D616E64616C2C20313938392023363934315D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>Serotonin
    1A has its own special serotonin syndrome <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>67, 68</span></sup><!--[if gte mso 9]><xml>
     <w:data>C488651D004EA3685610000832CF656E726600ACD929760001743F02000000060000058802000000295B4C617A6F736B792C20313939312023363336363B204569736F6E2C20313938392023333034315D000000</w:data>
    </xml><![endif]--></span><span class=GramE>, .</span> Both the azapirones
    and the benzodioxines conform to the properties <span class=GramE>of<span
    style='mso-spacerun:yes'>  </span>a</span> partial agonist at the serotonin
    1A level. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>69, 70</span></sup><!--[if gte mso 9]><xml>
     <w:data>41EDDCC1004FA3685610000832CF656E726600ACD9297600017456020000000600000484020000002A5B4D696C6C616E2C20313939312023373530353B204D6974746D616E2C20313938392023373539375D000000</w:data>
    </xml><![endif]--></span><span class=GramE>,.</span> <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>71</span></sup><!--[if gte mso 9]><xml>
     <w:data>1A221FCE003BA3685610000832CF656E726600ACD929760001746A02000000020000005502000000165B4F646167616B692C20313939352023383434375D000000</w:data>
    </xml><![endif]--></span>, Partial agonists may imply a mechanism for
    neuromodulation. These effects may have implications for high dose
    (post-synaptic) effects such as possible anti-aggressive effects in high
    threshold subpopulations such as mania. (<span class=GramE>hypothesized</span>
    in Cohorts 2,<span style='mso-spacerun:yes'>  </span>3 and 4 below ). The
    functions of serotonin could reflect serotonin 1A neuromodulation as well
    because serotonin 1A has remained unique amongst the serotonin receptor
    subtypes as the action of drugs acting on this receptor is both presynaptic
    directly at the raphe nucleus level and,<span style='mso-spacerun:yes'> 
    </span>in sufficient doses,<span style='mso-spacerun:yes'> 
    </span>post-synaptic at the hippocampus,<span style='mso-spacerun:yes'> 
    </span>amygdala,<span style='mso-spacerun:yes'>  </span>cerebral cortical
    level <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>20, 72</span></sup><!--[if gte mso 9]><xml>
     <w:data>BDEF4F40004CA3685610000832CF656E726600ACD92977000174820200000006000004D202000000275B4569736F6E2C20313939342023333034373B204E657070652C20313939332023383235385D000000</w:data>
    </xml><![endif]--></span>.<span style='mso-spacerun:yes'>  </span>Low doses
    (presynaptic or autoreceptor level doses) of such compounds acting at this
    level may also have implications for aggression (hypothesized in Cohorts 1<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>3</span> and 4 below).
    <b style='mso-bidi-font-weight:normal'><o:p></o:p></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>Serotonin 1A Drugs </u></b></p>
    <p class=MsoNormal style='margin-right:2.6pt'>There are three groups of
    drugs in which the serotonin 1A neuromodulation model <span class=GramE>can
    be tested</span>. <span class=GramE>The azapirone,<span
    style='mso-spacerun:yes'>  </span>buspirone (marketed for control of
    anxiety and mixed anxiety-depression)<span style='mso-spacerun:yes'> 
    </span>is ideal because of its specificity for the serotonin 1A receptor at
    therapeutic doses <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>20, 72</span></sup><!--[if gte mso 9]><xml>
     <w:data>B82F4F40004CA3685610000832CF656E726600ACD92977000174950200000006000004D202000000275B4569736F6E2C20313939342023333034373B204E657070652C20313939332023383235385D000000</w:data>
    </xml><![endif]--></span>-- its effects on the dopamine receptor in a
    non-sensitized individual should occur only an order of magnitude
    higher,<span style='mso-spacerun:yes'>  </span>say at doses of 300 or 400
    mg per day,<span style='mso-spacerun:yes'>  </span>although electrically
    firing at a dopaminergic cholinergic and noradrenergic levels occurs in
    pharmacologic doses.</span> <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>20, 73, 74</span></sup><!--[if gte mso 9]><xml>
     <w:data>C0CC59C0005EA3685610000832CF656E726600ACD92977000174A8020000000A000040F202000000395B4D6F73732C20313939332023373739333B204E657070652C20313938392023383232303B204E657070652C20313939332023383235385D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>19, 75</span></sup><!--[if gte mso 9]><xml>
     <w:data>4D993160004CA3685610000832CF656E726600ACD92978000174BC02000000060000042302000000275B4E657070652C20313938392023383232353B204E657070652C20313939302023383233315D000000</w:data>
    </xml><![endif]--></span><sup><o:p></o:p></sup></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>Serotonin
    1A receptor action can also be appraised non-specifically by the beta
    2-adrenergic receptor blockers like propranolol (which overall antagonize) <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>70, 76, 77, 78</span></sup><!--[if gte mso 9]><xml>
     <w:data>B76A8B790077A3685610000832CF656E726600ACD92978000174D3020000000E0005865702000000525B4D6974746D616E2C20313938392023373539373B204869636B732C20313939302023343737363B20416C6861696465722C203139393320233330363B204B686172696E2C20313939332023353734375D000000</w:data>
    </xml><![endif]--></span><span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>the</span> benzodioxines such as
    eltoprazine (which act probably as partial agonists) <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>69, 71, 79</span></sup><!--[if gte mso 9]><xml>
     <w:data>F123E0070063A3685610000832CF656E726600ACD92979000174E8020000000A00005AA4020000003E5B4D696C6C616E2C20313939312023373530363B204D696C6C616E2C20313939312023373530353B204F646167616B692C20313939352023383434375D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>80, 81</span></sup><!--[if gte mso 9]><xml>
     <w:data>393BD8940054A3685610000832CF656E726600ACD92979000174FC020000000600000448020000002F5B53696A6265736D612C2031393930202331303433303B2053636869707065722C2031393930202331303035305D000000</w:data>
    </xml><![endif]--></span> and lithium <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>82, 83</span></sup><!--[if gte mso 9]><xml>
     <w:data>01BD86C4004FA3685610000832CF656E726600ACD929790001751102000000060000040C020000002A5B4D697A7574612C20313938382023373630393B20476F6F6477696E2C20313938362023343132395D000000</w:data>
    </xml><![endif]--></span> (which acts as an agonist amongst possibly fifty
    other hypothesized actions).<span style='mso-spacerun:yes'>  </span>. All
    three of the prototypical drugs,<span style='mso-spacerun:yes'>  </span>the
    azapirones,<span style='mso-spacerun:yes'>  </span>benzodioxines and beta
    blockers,<span style='mso-spacerun:yes'>  </span>have K1 values which
    suggest serotonin 1A effects within therapeutic ranges <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>20</span></sup><!--[if gte mso 9]><xml>
     <w:data>33A578290039A3685610000832CF656E726600ACD9297A0001752602000000020000005202000000145B4E657070652C20313939332023383235385D000000</w:data>
    </xml><![endif]--></span> Psychopharmacologically,<span
    style='mso-spacerun:yes'>  </span>the availability of non-specific
    comparative 5HT 1A drugs,<span style='mso-spacerun:yes'>  </span>the
    beta-adrenergic blocking agents (used for many reasons medically,<span
    style='mso-spacerun:yes'>  </span>but psychiatrically including control of
    somatic anxiety)<span style='mso-spacerun:yes'>  </span>and the
    benzodioxines (being explored but not yet marketed for aggression),<span
    style='mso-spacerun:yes'>  </span>allow comparisons across serotonin
    receptor subtypes,<span style='mso-spacerun:yes'>  </span>and allow further
    exploration of diagnoses,<span style='mso-spacerun:yes'> 
    </span>symptomatology,<span style='mso-spacerun:yes'>  </span>and
    hypothesis testing for other receptor subtypes <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>20</span></sup><!--[if gte mso 9]><xml>
     <w:data>34A578290039A3685610000832CF656E726600ACD9297A0001753A02000000020000005202000000145B4E657070652C20313939332023383235385D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>Testing the theory of<span
    style='mso-spacerun:yes'>  </span>non-specific serotonin 1A drugs
    modulating aggression:</u></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>This
    theory <span class=GramE>can be tested</span> using other examples based on
    empirical data. </p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'>Lithium<o:p></o:p></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>Lithium
    has been well demonstrated to have some degree of anti-aggressive effect <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>84, 85</span></sup><!--[if gte mso 9]><xml>
     <w:data>E631C9DD0052A3685610000832CF656E726600ACD9297A0001754D0200000006000004C0020000002D5B436F72726967616E2C20313939332023323234373B205769636B68616D2C2031393837202331313939325D000000</w:data>
    </xml><![endif]--></span><span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>but</span> it is<span
    style='mso-spacerun:yes'>  </span>little-known that lithium acts as a
    post-synaptic serotonin 1A agonist in rodent models.<span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>83</span></sup><!--[if gte mso 9]><xml>
     <w:data>95F8284B003BA3685610000832CF656E726600ACD9297B0001756202000000020000005E02000000165B476F6F6477696E2C20313938362023343132395D000000</w:data>
    </xml><![endif]--></span> Administration of lithium chloride for 3-14 days
    enhances the components of the serotonin syndrome produced by
    8-hydroxy-2-(di-propylamino)tetralin (8-OH-DPAT) in the rat,<span
    style='mso-spacerun:yes'>  </span>but the hypothermic response ( ?
    presynaptic) was unaltered. By contrast,<span style='mso-spacerun:yes'>  
    </span>responses at <span class=GramE>the<span style='mso-spacerun:yes'> 
    </span>5</span>-HT1B receptor agonist were unaltered by repeated lithium
    administration <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>83</span></sup><!--[if gte mso 9]><xml>
     <w:data>9038284B003BA3685610000832CF656E726600ACD9297B0001757502000000020000005E02000000165B476F6F6477696E2C20313938362023343132395D000000</w:data>
    </xml><![endif]--></span>. .</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'>Beta-adrenergic blocking agents<o:p></o:p></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.8in 1.3in 1.8in 2.3in 2.8in 3.3in 3.8in 4.3in 4.8in 5.3in 5.8in 6.5in'><span
    style='mso-spacerun:yes'> </span>The beta2 adrenergic <span class=GramE>blockers<span
    style='mso-spacerun:yes'>  </span>predominantly</span> antagonize the
    serotonin 1A post-synaptic receptor but non-specifically.<span
    style='mso-spacerun:yes'>  </span>Beta1 and 2 adrenergic blockade makes
    interpretation of which action is occurring more <span class=GramE>difficult<span
    style='mso-spacerun:yes'>  </span>.</span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.8in 1.3in 1.8in 2.3in 2.8in 3.3in 3.8in 4.3in 4.8in 5.3in 5.8in 6.5in'>There
    are at least <span class=GramE>11 marketed</span> beta-blockers in various
    countries of which eight are non-cardioselective - they act on the beta 2
    receptor even in low doses. <span style='mso-field-code:" ADDIN ENRef "'><span
    class=GramE><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>86</span></sup><!--[if gte mso 9]><xml>
     <w:data>D8C907D50039A3685610000832CF656E726600ACD9297B0001758802000000020000005402000000145B4E657070652C20313938342023383132385D000000</w:data>
    </xml><![endif]--></span></span><span class=GramE>, <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>87</span></sup><!--[if gte mso 9]><xml>
     <w:data>DD0807D40039A3685610000832CF656E726600ACD9297C0001759E02000000020000005602000000145B4E657070652C20313938392023383231385D000000</w:data>
    </xml><![endif]--></span>.</span> Of these,<span style='mso-spacerun:yes'> 
    </span>propranolol <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>70, 76, 77, 78</span></sup><!--[if gte mso 9]><xml>
     <w:data>AE5A8B790077A3685610000832CF656E726600ACD9297C000175B7020000000E0005865702000000525B4D6974746D616E2C20313938392023373539373B204869636B732C20313939302023343737363B20416C6861696465722C203139393320233330363B204B686172696E2C20313939332023353734375D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>88</span></sup><!--[if gte mso 9]><xml>
     <w:data>D67BBE20003CA3685610000832CF656E726600ACD9297C000175CD02000000020000004802000000175B5370726F7573652C2031393836202331303735345D000000</w:data>
    </xml><![endif]--></span> and<span style='mso-spacerun:yes'> 
    </span>pindolol <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>64, 69, 77, 89</span></sup><!--[if gte mso 9]><xml>
     <w:data>B48953BF0076A3685610000832CF656E726600ACD9297D000175E7020000000E000557AE02000000515B4C6F70657A2C20313939342023363732373B204D696C6C616E2C20313939312023373530353B2044756D7569732C20313938382023323932303B20416C6861696465722C203139393320233330365D000000</w:data>
    </xml><![endif]--></span> particularly have been evaluated with regard to
    their<span style='mso-spacerun:yes'>  </span>serotonin 1A post-synaptic receptor
    action and<span style='mso-spacerun:yes'>  </span>alprenolol <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>79, 90</span></sup><!--[if gte mso 9]><xml>
     <w:data>4BBB239F004DA3685610000832CF656E726600ACD9297D000175FD02000000060000046502000000285B417269616E692C203139383920233530373B204D696C6C616E2C20313939312023373530365D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>91, 92</span></sup><!--[if gte mso 9]><xml>
     <w:data>B1332FBF0058A3685610000832CF656E726600ACD9297D0001761302000000060000043B02000000335B4665726E27616E64657A2C20313939302023333332353B2054737563686968617368692C2031393839202331313430355D000000</w:data>
    </xml><![endif]--></span>, timolol <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>92, 93</span></sup><!--[if gte mso 9]><xml>
     <w:data>E8BC7B1C0055A3685610000832CF656E726600ACD9297E0001762902000000060000041D02000000305B54737563686968617368692C2031393839202331313430353B204B616C6B6D616E2C20313938392023353530385D000000</w:data>
    </xml><![endif]--></span>, oxprenalol <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>94, 95</span></sup><!--[if gte mso 9]><xml>
     <w:data>0B027CAE0052A3685610000832CF656E726600ACD9297E000176410200000006000004D1020000002D5B4D6964646C656D6973732C20313938362023373438393B204E6F733A616C2C20313938352023383337325D000000</w:data>
    </xml><![endif]--></span> and possibly nadolol <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>74</span></sup><!--[if gte mso 9]><xml>
     <w:data>A0BBF82F0039A3685610000832CF656E726600ACD9297F0001766002000000020000005F02000000145B4E657070652C20313938392023383232305D000000</w:data>
    </xml><![endif]--></span> all been demonstrated to have serotonin 1A
    antagonism effect. The link to serotonin 1A of the beta 2 -adrenergic
    blocking agents was demonstrated definitively in 1988 when the genomic
    clone of serotonin 1A was produced from an attempt to isolate the beta 2
    adrenergic receptor which it<span style='mso-spacerun:yes'> 
    </span>resembles and is apparently part of <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>96</span></sup><!--[if gte mso 9]><xml>
     <w:data>CDCC943C003AA3685610000832CF656E726600ACD9297F0001767B02000000020000005502000000155B46617267696E2C20313938382023333235335D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>97</span></sup><!--[if gte mso 9]><xml>
     <w:data>A72D9A10003CA3685610000832CF656E726600ACD929800001769802000000020000005702000000175B46756A69776172612C20313939302023333636395D000000</w:data>
    </xml><![endif]--></span>. The 5HT1A <span class=GramE>receptor<span
    style='mso-spacerun:yes'>  </span>activity</span> of the beta-blockers
    may<span style='mso-spacerun:yes'>  </span>depend on<span
    style='mso-spacerun:yes'>  </span>the beta 2 -adrenergic effect :
    d-propranolol,<span style='mso-spacerun:yes'>  </span>the dextroisomer of
    propranolol is ineffective as a beta-adrenergic blocking agent <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>98, 99</span></sup><!--[if gte mso 9]><xml>
     <w:data>F39548460058A3685610000832CF656E726600ACD92980000176B602000000060000054902000000335B596F7368696D7572612C2031393837202331323237343B2054737563686968617368692C2031393838202331313430345D000000</w:data>
    </xml><![endif]--></span>,<span style='mso-spacerun:yes'>  </span>and also
    is an ineffective serotonin 1A antagonist. <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>100</span></sup><!--[if gte mso 9]><xml>
     <w:data>D65705B3003CA3685610000832CF656E726600ACD92981000176CB02000000030000009102000000175B416C6578616E6465722C203139383720233239345D000000</w:data>
    </xml><![endif]--></span>. This emphasizes how difficult it is to
    differentiate beta 2 from serotonin 1A effects.<span
    style='mso-spacerun:yes'>  </span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt'>Clinically<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>beta</span> blockers have been used in
    low dosage to lower somatic symptoms of anxiety,<span
    style='mso-spacerun:yes'>  </span>and with it there is a lowering of
    frustration with a lowering of aggression.<span style='mso-spacerun:yes'> 
    </span>This is probably an adrenergic<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>non</span>-serotonin related
    phenomenon,<span style='mso-spacerun:yes'>  </span>and frequently
    corresponds empirically with a pulse in the high 60's. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>86, 87</span></sup><!--[if gte mso 9]><xml>
     <w:data>597C2100004CA3685610000832CF656E726600ACD92981000176E302000000060000048402000000275B4E657070652C20313938342023383132383B204E657070652C20313938392023383231385D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>A pulse in
    the low 60's corresponds with high doses of lipid-soluble beta-adrenergic
    blocking agents such as propranolol and pindolol<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>and</span> these drugs in high doses have
    been used in the control of rage and aggression,<span
    style='mso-spacerun:yes'>  </span>particularly organic rage.<span
    style='mso-spacerun:yes'>  </span>This seems anomalous because (-) Pindolol
    and (-) propranolol displayed high affinity for 5-HT1A as potent
    antagonists at 5-HT1A receptors in rat hippocampus <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>101</span></sup><!--[if gte mso 9]><xml>
     <w:data>97A0C540003DA3685610000832CF656E726600ACD92981000176F702000000030000009502000000185B4F6B73656E626572672C20313938382023383439305D000000</w:data>
    </xml><![endif]--></span><span class=GramE>..</span> Moreover<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>(</span>-) propranolol
    has certain impinging effects on the serotonin 2 receptor ( e<span
    style='mso-spacerun:yes'>  </span>.g. relatively high doses of propranolol
    only partially antagonized the effects of LSD) <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>70</span></sup><!--[if gte mso 9]><xml>
     <w:data>FB03C530003BA3685610000832CF656E726600ACD929820001770C02000000020000005702000000165B4D6974746D616E2C20313938392023373539375D000000</w:data>
    </xml><![endif]--></span>. <sup><span style='mso-spacerun:yes'> </span></sup>Consequently<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>this</span> may imply
    that serotonin 2 antagonism is not the mechanism linked to anti-aggressive
    effects. However,<span style='mso-spacerun:yes'>   </span>like the
    beta-adrenergic antagonist<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>pindolol</span>,<span
    style='mso-spacerun:yes'>  </span>propranolol binds with high affinity to
    5-HT1B <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>76</span></sup><!--[if gte mso 9]><xml>
     <w:data>4EB5FD520039A3685610000832CF656E726600ACD929820001772302000000020000005B02000000145B4869636B732C20313939302023343737365D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>102</span></sup><!--[if gte mso 9]><xml>
     <w:data>3FF968B30039A3685610000832CF656E726600ACD929820001773802000000030000009902000000145B48616D656C2C20313939332023343437375D000000</w:data>
    </xml><![endif]--></span><sup> </sup>.Propranolol binds stereoselectively
    both at 5-HT1A and 5-HT1B sites (with a several-fold selectivity for the
    latter) and,<span style='mso-spacerun:yes'>  </span>whereas it is a 5-HT1A
    antagonist,<span style='mso-spacerun:yes'>  </span>it appears to be a
    5-HT1B agonist. As such<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>it</span> could serve as a lead compound for the development of new
    5-HT1A and 5-HT1B agents based on preliminary studies<span
    style='mso-spacerun:yes'>  </span>for the development of novel serotonergic
    agents <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>103</span></sup><!--[if gte mso 9]><xml>
     <w:data>37CDC30A003CA3685610000832CF656E726600ACD929830001774F02000000030000009D02000000175B4E616761746F6D6F2C20313938392023373934325D000000</w:data>
    </xml><![endif]--></span>. . Moreover<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>some</span> beta-adrenoceptor antagonists
    may behave as mixed agonists-antagonists at the 5-HT autoreceptor. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>104</span></sup><!--[if gte mso 9]><xml>
     <w:data>2AF1EBFF0039A3685610000832CF656E726600ACD929830001776302000000030000008102000000145B4D617572612C20313938372023373135385D000000</w:data>
    </xml><![endif]--></span> .Finally<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>(</span>-)-propranolol is a relatively
    weak antagonist of 5-HT itself,<span style='mso-spacerun:yes'> 
    </span>suggesting that the endogenous neurotransmitter may have actions on
    dorsal raphe neurons in addition to those mediated by 5-HT1A receptors. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>88</span></sup><!--[if gte mso 9]><xml>
     <w:data>C77BBE20003CA3685610000832CF656E726600ACD929830001777702000000020000004802000000175B5370726F7573652C2031393836202331303735345D000000</w:data>
    </xml><![endif]--></span><sup> </sup></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span><span
    style='mso-spacerun:yes'> </span>However<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>a</span> confounding factor is that beta
    blockers such as propranolol also act in serotonin 1B as agonists. <span
    style='mso-field-code:" ADDIN ENRef "'><span class=GramE><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>76, 105, 106</span></sup><!--[if gte mso 9]><xml>
     <w:data>636F4EEC0061A3685610000832CF656E726600ACD929840001778B020000000C00012DBB020000003C5B47616C7A696E2C20313939322023333736373B204D75727068792C20313938392023373838313B204869636B732C20313939302023343737365D000000</w:data>
    </xml><![endif]--></span></span><span class=GramE> The serotonin 1B
    receptor has at this point not been demonstrated in man <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>106, 107</span></sup><!--[if gte mso 9]><xml>
     <w:data>0E29EEB3004EA3685610000832CF656E726600ACD92984000177A002000000080000124902000000295B4D75727068792C20313939302023373838363B204D75727068792C20313938392023373838315D000000</w:data>
    </xml><![endif]--></span>,<span style='mso-spacerun:yes'>  </span>but many
    of the more perplexing features relating to the anti-aggressive action of
    beta blockers which may be 5HT 1A antagonists,<span
    style='mso-spacerun:yes'>  </span>may be explained on the basis of a
    possible presence of serotonin 1B in man at which the beta blockers may be
    agonists.</span> (Neppe,<span style='mso-spacerun:yes'>  </span>1990) The
    serotonin 1B receptor is a very potent anti-aggressive receptor<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>using</span> the rodent
    model. This may or may not be applicable in man because no serotonin 1B
    receptor <span class=GramE>has thus far been demonstrated</span> in
    humans.<span style='mso-spacerun:yes'>  </span>Moreover<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>the</span> effect potentially could still
    be non-serotonin related and beta adrenergic,<span
    style='mso-spacerun:yes'>  </span>so that these are complicating hypotheses.<span
    style='mso-spacerun:yes'>  </span>These <span class=GramE>are needed</span>
    to explain what has been found clinically with propranolol and aggression. </p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>The
    use of high dose propranolol in rage and aggression is very promising.
    Several studies of generally high doses of propranolol used for aggression
    in organic brain syndromes in children<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>Korsakoff's</span> psychosis,<span
    style='mso-spacerun:yes'>   </span>in schizophrenia,<span
    style='mso-spacerun:yes'>  </span>severe mental retardation,<span
    style='mso-spacerun:yes'>  </span>adult autism<span
    style='mso-spacerun:yes'>  </span>and chronic organic brain syndromes have
    suggested its usage. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>87, 108, 109</span></sup><!--[if gte mso 9]><xml>
     <w:data>C8B255CC0060A3685610000832CF656E726600ACD92984000177B6020000000C000156F6020000003B5B4272697A65722C20313938382023313438373B204E657070652C20313938352023383135353B204E657070652C20313938392023383231385D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>110, 111</span></sup><!--[if gte mso 9]><xml>
     <w:data>BF8845490050A3685610000832CF656E726600ACD92985000177CC020000000800001113020000002B5B5975646F66736B792C2031393930202331323330313B2045696D65722C20313938392023333032365D000000</w:data>
    </xml><![endif]--></span> Real rage requires higher<span
    style='mso-spacerun:yes'>  </span>doses of lipophilic drug and the effects
    are delayed weeks with the pulse being<span style='mso-spacerun:yes'> 
    </span>not in the mid-sixties as for somatic anxiety but lower suggesting a
    second different mechanism. Additionally<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>by</span> contrast,<span
    style='mso-spacerun:yes'>  </span>low doses and the<span
    style='mso-spacerun:yes'>  </span>peripheral effects of several
    beta-adrenergic blocking agents produce almost immediate relief of<span
    style='mso-spacerun:yes'>  </span>aggression linked to<span
    style='mso-spacerun:yes'>  </span>frustration <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>87</span></sup><!--[if gte mso 9]><xml>
     <w:data>3CAFF82B0039A3685610000832CF656E726600ACD92985000177E602000000020000005602000000145B4E657070652C20313938392023383231385D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'> 
    </span>Moreover,<span style='mso-spacerun:yes'>  </span>animal studies
    support the anti-aggression effect of propranolol. <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>112</span></sup><!--[if gte mso 9]><xml>
     <w:data>2BDD8C57003EA3685610000832CF656E726600ACD92986000177FA02000000030000009B02000000195B5765696E73746F636B2C2031393830202331313839345D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>Studies
    with other lipid soluble beta 2 -adrenergic blocking <span class=GramE>agents<span
    style='mso-spacerun:yes'>  </span>such</span> as pindolol<span
    style='mso-spacerun:yes'>  </span>exist. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>113</span></sup><!--[if gte mso 9]><xml>
     <w:data>5DCDBE26003AA3685610000832CF656E726600ACD929860001780E02000000030000009F02000000155B426F6E736F6E2C20313939342023313331385D000000</w:data>
    </xml><![endif]--></span> Some of the effects may well be beta-adrenergic
    in higher doses or the serotonin mechanisms or combinations <span
    class=GramE>can be invoked</span>. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>87</span></sup><!--[if gte mso 9]><xml>
     <w:data>CC7C07D40039A3685610000832CF656E726600ACD929860001782202000000020000005602000000145B4E657070652C20313938392023383231385D000000</w:data>
    </xml><![endif]--></span> </p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>Can
    one reconcile these three groups of drugs in relation to the pharmacology
    of aggression?<span style='mso-spacerun:yes'>  </span>Clearly<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>agonism</span> at
    serotonin 1A level<span style='mso-spacerun:yes'>  </span>could be
    supported by buspirone and by lithium,<span style='mso-spacerun:yes'> 
    </span>but is apparently contradicted by propranolol. These studies
    complement research in aggression with both the azapirones and lithium -
    relevant because lithium has amongst other actions<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>serotonin</span> 1A effects<span
    style='mso-spacerun:yes'>  </span>.</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.8in 1.3in 1.8in 2.3in 2.8in 3.3in 3.8in 4.3in 4.8in 5.3in 5.8in 6.5in'>We
    now review the literature on the more specific serotonin 1A compounds, the
    azapirones.</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>The azapirones <o:p></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>The
    exploration of serotonin 1A functions has had impetus with the development <span
    class=GramE>of<span style='mso-spacerun:yes'>  </span>a</span> series of
    compounds,<span style='mso-spacerun:yes'>  </span>the azapirones,<span
    style='mso-spacerun:yes'>  </span>which appear specific for this receptor
    in therapeutic doses. There are at least 11 azapirones being <span
    class=GramE>researched :</span> These drugs differ from the benzodiazepines
    structurally and also in that they have no significant effects on
    seizures,<span style='mso-spacerun:yes'>  </span>have no muscle relaxant
    effect and their anti-anxiety action is delayed for some two to three or
    four weeks. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>19, 114, 115</span></sup><!--[if gte mso 9]><xml>
     <w:data>0A75CFB5005FA3685610000832CF656E726600ACD9298700017836020000000C000131C3020000003A5B5A68752C2031393935202331323337323B205269626C65742C20313938322023393432353B204E657070652C20313939302023383233315D000000</w:data>
    </xml><![endif]--></span> However<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>the</span> only marketed one currently is
    buspirone in which there is patient experience on several million. One can
    measure the functional effects of buspirone because it can block the
    serotonin 1A <span class=GramE>specific<span style='mso-spacerun:yes'> 
    </span>agonist</span> effects of 8-hydroxy DPAT<span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>116</span></sup><!--[if gte mso 9]><xml>
     <w:data>207A7BBA0039A3685610000832CF656E726600ACD929870001784F02000000030000008B02000000145B44616D616A2C20313939342023323435385D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>117</span></sup><!--[if gte mso 9]><xml>
     <w:data>46A65DEE003AA3685610000832CF656E726600ACD929870001786402000000030000008F02000000155B596F6363612C2031393930202331323236395D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>implying
    some antagonist effects.<span style='mso-spacerun:yes'>  </span>But in high
    enough doses<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>buspirone</span>,<span style='mso-spacerun:yes'>  </span>and
    particularly its azapirone analog,<span style='mso-spacerun:yes'> 
    </span>gepirone,<span style='mso-spacerun:yes'>  </span>can induce a
    serotonin 1A related syndrome. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>118, 119</span></sup><!--[if gte mso 9]><xml>
     <w:data>42914A7B004EA3685610000832CF656E726600ACD929880001787D02000000080000153302000000295B4569736F6E2C20313939302023333034333B204A61636B736F6E2C20313938392023353138345D000000</w:data>
    </xml><![endif]--></span><span class=GramE>,</span><span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>117</span></sup><!--[if gte mso 9]><xml>
     <w:data>BBE5A211003AA3685610000832CF656E726600ACD929880001789102000000030000008F02000000155B596F6363612C2031393930202331323236395D000000</w:data>
    </xml><![endif]--></span>. This implies that functionally buspirone has
    both serotonin agonist and serotonin antagonist effects leading to the
    hypothesis of partial agonism. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>117, 120, 121</span></sup><!--[if gte mso 9]><xml>
     <w:data>0F11A4190065A3685610000832CF656E726600ACD92988000178A9020000000D0002394F02000000405B596F6363612C2031393930202331323236393B2050617577656C732C20313939332023383731383B20526F62696E736F6E2C20313939302023393536375D000000</w:data>
    </xml><![endif]--></span> Additionally<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>a</span> great deal of firing has been
    demonstrated at the presynaptic autoreceptor<span
    style='mso-spacerun:yes'>  </span>level in relation to serotonin 1A. This
    firing occurs in the dorsal <span class=GramE>raphe<span
    style='mso-spacerun:yes'>  </span>nucleus</span>.<span
    style='mso-spacerun:yes'>  </span>When presynaptic agonism occurs<span
    class=GramE>, <span style='mso-spacerun:yes'> </span>by</span> virtue of
    feedback loops,<span style='mso-spacerun:yes'>  </span>there will overall
    be<span style='mso-spacerun:yes'>  </span>less serotonin available
    post-synaptically for the synapse because ultimately there will be lowered
    serotonin tone. <span style='mso-field-code:" ADDIN ENRef "'><span
    class=GramE><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>72,
    118</span></sup><!--[if gte mso 9]><xml>
     <w:data>22CEDA28004DA3685610000832CF656E726600ACD92989000178C0020000000700000AD302000000285B4569736F6E2C2020313939342023333034373B204569736F6E2C20313939302023333034335D000000</w:data>
    </xml><![endif]--></span></span><span class=GramE>.</span> This would imply
    blockade not only at serotonin 1A levels,<span style='mso-spacerun:yes'> 
    </span>but serotonin 2 and possibly serotonin 3 levels with a functional
    post-synaptic serotonin antagonism overall,<span style='mso-spacerun:yes'> 
    </span>including a serotonin 2 antagonism <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>60, 118, 122, 123</span></sup><!--[if gte mso 9]><xml>
     <w:data>4BED85050072A3685610000832CF656E726600ACD92989000178D60200000011002186D6020000004D5B4569736F6E2C20313939302023333034333B204569736F6E2C20313938362023333033383B204569736F6E2C20313938352023333033373B204569736F6E2C20313939322023333034355D000000</w:data>
    </xml><![endif]--></span>. The azapirones act pre-synaptically as complete
    agonists. This produces firing at that level with an overall endpoint
    diminution in serotonergic tone post-synaptically. <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>60,
    118</span></sup><!--[if gte mso 9]><xml>
     <w:data>7F1CA876004CA3685610000832CF656E726600ACD9298A000178EC020000000700000AD602000000275B4569736F6E2C20313939302023333034333B204569736F6E2C20313939322023333034355D000000</w:data>
    </xml><![endif]--></span> In the animal model this has been
    well-demonstrated <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>117</span></sup><!--[if gte mso 9]><xml>
     <w:data>5F325DEE003AA3685610000832CF656E726600ACD9298A0001790202000000030000008F02000000155B596F6363612C2031393930202331323236395D000000</w:data>
    </xml><![endif]--></span>, although there may be some attenuation of this
    post-synaptic serotonergic tone <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>124</span></sup><!--[if gte mso 9]><xml>
     <w:data>01A5DD8F0038A3685610000832CF656E726600ACD9298A0001791702000000030000008502000000135B4D61756B2C20313938382023373135375D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>and
    overall antagonism at serotonin 1<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>2</span> and possibly 3 levels.<span
    style='mso-spacerun:yes'>  </span>This mechanism may be very important in
    using low doses of buspirone in <span class=GramE>aggression<span
    style='mso-spacerun:yes'>  </span>.</span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-spacerun:yes'> </span>In high <span class=GramE>doses</span>
    buspirone acts as a moderate but incomplete serotonin 1A agonist.<span
    style='mso-spacerun:yes'>  </span>The differentiation of pre-synaptic and
    post-synaptic effects has been argued to be appropriately modeled on such
    features as pre-synaptic hypothermia and post-synaptic elevations of <span
    class=GramE>prolactin which</span> can be blocked by serotonin antagonist
    type drugs. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>125, 126, 127, 128</span></sup><!--[if gte mso 9]><xml>
     <w:data>71816B420077A3685610000832CF656E726600ACD9298B0001792C020000001200555A4102000000525B436F636361726F2C20313939302023323039333B20436F77656E2C20313939302023323239333B20477265676F72792C20313939302023343235343B2053686172702C2031393839202331303331335D000000</w:data>
    </xml><![endif]--></span> Post-synaptic agonism may well imply some kind of
    reciprocal relationship with serotonin 2,<span style='mso-spacerun:yes'> 
    </span>implying again a serotonin 2 antagonism,<span
    style='mso-spacerun:yes'>  </span>using a variety of models,<span
    style='mso-spacerun:yes'>  </span>namely model of hypo/hyperthermia,<span
    style='mso-spacerun:yes'>  </span>hypotension / hypertension <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>129</span></sup><!--[if gte mso 9]><xml>
     <w:data>0A7309150038A3685610000832CF656E726600ACD9298B0001793F0200000003000000B102000000135B4B75626F2C20313939352023363134395D000000</w:data>
    </xml><![endif]--></span>,<span style='mso-spacerun:yes'>  </span>quipazine
    related effects,<span style='mso-spacerun:yes'>  </span>habituation of
    tactile startle via actions at 5-HT2 receptors <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>125,
    130, 131</span></sup><!--[if gte mso 9]><xml>
     <w:data>F190E0910067A3685610000832CF656E726600ACD9298B00017954020000000D0002310102000000425B436F636361726F2C20313939302023323039333B20596F756E672C2031393933202331323239303B204B6F6D69737361726F762C20313939302023353937365D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>and
    even<span style='mso-spacerun:yes'>  </span>migraine<span
    style='mso-spacerun:yes'>  </span><span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>132</span></sup><!--[if gte mso 9]><xml>
     <w:data>92065094003BA3685610000832CF656E726600ACD9298C0001796802000000030000009F02000000165B5061736375616C2C20313939312023383637375D000000</w:data>
    </xml><![endif]--></span> <sup><span style='mso-spacerun:yes'> </span></sup><span
    style='mso-spacerun:yes'>  </span>.<b style='mso-bidi-font-weight:normal'><u><o:p></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>A
    wide variety of human psychopathologies reflecting serotonin 1A involvement
    can therefore be analyzed in detail<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>particularly</span> so as buspirone is
    safe,<span style='mso-spacerun:yes'>  </span>used extensively in clinical
    practice and in low doses non-sedative. It <span class=GramE>has<span
    style='mso-spacerun:yes'>  </span>low</span> toxicity,<span
    style='mso-spacerun:yes'>  </span>few side-effects,<span
    style='mso-spacerun:yes'>  </span>no established lethality (LD 50 that has
    not even been established in man),<span style='mso-spacerun:yes'> 
    </span>very little cognitive and psychomotor impairment. <span class=GramE>and</span>
    no apparent potential for dependence.<span style='mso-spacerun:yes'> 
    </span>Buspirone despite its anxioselective action does not act on
    benzodiazepine or GABA receptors. Many typical anxiolytic drugs like the
    benzodiazepines which induce sedation<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>muscle</span> relaxation,<span
    style='mso-spacerun:yes'>  </span>anticonvulsant effects,<span
    style='mso-spacerun:yes'>  </span>act almost immediately and may induce
    dependence. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>19, 20</span></sup><!--[if gte mso 9]><xml>
     <w:data>3F804E98004CA3685610000832CF656E726600ACD9298C0001797C0200000006000004D302000000275B4E657070652C20313939332023383235383B204E657070652C20313939302023383233315D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span>This azapirone’s action appears
    to be broad<span class=GramE>,<span style='mso-spacerun:yes'>  </span>so</span>
    that the phrase &quot;anxioselective neuromodulator&quot; can be used. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>19</span></sup><!--[if gte mso 9]><xml>
     <w:data>A50278210039A3685610000832CF656E726600ACD9298C0001798F02000000020000004302000000145B4E657070652C20313939302023383233315D000000</w:data>
    </xml><![endif]--></span> Buspirone has a short half-life<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>requiring</span> thrice daily
    dosing,<span style='mso-spacerun:yes'>  </span>and has limited interactions
    with other drugs. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>19</span></sup><!--[if gte mso 9]><xml>
     <w:data>AFC678210039A3685610000832CF656E726600ACD9298D000179A402000000020000004302000000145B4E657070652C20313939302023383233315D000000</w:data>
    </xml><![endif]--></span> It <span class=GramE>has been used</span> with
    several hundred other psychotropic and other compounds without major
    interactions. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>133, 134</span></sup><!--[if gte mso 9]><xml>
     <w:data>70FB8BAE0052A3685610000832CF656E726600ACD9298D000179B902000000080000131B020000002D5B446F6D616E7461792C20313938392023323831323B20526F62696E736F6E2C20313938382023393536315D000000</w:data>
    </xml><![endif]--></span> Its major metabolite (like gepirone and
    tandospirone) is 1-2 pyrimidinyl piperazine or 1PP. <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>135,
    136, 137, 138, 139</span></sup><!--[if gte mso 9]><xml>
     <w:data>FC82FEBA0089A3685610000832CF656E726600ACD9298D000179CD02000000170AD4520302000000645B426C6965722C20313939312023313230393B204361636369612C20313938382023313638343B2043756C6C656E2C20313939342023323336343B2046756C6C65722C20313938392023333637393B204772617362792C20313939332023343139385D000000</w:data>
    </xml><![endif]--></span> There is some dispute as to the level of activity
    of 1PP<span class=GramE>,<span style='mso-spacerun:yes'>  </span>which</span>
    occurs in significant amounts. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>138, 140, 141</span></sup><!--[if gte mso 9]><xml>
     <w:data>65A09F3A0060A3685610000832CF656E726600ACD9298E000179E1020000000D000208F7020000003B5B456E67626572672C20313938392023333131363B2046756C6C65722C20313938392023333637393B2043616F2C20313939342023313736395D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt'><span style='mso-tab-count:
    1'>            </span>There is substantial animal evidence for buspirone
    being a potent anti-aggressive substance<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>and</span> this applies to other
    azapirones such as gepirone and ipsapirone<span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>38, 45, 142</span></sup><!--[if gte mso 9]><xml>
     <w:data>60A9F95C0067A3685610000832CF656E726600ACD9298E000179F5020000000B00008E1302000000425B4D634D696C6C656E2C20313938382023373239363B204D634D696C6C656E2C20313938372023373239353B204F6C69766965722C20313938392023383531365D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>143</span></sup><!--[if gte mso 9]><xml>
     <w:data>7592167F003DA3685610000832CF656E726600ACD9298E00017A0B02000000030000009502000000185B546F6D706B696E732C2031393830202331313332335D000000</w:data>
    </xml><![endif]--></span> as well.<span style='mso-spacerun:yes'> 
    </span>This anti-aggressive effect should be at the serotonin 1A receptor,
    and this in fact may be one of the fundamental actions at this level. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>20, 68</span></sup><!--[if gte mso 9]><xml>
     <w:data>EAFECF68004CA3685610000832CF656E726600ACD9298F00017A2002000000060000058202000000275B4569736F6E2C20313938392023333034313B204E657070652C20313939332023383235385D000000</w:data>
    </xml><![endif]--></span>] In fact,<span style='mso-spacerun:yes'> 
    </span>using every single animal model for aggression,<span
    style='mso-spacerun:yes'>  </span>relating to muricidal behavior and
    conflict-related aggression,<span style='mso-spacerun:yes'>  
    </span>inter-species and intra-species related aggression,<span
    style='mso-spacerun:yes'>   </span>isolation-induced models<span
    style='mso-spacerun:yes'>  </span>and group-related models,<span
    style='mso-spacerun:yes'>  </span>buspirone comes out as a very potent
    anti-aggressive agent in appropriate doses,<span style='mso-spacerun:yes'> 
    </span>and this property appears shared by gepirone. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>45, 115, 144</span></sup><!--[if gte mso 9]><xml>
     <w:data>CD516E7F0065A3685610000832CF656E726600ACD9298F00017A38020000000C00012D9E02000000405B4F6C69766965722C20313939322023383531383B205269626C65742C20313938322023393432353B204D634D696C6C656E2C20313938372023373239355D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>In the
    muricidal model<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>buspirone</span> requires higher doses,<span
    style='mso-spacerun:yes'>  </span>not having effects in lower doses<span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>45</span></sup><!--[if gte mso 9]><xml>
     <w:data>C7D2DF2B003CA3685610000832CF656E726600ACD9298F00017A4D02000000020000005E02000000175B4D634D696C6C656E2C20313938372023373239355D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>: it
    potently inhibited attacks against group housed intruder mice (ED50 =
    4<span style='mso-spacerun:yes'>  </span>.5 mg/kg i.p.) without causing
    sedation or ataxia. Inhibition of aggression <span class=GramE>was
    potentiated</span> by co-administration of methysergide. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>45</span></sup><!--[if gte mso 9]><xml>
     <w:data>CC6EDF2B003CA3685610000832CF656E726600ACD9299000017A6202000000020000005E02000000175B4D634D696C6C656E2C20313938372023373239355D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>This is
    particularly so as many of the paradigms used in animals to demonstrate the
    anxiolytic effect of buspirone <span class=GramE>can be also used</span> to
    demonstrate its anti-aggressive effect. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>68</span></sup><!--[if gte mso 9]><xml>
     <w:data>DBBC121C0039A3685610000832CF656E726600ACD9299000017A7702000000020000004602000000145B4569736F6E2C20313938392023333034315D000000</w:data>
    </xml><![endif]--></span> Theoretically<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>supporting</span> models exist in man. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>145</span></sup><!--[if gte mso 9]><xml>
     <w:data>6FE944A2003BA3685610000832CF656E726600ACD9299100017A8C02000000030000008D02000000165B436F636361726F2C20313939302023323039345D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt'><span style='mso-tab-count:
    1'>            </span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-spacerun:yes'> </span><span style='mso-tab-count:1'>           </span>However<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>double</span> blind
    studies in aggression in man are lacking. Irritability is an early target
    symptom of response with buspirone in generalized anxiety disorder possibly
    implying persistent low-<span class=GramE>dose<span
    style='mso-spacerun:yes'>  </span>effects</span>. <span style='mso-field-code:
    " ADDIN ENRef "'><span class=GramE><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>146, 147</span></sup><!--[if gte mso 9]><xml>
     <w:data>BFB3338A0052A3685610000832CF656E726600ACD9299100017AA2020000000800001341020000002D5B55686C656E687574682C2031393832202331313436303B205269626C65742C20313938332023393432365D000000</w:data>
    </xml><![endif]--></span></span><span class=GramE>, <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>19</span></sup><!--[if gte mso 9]><xml>
     <w:data>A85678210039A3685610000832CF656E726600ACD9299100017ABA02000000020000004302000000145B4E657070652C20313939302023383233315D000000</w:data>
    </xml><![endif]--></span>.</span><span style='mso-spacerun:yes'> 
    </span>Also,<span style='mso-spacerun:yes'>   </span>Ratey has published
    his uncontrolled data<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>on</span> 14 mental retardates,<span style='mso-spacerun:yes'> 
    </span>nine of whom responded favorably to the drug. <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>148, 149</span></sup><!--[if gte mso 9]><xml>
     <w:data>01CA9F7C004CA3685610000832CF656E726600ACD9299200017AD302000000080000147902000000275B52617465792C20313938392023393331333B2052617465792C20313939312023393331355D000000</w:data>
    </xml><![endif]--></span>.Numerous other case reports are scattered in a
    variety of different uses. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>150, 151, 152, 153, 154,
    155, 156, 157</span></sup><!--[if gte mso 9]><xml>
     <w:data>9061083600D0A3685610000832CF656E726600ACD9299200017AEB0200000026214434DC02000000AB5B4279726E652C20313939342023313637353B20436F6C656C6C612C20313939322023323134313B2046696E646C696E672C20313939332023333338383B2051756961736F6E2C20313939312023393230333B205374616E69736C61762C2031393934202331303738333B20486F6C7A65722C20313939352023343839373B20486F6C7474756D2C20313939342023343839323B20486572726D616E6E2C20313939332023343735355D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>A small
    amount of irritability ranking data exists in a double-blind study on
    pre-menstrual syndrome <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>151, 158</span></sup><!--[if gte mso 9]><xml>
     <w:data>B955A49F0050A3685610000832CF656E726600ACD9299200017B0102000000080000149F020000002B5B59617468616D2C2031393839202331323233393B20436F6C656C6C612C20313939322023323134315D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>159, 160, 161, 162</span></sup><!--[if gte mso 9]><xml>
     <w:data>C0AC548E0078A3685610000832CF656E726600ACD9299300017B1702000000120045187F02000000535B4261636B65726D616E2C203139393120233635303B20416E646572736F6E2C203139383920233432313B205269636B656C732C20313938392023393435343B20436F686E2C20313938392023323133325D000000</w:data>
    </xml><![endif]--></span> <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>159, 161</span></sup><!--[if gte mso 9]><xml>
     <w:data>A61D59090053A3685610000832CF656E726600ACD9299300017B2D0200000008000010FF020000002E5B5269636B656C732C2020313938392023393435343B204261636B65726D616E2C20203139393120233635305D000000</w:data>
    </xml><![endif]--></span>. In all <span class=GramE>studies</span>
    buspirone was very promising. Possible applications of aggression<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>research</span> in
    man,<span style='mso-spacerun:yes'>  </span>relate to psychogeriatric
    patients <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>20</span></sup><!--[if gte mso 9]><xml>
     <w:data>D51E87D60039A3685610000832CF656E726600ACD9299400017B4502000000020000005202000000145B4E657070652C20313939332023383235385D000000</w:data>
    </xml><![endif]--></span>], <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>163, 164, 165</span></sup><!--[if gte mso 9]><xml>
     <w:data>DE187BD80065A3685610000832CF656E726600ACD9299400017B5B020000000D00025A5102000000405B423A6F686D2C203139393020233632383B2053616B617579652C20313939332023393835383B205363686E65696465722C2031393933202331303130345D000000</w:data>
    </xml><![endif]--></span> the personality disordered people and people with
    frustration leading to aggression. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>125</span></sup><!--[if gte mso 9]><xml>
     <w:data>97A2BB5B003BA3685610000832CF656E726600ACD9299400017B7102000000030000008102000000165B436F636361726F2C20313939302023323039335D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u><o:p><span style='text-decoration:
     none'>&nbsp;</span></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>OUR STUDIES<o:p></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>I
    will also now contribute our small open pilot data in this regard using
    several cohorts. The data is preliminary with the typical limitations of
    real clinical patients. It <span class=GramE>should consequently be interpreted</span>
    with caution. However<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>several</span> new elements are important involving buspirone
    applications in the this out-of-labeling context<span
    style='mso-spacerun:yes'>  </span>.</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>1.
    use in a non-organic sample <i style='mso-bidi-font-style:normal'>in low
    doses</i><span style='mso-spacerun:yes'>  </span>(Cohort 1 and part of
    Cohort 3)</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>2.
    use in a manic-like sample (Cohort 2) and mania and other conditions (part
    of Cohort 3) <i style='mso-bidi-font-style:normal'>in high doses</i><span
    style='mso-spacerun:yes'>  </span>suggesting bimodal dosage</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>3.
    use in a temporal lobe dysfunction subgroup with carbamazepine<span
    style='mso-spacerun:yes'>  </span>.(Cohort 4)</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>None
    of these cohorts overlap<span style='mso-spacerun:yes'>  </span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'>Sample </b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>We
    evaluated the efficacy of buspirone in the management of in - and out-
    patients referred with main complaints of <span class=GramE>or<span
    style='mso-spacerun:yes'>  </span>with</span> major problems of aggression.
    Our study involved an open trial of buspirone to inpatients or outpatients
    referred for a variety of reasons<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>but</span> with a very major part of
    their presentation being aggression,<span style='mso-spacerun:yes'> 
    </span>irritability or violence as main complaints. These patients
    generally had little or no clinically significant anxiety (to distinguish
    the anxiety component of treatment).<span style='mso-spacerun:yes'> 
    </span>Because buspirone is marketed for generalized anxiety disorder (GAD)
    and this condition frequently has frustration and consequent irritability<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>we</span> excluded all
    patients specifically labeled as having GAD to definitely separate the two
    conditions.<span style='mso-spacerun:yes'>  </span>We included all
    successive referrals with aggression <span class=GramE>who</span> had been
    placed onto buspirone. We also included a small subpopulation of patients
    going into or coming out of a manic episode who were <span class=GramE>irritable<span
    style='mso-spacerun:yes'>  </span>.</span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-spacerun:yes'>  </span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>Cohort 1 :<span
    style='mso-spacerun:yes'>  </span>Short -term inpatients on low dose
    buspirone</u> </b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-spacerun:yes'> </span><span style='mso-tab-count:1'>           </span>These
    patients were given <i style='mso-bidi-font-style:normal'>low <span
    class=GramE>doses<span style='font-style:normal'><span
    style='mso-spacerun:yes'>  </span>of</span></span></i> buspirone,<span
    style='mso-spacerun:yes'>  </span>generally of the order of 15-25 mg per
    day.<span style='mso-spacerun:yes'>  </span>Our cohort is of nine such
    successive inpatients. Several of these were intractable and varied from
    being on no ancillary medication to other medications<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>for</span> example carbamazepine or
    fluoxetine. This study evaluated only short-term improvements for practical
    reasons:<span style='mso-spacerun:yes'>  </span>changes at the end of
    hospitalization or first follow-up.<span style='mso-spacerun:yes'> 
    </span>At the dose given (15mg to 25mg per day),<span
    style='mso-spacerun:yes'>  </span>all 9 subjects ( mean age : 29±11 years ;
    8 males ) exhibited some improvement both globally using clinical global
    assessments of change,<span style='mso-spacerun:yes'>   </span>and also
    specifically on hostility rankings based on a 0-6 ordinal ranking of the
    Kay criteria for the Brief Psychiatric Rating Scale (BPRS) (Table 1).<span
    style='mso-spacerun:yes'>  </span>The improvements ranged from slight in
    one (the <span class=GramE>female )</span>,<span style='mso-spacerun:yes'> 
    </span>moderate in two,<span style='mso-spacerun:yes'>  </span>and
    substantial in the rest. Using the ordinal scale of range 1{slight} through
    6 {very marked}<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>the</span><span style='mso-spacerun:yes'>  </span>mode was 4,<span
    style='mso-spacerun:yes'>   </span>and the median was 3.<span
    style='mso-spacerun:yes'>  </span>Using <span class=GramE>a<span
    style='mso-spacerun:yes'>  </span>binomial</span> ranking of improved vs
    not improved,<span style='mso-spacerun:yes'>  </span>these results are
    significant at the p&lt;0<span style='mso-spacerun:yes'>  </span>.001
    level. Response generally took about 4-5 days to be most overt although
    patients continued to note greater improvements.<span
    style='mso-spacerun:yes'>  </span>The biggest difficulty is interpreting
    the data clinically in the absence of controls - many inpatients improve with
    milieu and re-evaluating these patients retrospectively,<span
    style='mso-spacerun:yes'>  </span>we could have predicted that as many as
    five of the nine would have improved without the buspirone intervention.
    Because of this the Clinical Global Impressions Rankings (CGI) were <span
    class=GramE>useful :</span> the patients were generally severely ill
    initially and exhibited rankings of clinically relevant improvement on
    overall therapeutic efficacy with low side-effects and excellent efficacy
    index. (Table 1 )</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u><o:p><span style='text-decoration:
     none'>&nbsp;</span></o:p></u></b></p>
    <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u>TABLE 1<span
    style='mso-spacerun:yes'>    </span>CHANGES IN HOSTILITY AND GLOBAL
    RANKINGS </u></b><u><o:p></o:p></u></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
     style='border-collapse:collapse;border:none;mso-border-alt:solid gray 1.5pt;
     mso-padding-alt:0in 4.0pt 0in 4.0pt;mso-border-insideh:.75pt solid gray;
     mso-border-insidev:.75pt solid gray'>
     <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;page-break-inside:avoid;
      height:30.0pt'>
      <td width=53 valign=top style='width:40.0pt;border-top:1.5pt;border-left:
      1.5pt;border-bottom:1.0pt;border-right:1.0pt;border-color:gray;
      border-style:solid;mso-border-top-alt:1.5pt;mso-border-left-alt:1.5pt;
      mso-border-bottom-alt:.75pt;mso-border-right-alt:.75pt;mso-border-color-alt:
      gray;mso-border-style-alt:solid;padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>N=9</p>
      <p class=MsoNormal>8 male</p>      </td>
      <td width=54 valign=top style='width:40.5pt;border-top:solid gray 1.5pt;
      border-left:none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-left-alt:solid gray .75pt;mso-border-alt:solid gray .75pt;
      mso-border-top-alt:solid gray 1.5pt;padding:0in 4.0pt 0in 4.0pt;
      height:30.0pt'>
      <p class=MsoNormal>Age in</p>
      <p class=MsoNormal>Years</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:solid gray 1.5pt;
      border-left:none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-left-alt:solid gray .75pt;mso-border-alt:solid gray .75pt;
      mso-border-top-alt:solid gray 1.5pt;padding:0in 4.0pt 0in 4.0pt;
      height:30.0pt'>
      <p class=MsoNormal>CGI<sup>1</sup><span style='mso-spacerun:yes'> 
      </span></p>
      <p class=MsoNormal>Ranking</p>      </td>
      <td width=72 valign=top style='width:.75in;border-top:solid gray 1.5pt;
      border-left:none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-left-alt:solid gray .75pt;mso-border-alt:solid gray .75pt;
      mso-border-top-alt:solid gray 1.5pt;padding:0in 4.0pt 0in 4.0pt;
      height:30.0pt'>
      <p class=MsoNormal>Begin</p>
      <p class=MsoNormal>Hostility<sup>2</sup></p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:solid gray 1.5pt;
      border-left:none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-left-alt:solid gray .75pt;mso-border-alt:solid gray .75pt;
      mso-border-top-alt:solid gray 1.5pt;padding:0in 4.0pt 0in 4.0pt;
      height:30.0pt'>
      <p class=MsoNormal>End</p>
      <p class=MsoNormal>Hostility</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:solid gray 1.5pt;
      border-left:none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-left-alt:solid gray .75pt;mso-border-alt:solid gray .75pt;
      mso-border-top-alt:solid gray 1.5pt;padding:0in 4.0pt 0in 4.0pt;
      height:30.0pt'>
      <p class=MsoNormal>Change in</p>
      <p class=MsoNormal>Hostility *</p>      </td>
      <td width=96 valign=top style='width:1.0in;border-top:solid gray 1.5pt;
      border-left:none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-left-alt:solid gray .75pt;mso-border-alt:solid gray .75pt;
      mso-border-top-alt:solid gray 1.5pt;padding:0in 4.0pt 0in 4.0pt;
      height:30.0pt'>
      <p class=MsoNormal><span style='font-size:10.0pt'>Improvement degree on
      CGI </span><sup><span style='font-size:14.0pt;mso-bidi-font-size:10.0pt'>3</span></sup><span
      style='font-size:10.0pt'><o:p></o:p></span></p>      </td>
      <td width=72 valign=top style='width:.75in;border-top:solid gray 1.5pt;
      border-left:none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-left-alt:solid gray .75pt;mso-border-alt:solid gray .75pt;
      mso-border-top-alt:solid gray 1.5pt;padding:0in 4.0pt 0in 4.0pt;
      height:30.0pt'>
      <p class=MsoNormal><span style='font-size:10.0pt'>Therapeutic<span
      style='mso-spacerun:yes'>  </span>Efficacy</span><sup><span
      style='font-size:14.0pt;mso-bidi-font-size:10.0pt'>4</span></sup><span
      style='font-size:10.0pt'><o:p></o:p></span></p>      </td>
      <td width=62 valign=top style='width:46.6pt;border-top:solid gray 1.5pt;
      border-left:none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-left-alt:solid gray .75pt;mso-border-alt:solid gray .75pt;
      mso-border-top-alt:solid gray 1.5pt;padding:0in 4.0pt 0in 4.0pt;
      height:30.0pt'>
      <p class=MsoNormal>Side </p>
      <p class=MsoNormal>Effects<sup>5</sup></p>      </td>
      <td width=58 valign=top style='width:43.4pt;border-top:solid gray 1.5pt;
      border-left:none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.5pt;
      mso-border-left-alt:solid gray .75pt;mso-border-top-alt:1.5pt;mso-border-left-alt:
      .75pt;mso-border-bottom-alt:.75pt;mso-border-right-alt:1.5pt;mso-border-color-alt:
      gray;mso-border-style-alt:solid;padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal><span style='font-size:10.0pt'>Efficacy Index</span><sup><span
      style='font-size:14.0pt;mso-bidi-font-size:10.0pt'>6</span></sup></p>      </td>
     </tr>
     <tr style='mso-yfti-irow:1;page-break-inside:avoid;height:30.0pt'>
      <td width=53 valign=top style='width:40.0pt;border-top:none;border-left:
      solid gray 1.5pt;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-alt:solid gray .75pt;
      mso-border-left-alt:solid gray 1.5pt;padding:0in 4.0pt 0in 4.0pt;
      height:30.0pt'>
      <p class=MsoNormal>Mean</p>      </td>
      <td width=54 valign=top style='width:40.5pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>29</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>4<span style='mso-spacerun:yes'>  </span>.3</p>      </td>
      <td width=72 valign=top style='width:.75in;border-top:none;border-left:
      none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>4<span style='mso-spacerun:yes'>  </span>.7</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.4</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>3<span style='mso-spacerun:yes'>  </span>.2</p>      </td>
      <td width=96 valign=top style='width:1.0in;border-top:none;border-left:
      none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>2<span style='mso-spacerun:yes'>  </span>.0</p>      </td>
      <td width=72 valign=top style='width:.75in;border-top:none;border-left:
      none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.8</p>      </td>
      <td width=62 valign=top style='width:46.6pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.2</p>      </td>
      <td width=58 valign=top style='width:43.4pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.0pt;border-right:solid gray 1.5pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;mso-border-right-alt:solid gray 1.5pt;
      padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>2<span style='mso-spacerun:yes'>  </span>.0</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:2;mso-yfti-lastrow:yes;page-break-inside:avoid;
      height:30.0pt'>
      <td width=53 valign=top style='width:40.0pt;border-top:none;border-left:
      solid gray 1.5pt;border-bottom:solid gray 1.5pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-top-alt:.75pt;mso-border-left-alt:
      1.5pt;mso-border-bottom-alt:1.5pt;mso-border-right-alt:.75pt;mso-border-color-alt:
      gray;mso-border-style-alt:solid;padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>SD</p>      </td>
      <td width=54 valign=top style='width:40.5pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.5pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;mso-border-bottom-alt:solid gray 1.5pt;
      padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>11</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.5pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;mso-border-bottom-alt:solid gray 1.5pt;
      padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.7</p>      </td>
      <td width=72 valign=top style='width:.75in;border-top:none;border-left:
      none;border-bottom:solid gray 1.5pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;mso-border-bottom-alt:solid gray 1.5pt;
      padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.7</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.5pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;mso-border-bottom-alt:solid gray 1.5pt;
      padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.5</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.5pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;mso-border-bottom-alt:solid gray 1.5pt;
      padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.5</p>      </td>
      <td width=96 valign=top style='width:1.0in;border-top:none;border-left:
      none;border-bottom:solid gray 1.5pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;mso-border-bottom-alt:solid gray 1.5pt;
      padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.7</p>      </td>
      <td width=72 valign=top style='width:.75in;border-top:none;border-left:
      none;border-bottom:solid gray 1.5pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;mso-border-bottom-alt:solid gray 1.5pt;
      padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.7</p>      </td>
      <td width=62 valign=top style='width:46.6pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.5pt;border-right:solid gray 1.0pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      mso-border-alt:solid gray .75pt;mso-border-bottom-alt:solid gray 1.5pt;
      padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.7</p>      </td>
      <td width=58 valign=top style='width:43.4pt;border-top:none;border-left:
      none;border-bottom:solid gray 1.5pt;border-right:solid gray 1.5pt;
      mso-border-top-alt:solid gray .75pt;mso-border-left-alt:solid gray .75pt;
      padding:0in 4.0pt 0in 4.0pt;height:30.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.2</p>      </td>
     </tr>
    </table>
    <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
    mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>
    <p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .75pt;
    padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><span
    style='font-size:10.0pt'>1: CGI range 1 (<span class=GramE>normal )</span>
    to 7<span style='mso-spacerun:yes'>  </span>.<o:p></o:p></span></p>
    <p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .75pt;
    padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><span
    style='font-size:10.0pt'>2: Hostility<span style='mso-spacerun:yes'> 
    </span>based on 0-6 ordinal ranking (6 = most severe Kay criteria of
    BPRS<span style='mso-spacerun:yes'>  </span>(*:<span
    style='mso-spacerun:yes'>  </span>p &lt; 0<span style='mso-spacerun:yes'> 
    </span>.001 using a binomial)<o:p></o:p></span></p>
    <p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .75pt;
    padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><span
    style='font-size:10.0pt'>3: Improvement (1= much; 4= nil ; 7= worse )<o:p></o:p></span></p>
    <p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .75pt;
    padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><span
    style='font-size:10.0pt'>4: Lower the Therapeutic Efficacy the better
    {0-3}, <o:p></o:p></span></p>
    <p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .75pt;
    padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><span
    style='font-size:10.0pt'>5: Side-<span class=GramE>effects{</span>1-4} with
    1 being the absence<span style='mso-spacerun:yes'>  </span>.<o:p></o:p></span></p>
    <p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .75pt;
    padding:0in;mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt'><span
    style='font-size:10.0pt'>6:<span style='mso-spacerun:yes'>  </span>Efficacy
    Index; lower<span style='mso-spacerun:yes'>  </span>the better {1-7}</span></p>
    </div>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>Cohort 2 : High dose buspirone for
    manic irritability and confrontation</u></b></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-spacerun:yes'> </span><span style='mso-tab-count:1'>           </span>We
    have examined another cohort of twelve patients both inpatient and
    outpatient who have been receiving high doses of buspirone,<span
    style='mso-spacerun:yes'>  </span>approximately 60-160 mg per day of
    buspirone,<span style='mso-spacerun:yes'>  </span>for profound irritability
    linked with a manic like state. This group had associated marked agitation<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>restlessness</span>,<span
    style='mso-spacerun:yes'>  </span>anger,<span style='mso-spacerun:yes'> 
    </span>lability of mood and confrontation with enormous potential for
    tolerating high doses of medication. These patients were all exceptional:
    they were not typical manics who would respond to lithium<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>carbamazepine</span> or valproate alone
    or combinations of these.<span style='mso-spacerun:yes'>  </span>Buspirone
    was initiated outside labeling but on solid clinical grounds where <span
    class=GramE>lithium or neuroleptics</span> or benzodiazepines were
    contraindicated or where we did not want to escalate the doses of these drugs.<span
    style='mso-spacerun:yes'>  </span>Sometimes buspirone treatment was
    initiated coming out of the manic phase: for example<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>when</span> a patient had been lithium
    toxic and we did not want sedation. At times patients received the
    buspirone early in the manic like phase - for example<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>a</span> patient with AIDS involving the
    brain and ostensible organic brain disorder associated with manic features.
    Others received it during their manic episode:<span
    style='mso-spacerun:yes'>  </span>these patients had sometimes been
    routinely sedated<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>with</span> neuroleptics and/ or with benzodiazepines, <span
    style='mso-spacerun:yes'> </span>but for clinical reasons,<span
    style='mso-spacerun:yes'>  </span>we did not want to continue the
    sedation.<span style='mso-spacerun:yes'>  </span>As the mania began to
    improve a little<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>they</span> remained extraordinarily irritable,<span
    style='mso-spacerun:yes'>  </span>angry and hostile,<span
    style='mso-spacerun:yes'>  </span>pacing and agitated. </p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>All
    patients were generally begun directly on 60 mg of buspirone a day<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>20</span> mg t.i.d.
    All twelve improved on short-term follow up over days<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>generally</span> markedly.<span
    style='mso-spacerun:yes'>  </span>Improvements <span class=GramE>were noted</span>
    within twelve to 24 hours. The agitation and confrontation would improve
    markedly<span class=GramE>,<span style='mso-spacerun:yes'>  </span>however</span>,<span
    style='mso-spacerun:yes'>  </span>the psychotic features still required
    antipsychotics.<span style='mso-spacerun:yes'>  </span>Frequently<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>the</span> patients
    would report remarkable improvement in their sleep on the first night but
    this was not maintained and would require other interventions.<span
    style='mso-spacerun:yes'>  </span>Often<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>within</span> a day or two,<span
    style='mso-spacerun:yes'>  </span>they would complain of a tell-tale “non-vertiginous
    dizziness” which we used as a criterion for lowering dosage as they were no
    longer tolerating the higher dose.<span style='mso-spacerun:yes'> 
    </span>Some patients therefore received high dose buspirone for days and
    then required tapering generally when they became dizzy. The endpoint was
    frequently low dose buspirone -15mg per day.<span
    style='mso-spacerun:yes'>  </span>At least 3 patients<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>on</span> whom follow-up occurred within
    the system,<span style='mso-spacerun:yes'>  </span>were still taking
    buspirone in doses of 60mg per day or above several years later. With three
    exceptions of buspirone monotherapy<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>these</span> patients were on other
    therapies as well<span style='mso-spacerun:yes'>  </span>- lithium,<span
    style='mso-spacerun:yes'>  </span>valproate,<span
    style='mso-spacerun:yes'>  </span>carbamazepine,<span
    style='mso-spacerun:yes'>  </span>benzodiazepines,<span
    style='mso-spacerun:yes'>  </span>antidepressants and/ or neuroleptics<span
    style='mso-spacerun:yes'>  </span>.</p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span>As illustrations<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>our</span> first two
    cases had two similarities.<span style='mso-spacerun:yes'>  </span>In each
    instance<span class=GramE>,<span style='mso-spacerun:yes'>  </span>these</span>
    patients had been ill for many years and constituted the far end of
    severity for bipolar illness with chronic intractability. The families did
    not know what medications the patients had been on and in fact in each case<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>they</span> had
    encountered some difficulties with the patients' initial conditions.
    Spontaneously<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>they</span> both commented they had never seen these members of
    family so well,<span style='mso-spacerun:yes'>  </span>after a manic
    episode. Of the first twelve patients,<span style='mso-spacerun:yes'>  
    </span>four families have reported this amazement with response compared
    with previous episodes describing how the index patients <span class=GramE>were
    greatly improved</span> on the high dose buspirone. </p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span>We have seen three cases in
    which 60mg <span class=GramE>of<span style='mso-spacerun:yes'> 
    </span>buspirone</span> daily apparently markedly attenuated episodes of
    both depression and mania in patients who prior to that were intractably
    cycling despite the best known previous interventions including drugs such
    as lithium,<span style='mso-spacerun:yes'>  </span>carbamazepine,<span
    style='mso-spacerun:yes'>  </span>valproate,<span
    style='mso-spacerun:yes'>  </span>antidepressants and neuroleptics in
    varying combinations.<span style='mso-spacerun:yes'>  </span>In one <span
    class=GramE>case</span> the patient was controlled except for minor mood
    changes for three years<span style='mso-spacerun:yes'>   </span>She then
    went off the buspirone herself and relapsed.<span
    style='mso-spacerun:yes'>  </span>Could this imply a prophylactic effect of
    the drug in certain refractory bipolar illnesses<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>particularly</span> as their may be a
    pharmacologic justification - lithium has an effect on serotonin 1A? <span
    style='mso-spacerun:yes'> </span>Clearly<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>this</span> should be explored further -
    it may be that buspirone has prophylactic effects on bipolar disorder. </p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>Cohort 3 :<span
    style='mso-spacerun:yes'>  </span>Outpatients with buspirone for
    irritability<o:p></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>In
    conjunction with John Walenta (who analyzed data retrospectively)<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>we</span> have followed
    at the Pacific Neuropsychiatric Institute a group of adult non-organic
    patients (children are discussed separately <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>166</span></sup><!--[if gte mso 9]><xml>
     <w:data>1B8787E90042A3685610000832CF656E726600ACD9299500017B86020000000300000085020000001D5B4E657070652C203139393620696E2070726573732023383236335D000000</w:data>
    </xml><![endif]--></span> ) treated with buspirone for aggression.<span
    style='mso-spacerun:yes'>  </span>These patients had consented to allow
    their clinical data to <span class=GramE>be analyzed</span>.<span
    style='mso-spacerun:yes'>  </span>Follow ups were done based on their
    short-term response to buspirone (<span class=GramE>criterion :</span>
    their first two appointments after initiating buspirone,<span
    style='mso-spacerun:yes'>  </span>up to one month after start) and their
    last appointment ( very often current) while on buspirone.<span
    style='mso-spacerun:yes'>  </span>Their condition was ranked based on
    retrospective chart review using a five point ordinal scale <span
    class=GramE>( 2</span> being very much improved,<span
    style='mso-spacerun:yes'>   </span>0 being no change or equal<span
    style='mso-spacerun:yes'>  </span>features worse and better,<span
    style='mso-spacerun:yes'>   </span>and -2 being very much worse). The
    results are dramatic with 12 of <span class=GramE>13<span
    style='mso-spacerun:yes'>  </span>of</span> patients improving.<span
    style='mso-spacerun:yes'>  </span>Low dose <span class=GramE>response<span
    style='mso-spacerun:yes'>  </span>(</span>15-25mg per day ) as well as high
    dose response was excellent (&#8805; 50mg per day).<span
    style='mso-spacerun:yes'>  </span><span class=GramE>(Table 5).</span><span
    style='mso-spacerun:yes'>  </span>Our experience has been that <i
    style='mso-bidi-font-style:normal'>patients do better on lower doses of
    buspirone than mid-doses with regard to aggression<span
    style='mso-spacerun:yes'>   </span></i>but their anxiety and depression
    respond better at 30mg to 45 mg per day than 15mg per <span class=GramE>day<span
    style='mso-spacerun:yes'>  </span>.</span></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>A
    prototype example is of a <span class=GramE>patient<span
    style='mso-spacerun:yes'>  </span>in</span> his mid-thirties who was
    having,<span style='mso-spacerun:yes'>  </span>on average,<span
    style='mso-spacerun:yes'>  </span>four to five episodes a day<span
    style='mso-spacerun:yes'>  </span>of extreme aggression and anger which he
    found very difficult to control.<span style='mso-spacerun:yes'>  </span>The
    major precipitant was when vehicles would overtake him on the road<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>and</span> as he was a
    builder,<span style='mso-spacerun:yes'>  </span>he was involved in such
    episodes about three times per day as he drove several times per day. I
    have called this condition the <span class=GramE><i style='mso-bidi-font-style:
    normal'>West<span style='mso-spacerun:yes'>  </span>Coast</i></span><i
    style='mso-bidi-font-style:normal'><span style='mso-spacerun:yes'> 
    </span>Syndrome</i>.<span style='mso-spacerun:yes'>  </span>The patient
    charted his baseline episodes and then began on buspirone in doses of 15 mg
    per day.<span style='mso-spacerun:yes'>  </span>In the first week he had
    had two such episodes<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>and</span> then it dropped down to zero as the dose increased
    through 20 and 25 mg per day.<span style='mso-spacerun:yes'> 
    </span>However<span class=GramE>,<span style='mso-spacerun:yes'>  </span>by</span>
    the time he achieved 30 mg per day,<span style='mso-spacerun:yes'> 
    </span>he was recording again two episodes per week with equivalent
    stressors.<span style='mso-spacerun:yes'>  </span>We dropped him back and
    he <span class=GramE>has been stabilized</span> now for several years on 15
    mg per day.<span style='mso-spacerun:yes'>  </span>Follow-up is now the
    longest of any patient we have treated- nearly 6 years on buspirone.<span
    style='mso-spacerun:yes'>  </span>He's having no episodes of marked
    pathologic aggression<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>and</span> this is not only in the motoring context. His wife<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>who</span> had wanted
    to divorce him because she could not tolerate these,<span
    style='mso-spacerun:yes'>  </span>reports an enormous improvement as well.
    He irregularly becomes frustrated but well within normal range.<span
    style='mso-spacerun:yes'>  </span>He at one point<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>went</span> off the buspirone and was in
    remission for about a month,<span style='mso-spacerun:yes'>  </span>and
    then his symptoms began to return.<span style='mso-spacerun:yes'> 
    </span>Re-initiation of the drug produced the same dramatic improvement. This
    is the typical kind of case of a patient who does better on lower doses
    compared with higher doses of <span class=GramE>buspirone<span
    style='mso-spacerun:yes'>  </span>.</span></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>Table 2 : regular adults on
    buspirone for aggression</u></b></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
     style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .75pt;
     mso-padding-alt:0in 1.5pt 0in 1.5pt;mso-border-insideh:.75pt solid windowtext;
     mso-border-insidev:.75pt solid windowtext'>
     <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:13.0pt'>
      <td width=60 valign=top style='width:45.0pt;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>N=13<o:p></o:p></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>9M, 4F<o:p></o:p></b></p>      </td>
      <td width=44 valign=top style='width:33.0pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Age <o:p></o:p></span></b></p>      </td>
      <td width=72 valign=top style='width:.75in;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Frequency of dosing<o:p></o:p></span></b></p>      </td>
      <td width=42 valign=top style='width:31.5pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Dose in mg<o:p></o:p></span></b></p>      </td>
      <td width=59 valign=top style='width:44.25pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Other<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>medics<o:p></o:p></span></b></p>      </td>
      <td width=79 valign=top style='width:59.25pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Months on buspirone<o:p></o:p></span></b></p>      </td>
      <td width=68 valign=top style='width:51.0pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Early<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Response<o:p></o:p></span></b></p>      </td>
      <td width=76 valign=top style='width:57.0pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Later Behavioral Response<o:p></o:p></span></b></p>      </td>
      <td width=84 valign=top style='width:62.95pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Later<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Subjective<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Response<o:p></o:p></span></b></p>      </td>
     </tr>
     <tr style='mso-yfti-irow:1;height:13.0pt'>
      <td width=60 valign=top style='width:45.0pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>mean<o:p></o:p></b></p>      </td>
      <td width=44 valign=top style='width:33.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>39<span style='mso-spacerun:yes'>  </span>.5</p>      </td>
      <td width=72 valign=top style='width:.75in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>3<span style='mso-spacerun:yes'>  </span>.1</p>      </td>
      <td width=42 valign=top style='width:31.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>33<span style='mso-spacerun:yes'>  </span>.1</p>      </td>
      <td width=59 valign=top style='width:44.25pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.31</p>      </td>
      <td width=79 valign=top style='width:59.25pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>19<span style='mso-spacerun:yes'>  </span>.5</p>      </td>
      <td width=68 valign=top style='width:51.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.67</p>      </td>
      <td width=76 valign=top style='width:57.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.41</p>      </td>
      <td width=84 valign=top style='width:62.95pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><span style='mso-spacerun:yes'>  </span>.67</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:2;height:13.0pt'>
      <td width=60 valign=top style='width:45.0pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>SD<o:p></o:p></b></p>      </td>
      <td width=44 valign=top style='width:33.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>19<span style='mso-spacerun:yes'>  </span>.4</p>      </td>
      <td width=72 valign=top style='width:.75in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.28</p>      </td>
      <td width=42 valign=top style='width:31.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>25<span style='mso-spacerun:yes'>  </span>.9</p>      </td>
      <td width=59 valign=top style='width:44.25pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.18</p>      </td>
      <td width=79 valign=top style='width:59.25pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>14<span style='mso-spacerun:yes'>  </span>.33</p>      </td>
      <td width=68 valign=top style='width:51.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.49</p>      </td>
      <td width=76 valign=top style='width:57.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.31</p>      </td>
      <td width=84 valign=top style='width:62.95pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal style='tab-stops:39.5pt'><span
      style='mso-spacerun:yes'>  </span>.63</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:3;height:13.0pt'>
      <td width=60 valign=top style='width:45.0pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>median<o:p></o:p></b></p>      </td>
      <td width=44 valign=top style='width:33.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>37</p>      </td>
      <td width=72 valign=top style='width:.75in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>3</p>      </td>
      <td width=42 valign=top style='width:31.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>15</p>      </td>
      <td width=59 valign=top style='width:44.25pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1</p>      </td>
      <td width=79 valign=top style='width:59.25pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>18</p>      </td>
      <td width=68 valign=top style='width:51.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=76 valign=top style='width:57.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=84 valign=top style='width:62.95pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:4;height:13.0pt'>
      <td width=60 valign=top style='width:45.0pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>mode<o:p></o:p></b></p>      </td>
      <td width=44 valign=top style='width:33.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>19</p>      </td>
      <td width=72 valign=top style='width:.75in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>3</p>      </td>
      <td width=42 valign=top style='width:31.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>15</p>      </td>
      <td width=59 valign=top style='width:44.25pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=79 valign=top style='width:59.25pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=68 valign=top style='width:51.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=76 valign=top style='width:57.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=84 valign=top style='width:62.95pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>0</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes;height:13.0pt'>
      <td width=60 valign=top style='width:45.0pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>range<o:p></o:p></b></p>      </td>
      <td width=116 colspan=2 valign=top style='width:87.0pt;border-top:none;
      border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>17 to 78</p>      </td>
      <td width=42 valign=top style='width:31.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=59 valign=top style='width:44.25pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=79 valign=top style='width:59.25pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=68 valign=top style='width:51.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=76 valign=top style='width:57.0pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=84 valign=top style='width:62.95pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
     </tr>
    </table>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 1541.25pt'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>Cohort 4 :<span
    style='mso-spacerun:yes'>  </span>Buspirone and carbamazepine combination :
    special cases<o:p></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u><o:p><span style='text-decoration:
     none'>&nbsp;</span></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>Drugs
    such as carbamazepine have enormous potential in the management of episodic
    disorders particularly those linked with hostility. <span style='mso-field-code:
    " ADDIN ENRef "'><span class=GramE><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>167, 168</span></sup><!--[if gte mso 9]><xml>
     <w:data>C851C2AA004CA3685610000832CF656E726600ACD9299500017B9C02000000080000144102000000275B4E657070652C20313938362023383137393B204E657070652C20313939302023383233375D000000</w:data>
    </xml><![endif]--></span></span><span class=GramE>, <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>169,
    170, 171, 172</span></sup><!--[if gte mso 9]><xml>
     <w:data>FE38C0650079A3685610000832CF656E726600ACD9299500017BB302000000120044103902000000545B54756E6B732C2031393737202331313432373B2053756761726D616E2C2031393932202331313030373B20476172646E65722C20313938362023333831303B204C6577696E2C20313939322023363533375D000000</w:data>
    </xml><![endif]--></span>.</span> A subpopulation of patient exhibits
    features of a special kind of <span class=GramE>aggression which</span> is
    carbamazepine responsive and appears to not respond to buspirone
    alone.<span style='mso-spacerun:yes'>  </span>These patients have special
    episodes with explosive<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>uncontrolled</span>,<span style='mso-spacerun:yes'>  </span>poorly
    directed,<span style='mso-spacerun:yes'>  </span>limited precipitation kind
    of aggression with or without amnesia.<span style='mso-spacerun:yes'> 
    </span>These kinds of episodes on their own theoretically should not
    respond to buspirone as they are probably not modulated through serotonin
    1A but through episodic firing in the brain<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>possibly</span> the temporal lobes. </p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>These
    patients commonly have temporolimbic instability. This diagnosis is based
    on three key elements: </p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>1.
    History using subjective report measures such as the Inventory of Neppe of
    Symptoms of Epilepsy and the Temporal Lobe {<span class=GramE>INSET }where</span>
    they have several symptoms <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>173</span></sup><!--[if gte mso 9]><xml>
     <w:data>C2F487C90039A3685610000832CF656E726600ACD9299600017BC802000000030000009302000000145B4E657070652C20313939312023383234355D000000</w:data>
    </xml><![endif]--></span> .</p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>2.
    Examination including neurologic evaluation is often normal although higher
    brain function based on measures such as the BROCAS SCAN (Screening
    Cerebral Assessment of Neppe) <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>174</span></sup><!--[if gte mso 9]><xml>
     <w:data>C6D787C70039A3685610000832CF656E726600ACD9299600017BDC02000000030000008F02000000145B4E657070652C20313939322023383235315D000000</w:data>
    </xml><![endif]--></span> sometimes suggests compromise of frontal or
    parietal lobes and soft neurologic <span class=GramE>features<span
    style='mso-spacerun:yes'>  </span>.</span></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>3.<span
    style='mso-spacerun:yes'>  </span>Finally,<span style='mso-spacerun:yes'> 
    </span>a temporal lobe focus or paroxysmal firing is sometimes present on
    electroencephalography<span style='mso-spacerun:yes'>  </span>(routine wake
    and sleep EEGs with photic stimulation and hyperventilation ; or more
    sophisticatedly an important new technique of 48 hour, 18 channel home
    ambulatory computerized electroencephalography monitoring). <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>175</span></sup><!--[if gte mso 9]><xml>
     <w:data>9E32544F003DA3685610000832CF656E726600ACD9299600017BF002000000030000008B02000000185B5765696C627572672C2031393933202331313837365D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>176, 177, 178, 179</span></sup><!--[if gte mso 9]><xml>
     <w:data>65DCC9C5007DA3685610000832CF656E726600ACD9299700017C0C02000000120052838702000000585B5765696C627572672C2031393935202331313837373B204D6F727269732C20313939342023373735343B205661726E65792C2031393932202331313538383B20426561757265676172642C203139393120233838355D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>Many
    patients in this major subgroup have coarse neurobehavioral symptoms for
    which carbamazepine not buspirone is prescribed, <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>180,
    181</span></sup><!--[if gte mso 9]><xml>
     <w:data>EA083E18004CA3685610000832CF656E726600ACD9299700017C1F02000000080000134102000000275B4E657070652C20313938382023383139373B204E657070652C20313938392023383232365D000000</w:data>
    </xml><![endif]--></span> possibly qualify for diagnoses of intermittent
    explosive disorder,<span style='mso-spacerun:yes'>  </span>but are more
    correctly labeled paroxysmal neurobehavioral disorder * and are
    carbamazepine responsive. They do not require adjunctive buspirone. A
    special group,<span style='mso-spacerun:yes'>  </span>however,<span
    style='mso-spacerun:yes'>  </span>do : </p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>These
    patients frequently have added frustration and irritability and build up of
    <span class=GramE>distress which</span> they can control. The carbamazepine
    alone does not seem to help these features<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>but</span> the buspirone does.
    Consequently<span class=GramE>,<span style='mso-spacerun:yes'>  </span>we</span>
    have a cohort of patients on the combination of carbamazepine (always as
    Tegretol generally 600mg per day or titrated to serum levels of about 6-9
    ug per liter) and buspirone (variably low dose or high dose).<span
    style='mso-spacerun:yes'>  </span>These patients have responded well
    subjectively to the combination in 10 out of 12 cases (and behaviorally in
    11 or 12<span class=GramE>)<span style='mso-spacerun:yes'> 
    </span>continuing</span> the treatment. However<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>8</span> patients discontinued on the CBZ
    so the overall combination responsiveness was 10 out of 20 although all 8
    dropouts improved on the buspirone.<span style='mso-spacerun:yes'> 
    </span>Of <span class=GramE>the<span style='mso-spacerun:yes'>  </span>20</span>
    patients,<span style='mso-spacerun:yes'>  </span>2 were on carbamazepine
    for classical seizure phenomena with loss of consciousness not
    dyscontrol,<span style='mso-spacerun:yes'>  </span>and 9 others exhibited
    no dyscontrol features and were on the carbamazepine for other reasons -
    temporal lobe symptomatology or affective illness. It is relevant to
    mention that in no instances did buspirone directly impact on dyscontrol
    behavior when present,<span style='mso-spacerun:yes'>  </span>however,<span
    style='mso-spacerun:yes'>  </span>in the 18 of 20<span
    style='mso-spacerun:yes'>  </span>instances where buspirone helped the
    irritability-frustration continuum,<span style='mso-spacerun:yes'> 
    </span>our impression was that the patients would report less dyscontrol
    when present,<span style='mso-spacerun:yes'>  </span>but we have not
    specifically kept such data.<span style='mso-spacerun:yes'>  </span>In 3
    cases<span class=GramE>,<span style='mso-spacerun:yes'>  </span>the</span>
    carbamazepine<span style='mso-spacerun:yes'>  </span>was initiated
    first,<span style='mso-spacerun:yes'>  </span>and because of the distortion
    of this sample,<span style='mso-spacerun:yes'>  </span>by definition,<span
    style='mso-spacerun:yes'>  </span>none responded dramatically otherwise
    this would not be necessitating the buspirone. Once the combination was
    used but 12 improved and 8 remained the same or deteriorated requiring
    discontinuation of the carbamazepine <span class=GramE>( 5</span> of them
    took other anticonvulsants instead of carbamazepine and of these 4 have
    remained on either valproate or phenytoin. ). Longest follow-up has been
    four and a half years on the combination. (Table 4 reflects months on
    buspirone<span class=GramE>)<span style='mso-spacerun:yes'>  </span>.</span></p>
    <p class=MsoNormal style='margin-right:7.1pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>Table 3: Buspirone and carbamazepine
    combination<o:p></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
     style='margin-left:6.0pt;border-collapse:collapse;border:none;mso-border-alt:
     solid windowtext .75pt;mso-padding-alt:0in 1.5pt 0in 1.5pt;mso-border-insideh:
     .75pt solid windowtext;mso-border-insidev:.75pt solid windowtext'>
     <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:13.0pt'>
      <td width=66 valign=top style='width:49.5pt;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>N=14;<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>10M,<span style='mso-spacerun:yes'>  </span>4F <o:p></o:p></span></b></p>      </td>
      <td width=37 valign=top style='width:27.95pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Age <o:p></o:p></span></b></p>      </td>
      <td width=71 valign=top style='width:53.05pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Frequency of dosing<o:p></o:p></span></b></p>      </td>
      <td width=48 valign=top style='width:.5in;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Dose in mg<o:p></o:p></span></b></p>      </td>
      <td width=54 valign=top style='width:40.5pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Other<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>medics*<o:p></o:p></span></b></p>      </td>
      <td width=78 valign=top style='width:58.5pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Months on buspirone<o:p></o:p></span></b></p>      </td>
      <td width=66 valign=top style='width:49.5pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Early<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Response<o:p></o:p></span></b></p>      </td>
      <td width=78 valign=top style='width:58.5pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Later Behavioral Response<o:p></o:p></span></b></p>      </td>
      <td width=96 valign=top style='width:1.0in;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Later<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Subjective<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Response<o:p></o:p></span></b></p>      </td>
     </tr>
     <tr style='mso-yfti-irow:1;height:13.0pt'>
      <td width=66 valign=top style='width:49.5pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>mean<o:p></o:p></b></p>      </td>
      <td width=37 valign=top style='width:27.95pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>33<span style='mso-spacerun:yes'>  </span>.7</p>      </td>
      <td width=71 valign=top style='width:53.05pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>3</p>      </td>
      <td width=48 valign=top style='width:.5in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>47<span style='mso-spacerun:yes'>  </span>.9</p>      </td>
      <td width=54 valign=top style='width:40.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2<span style='mso-spacerun:yes'>  </span>.71</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>22<span style='mso-spacerun:yes'>  </span>.43</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.86</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.85</p>      </td>
      <td width=96 valign=top style='width:1.0in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.53</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:2;height:13.0pt'>
      <td width=66 valign=top style='width:49.5pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>SD<o:p></o:p></b></p>      </td>
      <td width=37 valign=top style='width:27.95pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>14<span style='mso-spacerun:yes'>  </span>.3</p>      </td>
      <td width=71 valign=top style='width:53.05pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.39</p>      </td>
      <td width=48 valign=top style='width:.5in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>37<span style='mso-spacerun:yes'>  </span>.3</p>      </td>
      <td width=54 valign=top style='width:40.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.59</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>14<span style='mso-spacerun:yes'>  </span>.22</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.36</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><span style='mso-spacerun:yes'>  </span>.67</p>      </td>
      <td width=96 valign=top style='width:1.0in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><span style='mso-spacerun:yes'>  </span>.77</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:3;height:13.0pt'>
      <td width=66 valign=top style='width:49.5pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>median<o:p></o:p></b></p>      </td>
      <td width=37 valign=top style='width:27.95pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>34</p>      </td>
      <td width=71 valign=top style='width:53.05pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>3</p>      </td>
      <td width=48 valign=top style='width:.5in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>30</p>      </td>
      <td width=54 valign=top style='width:40.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2<span style='mso-spacerun:yes'>  </span>.5</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>22<span style='mso-spacerun:yes'>  </span>.5</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=96 valign=top style='width:1.0in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:4;height:13.0pt'>
      <td width=66 valign=top style='width:49.5pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>mode<o:p></o:p></b></p>      </td>
      <td width=37 valign=top style='width:27.95pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>-</p>      </td>
      <td width=71 valign=top style='width:53.05pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>3</p>      </td>
      <td width=48 valign=top style='width:.5in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>75</p>      </td>
      <td width=54 valign=top style='width:40.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>4</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>32</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=96 valign=top style='width:1.0in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes;height:13.0pt'>
      <td width=66 valign=top style='width:49.5pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>range<o:p></o:p></b></p>      </td>
      <td width=108 colspan=2 valign=top style='width:81.0pt;border-top:none;
      border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>12 to 57 </p>      </td>
      <td width=48 valign=top style='width:.5in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=54 valign=top style='width:40.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=96 valign=top style='width:1.0in;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
     </tr>
    </table>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>*
    this refers to other prescription medications besides the buspirone taking
    concomitantly</p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u><o:p><span style='text-decoration:
     none'>&nbsp;</span></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>Table 4: Carbamazepine dropouts on
    buspirone</u></b></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
     style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .75pt;
     mso-padding-alt:0in 1.5pt 0in 1.5pt;mso-border-insideh:.75pt solid windowtext;
     mso-border-insidev:.75pt solid windowtext'>
     <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:13.0pt'>
      <td width=80 valign=top style='width:60.0pt;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>N=8<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>4M,<span style='mso-spacerun:yes'>  </span>4F<o:p></o:p></span></b></p>      </td>
      <td width=49 valign=top style='width:36.6pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Age <o:p></o:p></span></b></p>      </td>
      <td width=77 valign=top style='width:57.9pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Frequency of dosing<o:p></o:p></span></b></p>      </td>
      <td width=42 valign=top style='width:31.5pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Dose in mg<o:p></o:p></span></b></p>      </td>
      <td width=54 valign=top style='width:40.6pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Other<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>medics<o:p></o:p></span></b></p>      </td>
      <td width=84 valign=top style='width:62.9pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Months on buspirone<o:p></o:p></span></b></p>      </td>
      <td width=66 valign=top style='width:49.5pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Early<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Response<o:p></o:p></span></b></p>      </td>
      <td width=78 valign=top style='width:58.5pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Later Behavioral Response<o:p></o:p></span></b></p>      </td>
      <td width=78 valign=top style='width:58.6pt;border:solid windowtext 1.0pt;
      border-left:none;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Later<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Subjective<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.0pt'>Response<o:p></o:p></span></b></p>      </td>
     </tr>
     <tr style='mso-yfti-irow:1;height:13.0pt'>
      <td width=80 valign=top style='width:60.0pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>mean<o:p></o:p></b></p>      </td>
      <td width=49 valign=top style='width:36.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>43<span style='mso-spacerun:yes'>  </span>.8</p>      </td>
      <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>3</p>      </td>
      <td width=42 valign=top style='width:31.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>36<span style='mso-spacerun:yes'>  </span>.3</p>      </td>
      <td width=54 valign=top style='width:40.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.88</p>      </td>
      <td width=84 valign=top style='width:62.9pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>19<span style='mso-spacerun:yes'>  </span>.5</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><span style='mso-spacerun:yes'>  </span>.75</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.58</p>      </td>
      <td width=78 valign=top style='width:58.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1<span style='mso-spacerun:yes'>  </span>.58</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:2;height:13.0pt'>
      <td width=80 valign=top style='width:60.0pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>SD<o:p></o:p></b></p>      </td>
      <td width=49 valign=top style='width:36.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>13<span style='mso-spacerun:yes'>  </span>.5</p>      </td>
      <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>0</p>      </td>
      <td width=42 valign=top style='width:31.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>23</p>      </td>
      <td width=54 valign=top style='width:40.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.84</p>      </td>
      <td width=84 valign=top style='width:62.9pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>14<span style='mso-spacerun:yes'>  </span>.33</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.89</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.53</p>      </td>
      <td width=78 valign=top style='width:58.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>0<span style='mso-spacerun:yes'>  </span>.53</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:3;height:13.0pt'>
      <td width=80 valign=top style='width:60.0pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>median<o:p></o:p></b></p>      </td>
      <td width=49 valign=top style='width:36.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>42<span style='mso-spacerun:yes'>  </span>.5</p>      </td>
      <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>3</p>      </td>
      <td width=42 valign=top style='width:31.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>32<span style='mso-spacerun:yes'>  </span>.5</p>      </td>
      <td width=54 valign=top style='width:40.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=84 valign=top style='width:62.9pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>18</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=78 valign=top style='width:58.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:4;height:13.0pt'>
      <td width=80 valign=top style='width:60.0pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>mode<o:p></o:p></b></p>      </td>
      <td width=49 valign=top style='width:36.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal style='tab-stops:1541.25pt'>-</p>      </td>
      <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>3</p>      </td>
      <td width=42 valign=top style='width:31.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>15</p>      </td>
      <td width=54 valign=top style='width:40.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1</p>      </td>
      <td width=84 valign=top style='width:62.9pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>1</p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
      <td width=78 valign=top style='width:58.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>2</p>      </td>
     </tr>
     <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes;height:13.0pt'>
      <td width=80 valign=top style='width:60.0pt;border:solid windowtext 1.0pt;
      border-top:none;mso-border-top-alt:solid windowtext .75pt;mso-border-alt:
      solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;height:13.0pt'>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'>range<o:p></o:p></b></p>      </td>
      <td width=126 colspan=2 valign=top style='width:94.5pt;border-top:none;
      border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal>26 to 65</p>      </td>
      <td width=42 valign=top style='width:31.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=54 valign=top style='width:40.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=84 valign=top style='width:62.9pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=66 valign=top style='width:49.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
      <td width=78 valign=top style='width:58.6pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      mso-border-alt:solid windowtext .75pt;padding:0in 1.5pt 0in 1.5pt;
      height:13.0pt'>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>      </td>
     </tr>
    </table>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
    mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
    margin-left:0in;margin-right:-31.5pt'>
    <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
    border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
    1.0pt 1.0pt 1.0pt 1.0pt'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
    border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
    1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'><u>Table 5
    :<span style='mso-spacerun:yes'>  </span>Outpatient responsive to buspirone
    based on dosage<o:p></o:p></u></b></p>
    <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
    border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
    1.0pt 1.0pt 1.0pt 1.0pt'><u><o:p><span style='text-decoration:none'>&nbsp;</span></o:p></u></p>
    </div>
    <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
     style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .75pt;
     mso-padding-alt:0in 5.4pt 0in 5.4pt'>
     <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
      <td width=103 valign=top style='width:77.4pt;border-top:solid windowtext 1.0pt;
      border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;
      mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>Buspirone</b></p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;border-top:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>10-25mg/d<span
      style='mso-spacerun:yes'>  </span>bus<o:p></o:p></b></p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;border-top:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;border-top:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>30-55mg/day<o:p></o:p></b></p>
      </div>      </td>
      <td width=76 valign=top style='width:57.2pt;border:none;border-top:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;border-top:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>60-140mg/day
      <o:p></o:p></b></p>
      </div>      </td>
      <td width=138 valign=top style='width:103.5pt;border-top:solid windowtext 1.0pt;
      border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
      mso-border-top-alt:solid windowtext .75pt;mso-border-right-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>^^<o:p></o:p></b></p>
      </div>      </td>
     </tr>
     <tr style='mso-yfti-irow:1'>
      <td width=103 valign=top style='width:77.4pt;border:none;border-left:
      solid windowtext 1.0pt;mso-border-left-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><o:p>&nbsp;</o:p></p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>SIZE<o:p></o:p></b></p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>response<o:p></o:p></b></p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>SIZE<o:p></o:p></b></p>
      </div>      </td>
      <td width=76 valign=top style='width:57.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>response<o:p></o:p></b></p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>SIZE<o:p></o:p></b></p>
      </div>      </td>
      <td width=138 valign=top style='width:103.5pt;border:none;border-right:
      solid windowtext 1.0pt;mso-border-right-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>response<o:p></o:p></b></p>
      </div>      </td>
     </tr>
     <tr style='mso-yfti-irow:2'>
      <td width=103 valign=top style='width:77.4pt;border:none;border-left:
      solid windowtext 1.0pt;mso-border-left-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>Cohort 3</p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>9</p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>9</p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>0</p>
      </div>      </td>
      <td width=76 valign=top style='width:57.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>0</p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>4</p>
      </div>      </td>
      <td width=138 valign=top style='width:103.5pt;border:none;border-right:
      solid windowtext 1.0pt;mso-border-right-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>3</p>
      </div>      </td>
     </tr>
     <tr style='mso-yfti-irow:3'>
      <td width=103 valign=top style='width:77.4pt;border:none;border-left:
      solid windowtext 1.0pt;mso-border-left-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>CBZ+ BSP</p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>5</p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>5</p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>3</p>
      </div>      </td>
      <td width=76 valign=top style='width:57.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>3</p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>4</p>
      </div>      </td>
      <td width=138 valign=top style='width:103.5pt;border:none;border-right:
      solid windowtext 1.0pt;mso-border-right-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>3 (2 subjectively)</p>
      </div>      </td>
     </tr>
     <tr style='mso-yfti-irow:4'>
      <td width=103 valign=top style='width:77.4pt;border:none;border-left:
      solid windowtext 1.0pt;mso-border-left-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>CBZ dropouts</p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>4</p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>4</p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>0</p>
      </div>      </td>
      <td width=76 valign=top style='width:57.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>0</p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>4</p>
      </div>      </td>
      <td width=138 valign=top style='width:103.5pt;border:none;border-right:
      solid windowtext 1.0pt;mso-border-right-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>4</p>
      </div>      </td>
     </tr>
     <tr style='mso-yfti-irow:5'>
      <td width=103 valign=top style='width:77.4pt;border:none;border-left:
      solid windowtext 1.0pt;mso-border-left-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'># RESPOND^</p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><o:p>&nbsp;</o:p></p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>18</p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><o:p>&nbsp;</o:p></p>
      </div>      </td>
      <td width=76 valign=top style='width:57.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>3</p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><o:p>&nbsp;</o:p></p>
      </div>      </td>
      <td width=138 valign=top style='width:103.5pt;border:none;border-right:
      solid windowtext 1.0pt;mso-border-right-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>10 (9 subjectively)</p>
      </div>      </td>
     </tr>
     <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
      <td width=103 valign=top style='width:77.4pt;border-top:none;border-left:
      solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
      none;mso-border-left-alt:solid windowtext .75pt;mso-border-bottom-alt:
      solid windowtext .75pt;padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><b style='mso-bidi-font-weight:normal'>TOTALS</b></p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;border-bottom:
      solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>18</p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;border-bottom:
      solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><o:p>&nbsp;</o:p></p>
      </div>      </td>
      <td width=88 valign=top style='width:65.9pt;border:none;border-bottom:
      solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>3</p>
      </div>      </td>
      <td width=76 valign=top style='width:57.2pt;border:none;border-bottom:
      solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><o:p>&nbsp;</o:p></p>
      </div>      </td>
      <td width=96 valign=top style='width:1.0in;border:none;border-bottom:
      solid windowtext 1.0pt;mso-border-bottom-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'>12</p>
      </div>      </td>
      <td width=138 valign=top style='width:103.5pt;border-top:none;border-left:
      none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
      mso-border-bottom-alt:solid windowtext .75pt;mso-border-right-alt:solid windowtext .75pt;
      padding:0in 5.4pt 0in 5.4pt'>
      <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
      mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
      margin-left:0in;margin-right:-31.5pt'>
      <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
      border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
      1.0pt 1.0pt 1.0pt 1.0pt'><o:p>&nbsp;</o:p></p>
      </div>      </td>
     </tr>
    </table>
    <div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
    mso-border-alt:solid windowtext .75pt;padding:1.0pt 1.0pt 1.0pt 1.0pt;
    margin-left:0in;margin-right:2.6pt'>
    <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
    border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
    1.0pt 1.0pt 1.0pt 1.0pt'>^ responses based on yes or no for early and late
    patients identical except one less patient<span style='mso-spacerun:yes'> 
    </span>in CBZ+ BSP group assessed (new patient) in the late group and one
    less in high dose CBZ+BSP group (Cohort 4A) subjectively responded</p>
    <p class=MsoNormal style='tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in;
    border:none;mso-border-alt:solid windowtext .75pt;padding:0in;mso-padding-alt:
    1.0pt 1.0pt 1.0pt 1.0pt'>^^ a patient with aggression on 140mg / day for
    tardive dyskinesia</p>
    </div>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span><b style='mso-bidi-font-weight:
    normal'>Discussion</b> </p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>Our
    results are remarkable for how well patients seem to have done. These
    results <span class=GramE>are<span style='mso-spacerun:yes'>  </span>highly</span>
    preliminary although highly statistically significant because of the global
    response.<span style='mso-spacerun:yes'>  </span>However<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>this</span> was<span
    style='mso-spacerun:yes'>  </span>not unexpected given the special
    selection of the population. <span class=GramE>The sample of patients that
    present in an academic setting is specialized and does not reflect the
    general population.</span> In addition<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>in</span> the inpatients,<span
    style='mso-spacerun:yes'>  </span>their status in hospital compromised interpretation
    of the improvement as milieu or removal away from the stressors may have
    been the explanation. Moreover<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>our</span> outpatients<span
    style='mso-spacerun:yes'>  </span>were frequently highly motivated to get
    better. In addition<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>these</span> patients were very complex and they were often
    very<span style='mso-spacerun:yes'>  </span>ill at presentation,<span
    style='mso-spacerun:yes'>  </span>implying they had significant room to
    improve particularly in an environment where each patient was intensely
    evaluated and medication was very carefully chosen and adjusted for best
    fit at follow up.<span style='mso-spacerun:yes'>  </span>Additionally,<span
    style='mso-spacerun:yes'>   </span>in general<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>their</span> conditions necessitated
    polypharmacy (Tables 2, 3 and 4). The object was to help the patients and
    it is impossible to assess the contribution of each drug or the environment
    or therapeutic milieu. Many<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>if</span> not most patients given these
    criteria,<span style='mso-spacerun:yes'>  </span>will improve - and the
    particular sample is further distorted by those who chose to
    follow-up.<span style='mso-spacerun:yes'>  </span>In eleven cases<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>the</span> patients
    are not being followed up by us at this point ( six for geographic reasons
    or 4 because their primary physicians have taken them over and because she
    is subjectively so improved she deems it unnecessary. However,<span
    style='mso-spacerun:yes'>  </span>in reality,<span
    style='mso-spacerun:yes'>   </span>several of these patients may in
    fact,<span style='mso-spacerun:yes'>  </span>have not followed up with us
    because they are not doing well which further distorts the positive results
    which technically is overwhelmingly statistically significant for
    improvement (vs not improved ) as a group and also significant in each
    individual group.<span style='mso-spacerun:yes'>  </span>These factors
    emphasize the need for controlled prospective studies and the limitations
    of clinical data. Besides the above<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>the</span> operational criteria for entry
    into the analysis namely aggression,<span style='mso-spacerun:yes'> 
    </span>irritability and violence are suspect because they have been lumped
    together. Finally<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>the</span> methods of ranking are suspect because in general they
    were too global,<span style='mso-spacerun:yes'>  </span>and although based
    on detailed chart review a five point ordinal scoring of change either
    globally or on one criterion - aggression is simplistic and even
    inappropriate.<span style='mso-spacerun:yes'>  </span>On the other hand<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>the</span> results in
    4 different cohorts are consistent and encourage hypothesis testing.
    Nevertheless<span class=GramE>,<span style='mso-spacerun:yes'>  </span>the</span>
    <i style='mso-bidi-font-style:normal'>comments below should be perceived
    with a full realization of the inadequacies of this research. </i></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span>If the results can be replicated
    and are real<span class=GramE>,<span style='mso-spacerun:yes'> 
    </span>these</span> open pilot studies suggest that there may be two
    subpopulations of patient responsive to buspirone for aggression,<span
    style='mso-spacerun:yes'>  </span>irritability and impulsivity.<span
    style='mso-spacerun:yes'>  </span>Preliminarily,<span
    style='mso-spacerun:yes'>  </span>based on our experience,<span
    style='mso-spacerun:yes'>  </span>low dose buspirone therapy (10-25 mg per
    day usually) produces responsiveness in non-organic patients with high
    levels of frustration and /or<span style='mso-spacerun:yes'>  </span>high
    stress levels who have significant chronic irritability and impulsive
    directed acting out behavior with a range through from verbal to physical
    aggression.<span style='mso-spacerun:yes'>  </span>High doses of buspirone<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>generally</span>
    60-90mg per day,<span style='mso-spacerun:yes'>  </span>appear to act
    within hours,<span style='mso-spacerun:yes'>  </span>not within the days
    that low doses require,<span style='mso-spacerun:yes'>  </span>and to be
    associated with alleviation of the high level irritability and agitation of
    patients who are hypomanic and confronting.<span style='mso-spacerun:yes'> 
    </span>Very preliminarily and based on only limited clinical
    experience,<span style='mso-spacerun:yes'>  </span>high doses also might be
    logical when there has been limited low dose response,<span
    style='mso-spacerun:yes'>  </span>or when other diagnoses requiring higher
    doses of buspirone are present such as obsessive compulsive disorder or the
    marked agitation of the severe Alzheimer patient. </p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span><span class=GramE>In the<span
    style='mso-spacerun:yes'>  </span>two very preliminary open studies in
    which low doses such as 10-25 mg per day of buspirone appear to be very
    effective anti-aggressive agents in two different population cohorts,<span
    style='mso-spacerun:yes'>  </span>namely,<span style='mso-spacerun:yes'> 
    </span>mentally-retarded,<span style='mso-spacerun:yes'> 
    </span>brain-damaged,<span style='mso-spacerun:yes'>  </span>aggressive
    patients <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>148, 149</span></sup><!--[if gte mso 9]><xml>
     <w:data>F8DD6083004CA3685610000832CF656E726600ACD9299800017C3402000000080000147902000000275B52617465792C20313938392023393331333B2052617465792C20313939312023393331355D000000</w:data>
    </xml><![endif]--></span>,<span style='mso-spacerun:yes'>   </span>and my
    own study (Cohorts 1-4) with predominantly non-organic aggressive patients <span
    style='mso-field-code:" ADDIN ENRef "'><sup><span style='font-size:9.0pt;
    mso-bidi-font-size:10.0pt'>182</span></sup><!--[if gte mso 9]><xml>
     <w:data>4A89582D003AA3685610000832CF656E726600ACD9299800017C4A02000000030000008902000000155B4E657070652C2020313939332023383235365D000000</w:data>
    </xml><![endif]--></span>, <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>183</span></sup><!--[if gte mso 9]><xml>
     <w:data>40C9582F003AA3685610000832CF656E726600ACD9299800017C6102000000030000008D02000000155B4E657070652C2020313939332023383235375D000000</w:data>
    </xml><![endif]--></span> who did not have generalized anxiety disorder
    superimposed,<span style='mso-spacerun:yes'>   </span>as the dose increased
    to about 30mg per day,<span style='mso-spacerun:yes'>  </span>the
    anti-aggressive effects waned,<span style='mso-spacerun:yes'> 
    </span>although there remained some residual effect.</span> This low dose
    effect may correspond with a presynaptic autoreceptor serotonin 1A agonist
    firing with consequent diminished postsynaptic tone across all serotonin
    receptors. These presynaptic results are to some degree contradicted by our
    ADHD and aggression studies in children described in this issue and usually
    involving doses of 30mg per day of buspirone. <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>166</span></sup><!--[if gte mso 9]><xml>
     <w:data>E42878160042A3685610000832CF656E726600ACD9299900017C7B020000000300000085020000001D5B4E657070652C203139393620696E2070726573732023383236335D000000</w:data>
    </xml><![endif]--></span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span>Our results suggest two
    potentially different mechanisms for the management of aggression using
    buspirone: Low doses may correspond with a presynaptic agonism with a
    feedback loop producing overall postsynaptic antagonism at all serotonin
    receptors. This would imply a short delay<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>such</span> as days,<span
    style='mso-spacerun:yes'>  </span>which is what one finds. Conversely<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>high</span>
    dosage,<span style='mso-spacerun:yes'>  </span>postsynaptic agonism in the
    irritable hyperactive agitated kind of patient would imply a secondary
    regulation of the serotonin 2A receptor,<span style='mso-spacerun:yes'> 
    </span>with consequent serotonin 2 antagonism : this may characterize an
    intimate,<span style='mso-spacerun:yes'>  </span>inverse feedback relationship
    with serotonin 2 mechanisms. It may alternatively reflect receptor
    subsensitivity in manic and related psychotic or agitated states implying
    higher doses. </p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u><o:p><span style='text-decoration:
     none'>&nbsp;</span></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:2.6pt'>Appropriate dosage of
    buspirone is critical to success.<span style='mso-spacerun:yes'>  </span>I
    believe that one useful way to modulate the dose is based on the <span
    class=GramE>side-effect</span> of dizziness. The dizziness that occurs with
    buspirone is special and <span class=GramE>Neppe<span
    style='mso-spacerun:yes'>  </span>has</span> used the term “non-vertiginous
    dizziness” (NVD) for it. <span style='mso-field-code:" ADDIN ENRef "'><sup><span
    style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>20</span></sup><!--[if gte mso 9]><xml>
     <w:data>4B0D583F003AA3685610000832CF656E726600ACD9299900017C8F02000000020000005202000000155B4E657070652C2020313939332023383235385D000000</w:data>
    </xml><![endif]--></span> This dizziness is by far the most common side <span
    class=GramE>effect<span style='mso-spacerun:yes'>  </span>in</span>
    adults,<span style='mso-spacerun:yes'>  </span>possibly occurring in 30-40%
    of patients but when the dose is built up to 60mg per day in possibly 60%
    based on my guesstimate on hundreds of my own patients.<span
    style='mso-spacerun:yes'>  </span>It apparently <span class=GramE>can be
    used</span> as an index of what dosage of buspirone we ought to be able to
    achieve. Increasing the dosage is often critical management so that this
    side-effect can be used to monitor dosage exemplified by the
    following:<span style='mso-spacerun:yes'>  </span>A patient started on 5
    mgs of buspirone 3 times a day<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>and</span> instead of improving,<span
    style='mso-spacerun:yes'>  </span>the patient reported a few days
    later,<span style='mso-spacerun:yes'>  </span>&quot;About<span
    style='mso-spacerun:yes'>  </span>thirty minutes after I take the
    drug,<span style='mso-spacerun:yes'>  </span>I get this horrible sensation
    in my head.<span style='mso-spacerun:yes'>  </span>It's a dizziness,<span
    style='mso-spacerun:yes'>  </span>it's an uncomfortability,<span
    style='mso-spacerun:yes'>  </span>it's a light headedness,<span
    style='mso-spacerun:yes'>  </span>it's indescribable.<span
    style='mso-spacerun:yes'>  </span>It goes behind my ears and I <span
    class=GramE>don't</span> like it. It lasts about 30 minutes and then it
    goes <span class=GramE>away<span style='mso-spacerun:yes'>  </span>.”</span><span
    style='mso-spacerun:yes'>   </span>The same scenario might occur while
    building up the dose at (say) 40 mgs a day.<span style='mso-spacerun:yes'> 
    </span>In every instance when one gets this<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>we</span> believe this is as much a<span
    style='mso-spacerun:yes'>  </span>symptom of serotonin 1A responsiveness as
    is<span style='mso-spacerun:yes'>  </span>irritability and concentration.<span
    style='mso-spacerun:yes'>  </span>It is a direct serotonin 1A related side
    effect.<span style='mso-spacerun:yes'>  </span>It apparently occurs with
    other <span class=GramE>azapirones<span style='mso-spacerun:yes'> 
    </span>in</span> research and also,<span style='mso-spacerun:yes'> 
    </span>in may experience,<span style='mso-spacerun:yes'>   </span>occurs
    occasionally,<span style='mso-spacerun:yes'>  </span>for example,<span
    style='mso-spacerun:yes'>  </span>with the other serotonin 1A non specific
    drugs such as lithium and propranolol.<span style='mso-spacerun:yes'> 
    </span>When this side effect occurs,<span style='mso-spacerun:yes'> 
    </span>this may be hypothesized to be a symptom of serotonin 1A
    overmodulation or excess and I find that dropping down the dosage of buspirone
    is all that is needed (<span style='mso-spacerun:yes'>  </span>e<span
    style='mso-spacerun:yes'>  </span>.g.<span style='mso-spacerun:yes'> 
    </span><span class=GramE>if</span> 15 mgs a day produces NVD,<span
    style='mso-spacerun:yes'>  </span>drop to 10 mg per day.<span
    style='mso-spacerun:yes'>  </span>If the patient <span class=GramE>is<span
    style='mso-spacerun:yes'>  </span>still</span> getting “non-vertiginous
    dizziness”,<span style='mso-spacerun:yes'>  </span>drop to 5 mgs a day -
    2<span style='mso-spacerun:yes'>  </span>.5 mg bid- until the
    “non-vertiginous dizziness” disappears: this should be the correct dosing.<span
    style='mso-spacerun:yes'>  </span>Using this technique<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>far</span> fewer patients in my experience,<span
    style='mso-spacerun:yes'>  </span>drop-out and also far more patients
    appear stabilized. </p>
    <p class=MsoNormal style='margin-right:2.6pt'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u><o:p><span style='text-decoration:
     none'>&nbsp;</span></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><b
    style='mso-bidi-font-weight:normal'><u>An integrated model<span
    style='mso-spacerun:yes'>  </span><o:p></o:p></u></b></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-spacerun:yes'> </span></p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'>The
    perspective of dose dependency appears extremely important<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>not</span> only on the
    basis of side effects but also therapeutic effects.<span
    style='mso-spacerun:yes'>  </span>This is illustrated by comparing effects
    of specific versus nonspecific serotonin 1A modulators <span class=GramE>where<span
    style='mso-spacerun:yes'>  </span>different</span> effects speculatively
    occur at different levels. The consistency of the chemistry<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>the</span>
    receptorology,<span style='mso-spacerun:yes'>  </span>animal models and
    clinical implications may provide a viable approach to examining this and
    other receptors during the 1990's<span style='mso-spacerun:yes'>  </span>.</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-right:2.6pt'><span style='mso-tab-count:
    1'>            </span>A model for aggression <span class=GramE>can be drawn</span>
    using the serotonin 1A receptor.<span style='mso-spacerun:yes'> 
    </span>Presynaptic agonism produces a functional overall post-synaptic
    antagonism<span class=GramE>,<span style='mso-spacerun:yes'>  </span>and</span>
    this could be the mechanism for low-dose buspirone in the agitated,<span
    style='mso-spacerun:yes'>  </span>generally non-organically impaired
    angry,<span style='mso-spacerun:yes'>  </span>frustrated,<span
    style='mso-spacerun:yes'>  </span>hostile,<span style='mso-spacerun:yes'> 
    </span>irritable individual.<span style='mso-spacerun:yes'>  </span>High
    doses of serotonin 1A agonist in the context of high doses of buspirone<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>or</span> of
    lithium,<span style='mso-spacerun:yes'>  </span>produces post-synaptic
    serotonin 2 antagonism as a reciprocal effect for the serotonin 1A agonist
    effect.<span style='mso-spacerun:yes'>  </span>Beta adrenergic blocking
    agents in low doses probably do not act by the serotonin 1A receptor<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>but</span> in higher
    doses act as serotonin 1A antagonists and also serotonin 1B agonist type
    drugs.<span style='mso-spacerun:yes'>  </span>Under those circumstances<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>if</span> serotonin 1B
    indeed does exist in man,<span style='mso-spacerun:yes'>  </span>this would
    explain the paradoxical effect. However<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>the</span> high dose serotonin 1A agonist
    theory appears compromised unless the serotonin 1B agonist effects that
    propranolol exhibits in rodents can be translated into equivalent,<span
    style='mso-spacerun:yes'>  </span>currently undiscovered human effects.
    This is unlikely at this point and a more logical hypothesis for
    beta-blockers could relate to down regulation of the serotonin 2 <span
    class=GramE>receptors which</span> may produce the equivalent of serotonin
    2 blockade. As an aside, because gepirone potently inhibits serotonergic
    impulse flow recorded from the dorsal raphe nucleus and this effect is
    partially reversed by serotonergic antagonists, this presynaptic effect may
    be its primary <span class=GramE>effect<span style='mso-spacerun:yes'> 
    </span>decreasing</span> 5HT neurotransmission. <span style='mso-field-code:
    " ADDIN ENRef "'><sup><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt'>45</span></sup><!--[if gte mso 9]><xml>
     <w:data>3DB520D4003CA3685610000832CF656E726600ACD9299900017CA602000000020000005E02000000175B4D634D696C6C656E2C20313938372023373239355D000000</w:data>
    </xml><![endif]--></span><span style='mso-spacerun:yes'>  </span>Thus<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>theoretically</span>,<span
    style='mso-spacerun:yes'>  </span>gepirone may turn out even better than
    buspirone as an anti-aggressive agent .</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span>Neurochemically<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>a</span> very
    important theoretical and practical area in relation to serotonin and
    serotonin 1A has emerged.<span style='mso-spacerun:yes'>  </span>It has
    implications far beyond serotonin 1A<span class=GramE>,<span
    style='mso-spacerun:yes'>  </span>as</span> a cascade of mechanisms across
    many chemical levels can occur.<span style='mso-spacerun:yes'>  </span>For
    example<span class=GramE>,<span style='mso-spacerun:yes'>  </span>the</span>
    possibility of some degree of inverse relationship with serotonin 2
    mechanisms is only a beginning and influence in relation to electrical
    firing at dopaminergic,<span style='mso-spacerun:yes'> 
    </span>acetylcholine and norepinephric levels occur.<span
    style='mso-spacerun:yes'>  </span>The exact effects will vary depending on
    the particular parent compound.</p>
    <p class=MsoNormal style='margin-right:2.6pt;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><span
    style='mso-tab-count:1'>            </span>The time has arrived for the
    azapirones to be thoroughly investigated and possibly to be marketed
    thereafter as the first anti-aggressive agents without sedation<span
    class=GramE>,<span style='mso-spacerun:yes'>  </span>addiction</span> and
    neuroleptic effects and with significant safety<span
    style='mso-spacerun:yes'>  </span>.</p>
    <p class=MsoNormal style='margin-right:-.5in;tab-stops:.5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>
    <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal><!--[if supportFields]><span style='mso-element:field-begin'></span><span
    style='mso-spacerun:yes'> </span>ADDIN ENBib <span style='mso-element:field-separator'></span><![endif]--><span
    class=GramE>1.<span style='mso-tab-count:1'>         </span>American
    Psychiatric Association Committee.</span> Diagnostic and Statistical Manual
    : DSM 111 R , Third ( revised ),<span style='mso-spacerun:yes'> 
    </span>Washington , D.C.: American Psychiatric Association,<span
    style='mso-spacerun:yes'>   </span>1987 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal><span class=GramE>2.<span style='mso-tab-count:1'>         </span>American
    Psychiatric Association Committee.</span> Diagnostic and Statistical Manual
    : DSM IV , Fourth,<span style='mso-spacerun:yes'>  </span>Washington ,
    D.C.: American Psychiatric Association,<span style='mso-spacerun:yes'>  
    </span>1994 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>3.<span style='mso-tab-count:1'>         </span>Neppe
    VM, Blumer <span class=GramE>D :</span><span style='mso-spacerun:yes'> 
    </span>33 :Nomenclature of psychiatric disorders of epilepsy- Axis 1:
    Psychopathology. Suppl. 3, 17-18, Epilepsia, 1992 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>4.<span style='mso-tab-count:1'>         </span>Blumer
    D, Neppe VM. Atypical spells in the non-epileptic and <span class=GramE>psychopathology
    :</span> a classification. In:<span style='mso-spacerun:yes'> 
    </span>Psychiatric Aspects of Epilepsy, Second, Blumer D ed. Washington,DC:
    APA Press,<span style='mso-spacerun:yes'>  </span>1995- in press</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>5.<span style='mso-tab-count:1'>         </span>Blumer
    D, Neppe V, Benson <span class=GramE>DF :</span><span
    style='mso-spacerun:yes'>  </span>147 (5):Diagnostic criteria for
    epilepsy-related mental changes. 676-7, Am J Psychiatry, 1990 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>6.<span style='mso-tab-count:1'>         </span>Yudofsky
    SC, Silver JM, Jackson W, Endicott J, Williams <span class=GramE>D :</span>
    The Overt Aggression Scale for the objective rating of verbal and physical
    aggression.<span style='mso-spacerun:yes'>  </span>Am J Psychiatry<span
    style='mso-spacerun:yes'>  </span>143 (1):35-9, 1986</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>7.<span style='mso-tab-count:1'>         </span>Kay SR,
    Wolkenfeld F, Murrill <span class=GramE>LM :</span> Profiles of aggression
    among psychiatric patients. <span class=GramE>II. Covariates and
    predictors.</span><span style='mso-spacerun:yes'>  </span>J Nerv Ment
    Dis<span style='mso-spacerun:yes'>  </span>176 (9):547-57, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>8.<span style='mso-tab-count:1'>         </span>Palmstierna
    T, Wistedt <span class=GramE>B :</span> Staff observation aggression scale,
    SOAS: presentation and evaluation.<span style='mso-spacerun:yes'> 
    </span>Acta Psychiatr Scand<span style='mso-spacerun:yes'>  </span>76
    (6):657-63, 1987</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>9.<span style='mso-tab-count:1'>         </span>Palmstierna
    T, Lassenius R, Wistedt <span class=GramE>B :</span> Evaluation of the
    Brief Psychopathological Rating Scale in relation to aggressive behavior by
    acute involuntarily admitted patients.<span style='mso-spacerun:yes'> 
    </span>Acta Psychiatr Scand<span style='mso-spacerun:yes'>  </span>79
    (4):313-6, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>10.<span style='mso-tab-count:1'>       </span>Ryden MB,
    Bossenmaier M, McLachlan <span class=GramE>C :</span> Aggressive behavior
    in cognitively impaired nursing home residents.<span
    style='mso-spacerun:yes'>  </span>Res Nurs Health<span
    style='mso-spacerun:yes'>  </span>14 (2):87-95, 1991</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>11.<span style='mso-tab-count:1'>       </span>Overall
    JC, Gorham <span class=GramE>DP :</span> The Brief Psychiatric Rating
    Scale.<span style='mso-spacerun:yes'>  </span>Psychol Rep<span
    style='mso-spacerun:yes'>  </span>10 :799-802, 1962</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>12.<span style='mso-tab-count:1'>       </span>Kay SR,
    Fiszbein A, Opler <span class=GramE>LA :</span> Negative Symptom Rating
    Scale: limitations in psychometric and research methodology.<span
    style='mso-spacerun:yes'>  </span>Psychiatry Res<span
    style='mso-spacerun:yes'>  </span>19 (2):169-73, 1986</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>13.<span style='mso-tab-count:1'>       </span>Kay SR,
    Fiszbein A, Opler <span class=GramE>LA :</span> The positive and negative
    syndrome scale (PANSS) for schizophrenia.<span style='mso-spacerun:yes'> 
    </span>Schizophr Bull<span style='mso-spacerun:yes'>  </span>13 (2):261-76,
    1987</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>14.<span style='mso-tab-count:1'>       </span>Kay SR,
    Opler LA, Lindenmayer <span class=GramE>JP :</span> Reliability and
    validity of the positive and negative syndrome scale for
    schizophrenics.<span style='mso-spacerun:yes'>  </span>Psychiatry Res<span
    style='mso-spacerun:yes'>  </span>23 (1):99-110, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>15.<span style='mso-tab-count:1'>       </span>Abramets <span
    class=GramE>II :</span> [The types of central serotonin receptors, their
    functional role and participation in the action of psychopharmacologic
    agents].<span style='mso-spacerun:yes'>  </span>Farmakol Toksikol<span
    style='mso-spacerun:yes'>  </span>53 (5):70-5, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>16.<span style='mso-tab-count:1'>       </span>Peroutka
    SJ. <span class=GramE>Serotonin receptors.</span> In:<span
    style='mso-spacerun:yes'>  </span><span class=GramE>Psychopharmacology :</span>
    The Third Generation of Progress, Meltzer<span style='mso-spacerun:yes'> 
    </span>HY ed. New York: Raven Press,<span style='mso-spacerun:yes'> 
    </span>303-311, 1987</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>17.<span style='mso-tab-count:1'>       </span>Peroutka
    SJ, Snyder <span class=GramE>SH :</span> Multiple serotonin receptors :
    Differential binding of 5 hydroxytryptamine , lysergic acid diethylamide
    and spiroperidol .<span style='mso-spacerun:yes'>  </span>Mol
    Pharmacol<span style='mso-spacerun:yes'>  </span>16 :687-699, 1979</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>18.<span style='mso-tab-count:1'>       </span>Fillion <span
    class=GramE>G :</span> Central serotonin receptors: regulation mechanism at
    the molecular level.<span style='mso-spacerun:yes'>  </span>Adv Biochem
    Psychopharmacol<span style='mso-spacerun:yes'>  </span>36 (115):115-23,
    1983</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>19.<span style='mso-tab-count:1'>       </span>Neppe VM.
    <span class=GramE>Buspirone :</span> an anxioselective neuromodulator.
    In:<span style='mso-spacerun:yes'>  </span>Innovative
    Psychopharmacotherapy, Revised 1st edition, <span class=GramE>Neppe<span
    style='mso-spacerun:yes'>  </span>VM</span> ed. New York: Raven<span
    style='mso-spacerun:yes'>  </span>Press,<span style='mso-spacerun:yes'>  
    </span>35-57 , Ch 2, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>20.<span style='mso-tab-count:1'>       </span>Neppe VM.
    Serotonin 1A <span class=GramE>neuromodulators :</span> clinical
    implications for the elderly. In:<span style='mso-spacerun:yes'> 
    </span>Psychopharmacology for the Elderly: Research and Clinical
    Implications, Bergener M, Belmaker RH, Tropper MS ed. New York: Springer
    Publ Co,<span style='mso-spacerun:yes'>  </span>222-238, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>21.<span style='mso-tab-count:1'>       </span>Peroutka <span
    class=GramE>SJ :</span> Developments in 5-hydroxytryptamine receptor
    pharmacology in migraine.<span style='mso-spacerun:yes'>  </span>Neurol
    Clin<span style='mso-spacerun:yes'>  </span>8 (4):829-39, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>22.<span style='mso-tab-count:1'>       </span>Eison <span
    class=GramE>MS :</span> Serotonin: a common neurobiologic substrate in
    anxiety and depression.<span style='mso-spacerun:yes'>  </span>J Clin
    Psychopharmacol<span style='mso-spacerun:yes'>  </span>1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>23.<span style='mso-tab-count:1'>       </span>Hoyer D,
    Engel G, Kalkman <span class=GramE>HO :</span> Characterization of the
    5-HT1B recognition site in rat brain: binding studies with
    (-)[125I]iodocyanopindolol.<span style='mso-spacerun:yes'>  </span>Eur J
    Pharmacol<span style='mso-spacerun:yes'>  </span>118 (1-2):1-12, 1985</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>24.<span style='mso-tab-count:1'>       </span>Hoyer D, <span
    class=GramE>Schoefter<span style='mso-spacerun:yes'>  </span>P</span>,
    Waeber C, Palacios<span style='mso-spacerun:yes'>  </span>JM :<span
    style='mso-spacerun:yes'>  </span>Abstracts :The<span
    style='mso-spacerun:yes'>  </span>serotonin 5 HT1D receptors. 12, The
    Neuropharmacology of Serotonin, New York, New York Academy of Sciences,
    1989 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>25.<span style='mso-tab-count:1'>       </span>Bolanos
    FJ, Schechter LE, Miquel MC, et al<span class=GramE>. :</span> Common
    pharmacological and physico-chemical properties of 5-HT3 binding sites in
    the rat cerebral cortex and NG 108-15 clonal cells.<span
    style='mso-spacerun:yes'>  </span>Biochem Pharmacol<span
    style='mso-spacerun:yes'>  </span>40 (7):1541-50, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>26.<span style='mso-tab-count:1'>       </span>Fagni L,
    Dumuis A, Sebben M, Bockaert <span class=GramE>J :</span> The 5-HT4
    receptor subtype inhibits K+ current in colliculi neurones via activation
    of a cyclic AMP-dependent protein kinase [published erratum appears in Br J
    Pharmacol 1992 Jul;106(3):756].<span style='mso-spacerun:yes'>  </span>Br J
    Pharmacol<span style='mso-spacerun:yes'>  </span>105 (4):973-9, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>27.<span style='mso-tab-count:1'>       </span>Adham N,
    Kao HT, Schecter LE, et al<span class=GramE>. :</span> Cloning of another
    human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled
    to the inhibition of adenylate cyclase.<span style='mso-spacerun:yes'> 
    </span>Proc Natl Acad Sci U S A<span style='mso-spacerun:yes'>  </span>90
    (2):408-12, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>28.<span style='mso-tab-count:1'>       </span>Berendsen
    <span class=GramE>HH :</span> Interactions between 5-hydroxytryptamine
    receptor subtypes: is a disturbed receptor balance contributing to the
    symptomatology of depression in humans?<span style='mso-spacerun:yes'> 
    </span>Pharmacol Ther<span style='mso-spacerun:yes'>  </span>66 (1):17-37,
    1995</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>29.<span style='mso-tab-count:1'>       </span>Pandey
    SC, Davis JM, Pandey <span class=GramE>GN :</span> Phosphoinositide
    system-linked serotonin receptor subtypes and their pharmacological
    properties and clinical correlates.<span style='mso-spacerun:yes'> 
    </span>J Psychiatry Neurosci<span style='mso-spacerun:yes'>  </span>20
    (3):215-25, 1995</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>30.<span style='mso-tab-count:1'>       </span>Halperin
    JM, Sharma V, Siever LJ, et al<span class=GramE>. :</span> Serotonergic
    function in aggressive and nonaggressive boys with attention deficit
    hyperactivity disorder.<span style='mso-spacerun:yes'>  </span>Am J
    Psychiatry<span style='mso-spacerun:yes'>  </span>151 (2):243-8, 1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>31.<span style='mso-tab-count:1'>       </span>Moeller
    FG, Steinberg JL, Petty F, et al<span class=GramE>. :</span> Serotonin and
    impulsive/aggressive behavior in cocaine dependent subjects.<span
    style='mso-spacerun:yes'>  </span>Prog Neuropsychopharmacol Biol
    Psychiatry<span style='mso-spacerun:yes'>  </span>18 (6):1027-35, 1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>32.<span style='mso-tab-count:1'>       </span>Miczek
    KA, Weerts E, Haney M, Tidey <span class=GramE>J :</span> Neurobiological
    mechanisms controlling aggression: preclinical developments for
    pharmacotherapeutic interventions.<span style='mso-spacerun:yes'> 
    </span>Neurosci Biobehav Rev<span style='mso-spacerun:yes'>  </span>18
    (1):97-110, 1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>33.<span style='mso-tab-count:1'>       </span>Barrett
    JE, Vanover <span class=GramE>KE :</span> 5-HT receptors as targets for the
    development of novel anxiolytic drugs: models, mechanisms and future
    directions.<span style='mso-spacerun:yes'>  </span>Psychopharmacology
    Berl<span style='mso-spacerun:yes'>  </span>112 (1):1-12, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>34.<span style='mso-tab-count:1'>       </span>S'anchez
    C, Arnt J, Hyttel J, Moltzen <span class=GramE>EK :</span> The role of
    serotonergic mechanisms in inhibition of isolation-induced aggression in
    male mice.<span style='mso-spacerun:yes'>  </span>Psychopharmacology
    Berl<span style='mso-spacerun:yes'>  </span>110 (1-2):53-59, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>35.<span style='mso-tab-count:1'>       </span>Coccaro <span
    class=GramE>EF :</span> Impulsive aggression and central serotonergic
    system function in humans: an example of a dimensional brain-behavior
    relationship.<span style='mso-spacerun:yes'>  </span>Int Clin
    Psychopharmacol<span style='mso-spacerun:yes'>  </span>7 (1):3-12, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>36.<span style='mso-tab-count:1'>       </span>Leonard <span
    class=GramE>BE :</span> Sub-types of serotonin receptors: biochemical
    changes and pharmacological consequences.<span style='mso-spacerun:yes'> 
    </span>Int Clin Psychopharmacol<span style='mso-spacerun:yes'>  </span>7
    (1):13-21, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>37.<span style='mso-tab-count:1'>       </span>Coccaro
    EF, Siever LJ, Klar HM, et al<span class=GramE>. :</span> Serotonergic
    studies in patients with affective and personality disorders. <span
    class=GramE>Correlates with suicidal and impulsive aggressive behavior.</span><span
    style='mso-spacerun:yes'>  </span>Arch Gen Psychiatry<span
    style='mso-spacerun:yes'>  </span>46 (7):587-99, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>38.<span style='mso-tab-count:1'>       </span>Olivier
    B, Mos J, van der Heyden J, Hartog <span class=GramE>J :</span>
    Serotonergic modulation of social interactions in isolated male mice.<span
    style='mso-spacerun:yes'>  </span>Psychopharmacology (Berlin)<span
    style='mso-spacerun:yes'>  </span>97 (2):154-6, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>39.<span style='mso-tab-count:1'>       </span>Kent TA,
    Brown CS, Bryant SG, Barratt ES, Felthous AR, Rose RM : Blood platelet
    uptake of serotonin in episodic aggression: correlation with red blood cell
    proton T1 and impulsivity.<span style='mso-spacerun:yes'>  </span>J Clin
    Psychopharmacol<span style='mso-spacerun:yes'>  </span>9 (2):122-5, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>40.<span style='mso-tab-count:1'>       </span>Molina V,
    Ciesielski L, Gobaille S, Isel F, Mandel <span class=GramE>P :</span>
    Inhibition of mouse killing behavior by serotonin-mimetic drugs: effects of
    partial alterations of serotonin neurotransmission.<span
    style='mso-spacerun:yes'>  </span>Pharmacol Biochem Behav<span
    style='mso-spacerun:yes'>  </span>27 (1):123-31, 1987</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>41.<span style='mso-tab-count:1'>       </span>Singhal
    RL, Telner <span class=GramE>JI :</span> A perspective:
    psychopharmacological aspects of aggression in animals and man.<span
    style='mso-spacerun:yes'>  </span>Psychiatr J Univ Ott<span
    style='mso-spacerun:yes'>  </span>8 (3):145-53, 1983</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>42.<span style='mso-tab-count:1'>       </span>Carlini
    EA, Lindsey <span class=GramE>CJ :</span> Effect of serotonergic drugs on
    the aggressiveness induced by delta 9-tetrahydrocannabinol in
    rem-sleep-deprived rats.<span style='mso-spacerun:yes'>  </span>Braz J Med
    Biol Res<span style='mso-spacerun:yes'>  </span>15 (4-5):281-3, 1982</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>43.<span style='mso-tab-count:1'>       </span>Mandel P,
    Mack G, Kempf E, Ebel A, Simler S : Molecular aspects of a model of
    aggressive behavior: neurotransmitter interactions.<span
    style='mso-spacerun:yes'>  </span>pp. 285-303.<span
    style='mso-spacerun:yes'>  </span>In: Garattini S, et al., ed.<span
    style='mso-spacerun:yes'>  </span><span class=GramE>Interactions between
    putative neurotransmitters in the brain.</span><span
    style='mso-spacerun:yes'>  </span>New York, Raven Press<span
    style='mso-spacerun:yes'>  </span>1978</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>44.<span style='mso-tab-count:1'>       </span>Miczek
    KA, Mos J, Olivier <span class=GramE>B :</span> Brain 5-HT and inhibition
    of aggressive behavior in animals: 5-HIAA and receptor subtypes.<span
    style='mso-spacerun:yes'>  </span>Psychoharmacol Bull<span
    style='mso-spacerun:yes'>  </span>25 (3):399-403, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>45.<span style='mso-tab-count:1'>       </span>McMillen
    BA, Scott SM, Williams HL, Sanghera <span class=GramE>MK :</span> Effects
    of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and
    brain monoaminergic neurotransmission.<span style='mso-spacerun:yes'> 
    </span>Naunyn Schmiedebergs Arch Pharmacol<span style='mso-spacerun:yes'> 
    </span>335 (4):454-64, 1987</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>46.<span style='mso-tab-count:1'>       </span>Maj J,
    Rog<span class=GramE>:o</span>~z Z, Skuza G, Sowi:nska H : Effects of
    chronic treatment with antidepressants on aggressiveness induced by
    clonidine in mice. <span style='mso-spacerun:yes'> </span>J Neural
    Transm<span style='mso-spacerun:yes'>  </span>55 (1):19-25, 1982</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>47.<span style='mso-tab-count:1'>       </span>Montgomery
    SA, Fineberg <span class=GramE>N :</span> Is there a relationship between
    serotonin receptor subtypes and selectivity of response in specific
    psychiatric illnesses?<span style='mso-spacerun:yes'>  </span>Br J
    Psychiatry Suppl<span style='mso-spacerun:yes'>  </span>1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>48.<span style='mso-tab-count:1'>       </span>Neppe VM.
    <span class=GramE>Psychopharmacological strategies in non-responsive
    psychotics.</span> In:<span style='mso-spacerun:yes'>  </span>Innovative
    Psychopharmacotherapy, <span class=GramE>Neppe<span
    style='mso-spacerun:yes'>  </span>VM</span> ed. New York: Raven Press,<span
    style='mso-spacerun:yes'>  </span>Ch 4, 94-122, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>49.<span style='mso-tab-count:1'>       </span>Neppe VM,
    Holden T. Innovations in schizophrenia management. In:<span
    style='mso-spacerun:yes'>  </span>Innovative Psychopharmacotherapy, <span
    class=GramE>Neppe<span style='mso-spacerun:yes'>  </span>VM</span> ed. New
    York: Raven Press,<span style='mso-spacerun:yes'>   </span>Ch 3, 58-93,
    1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>50.<span style='mso-tab-count:1'>       </span>Itil TM,
    Wadud <span class=GramE>A :</span> Treatment of human aggression with major
    tranquilizers, antidepressants, and newer psychotropic drugs.<span
    style='mso-spacerun:yes'>  </span>J Nerv Ment Dis<span
    style='mso-spacerun:yes'>  </span>160 (2-1):83-99, 1975</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>51.<span style='mso-tab-count:1'>       </span>Itil TM,
    Mukhopadhyay <span class=GramE>S :</span> Pharmacological management of
    human violence.<span style='mso-spacerun:yes'>  </span>Mod Probl
    Pharmacopsychiatry<span style='mso-spacerun:yes'>  </span>13 (139):139-58,
    1978</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>52.<span style='mso-tab-count:1'>       </span>Lion <span
    class=GramE>JR :</span> Conceptual issues in the use of drugs for the
    treatment of aggression in man.<span style='mso-spacerun:yes'>  </span>J
    Nerv Ment Dis<span style='mso-spacerun:yes'>  </span>160 (2-1):76-82, 1975</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>53.<span style='mso-tab-count:1'>       </span>Bernstein
    <span class=GramE>L :</span> Trazodone treatment of targeted aggression in
    a mentally retarded man.<span style='mso-spacerun:yes'>  </span>J
    Neuropsychiatry Clin Neurosci<span style='mso-spacerun:yes'>  </span>4
    (3):348, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>54.<span style='mso-tab-count:1'>       </span>Gedye <span
    class=GramE>A :</span> Trazodone reduced aggressive and self-injurious
    movements in a mentally handicapped male patient with autism.<span
    style='mso-spacerun:yes'>  </span>J Clin Psychopharmacol<span
    style='mso-spacerun:yes'>  </span>11 (4):275-6, 1991</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>55.<span style='mso-tab-count:1'>       </span>O'Neil M,
    Page N, Adkins WN, Eichelman <span class=GramE>B :</span>
    Tryptophan-trazodone treatment of aggressive behaviour.<span
    style='mso-spacerun:yes'>  </span>Lancet<span style='mso-spacerun:yes'> 
    </span>2 (8511):859-60, 1986</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>56.<span style='mso-tab-count:1'>       </span>Pinner E,
    Rich <span class=GramE>CL :</span> Effects of trazodone on aggressive
    behavior in seven patients with organic mental disorders.<span
    style='mso-spacerun:yes'>  </span>Am J Psychiatry<span
    style='mso-spacerun:yes'>  </span>145 (10):1295-6, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>57.<span style='mso-tab-count:1'>       </span>Simpson
    DM, Foster <span class=GramE>D :</span> Improvement in organically
    disturbed behavior with trazodone treatment.<span
    style='mso-spacerun:yes'>  </span>J Clin Psychiatry<span
    style='mso-spacerun:yes'>  </span>47 (4):191-3, 1986</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>58.<span style='mso-tab-count:1'>       </span>Wilcock
    GK, Stevens J, Perkins <span class=GramE>A :</span> Trazodone/tryptophan
    for aggressive behaviour.<span style='mso-spacerun:yes'> 
    </span>Lancet<span style='mso-spacerun:yes'>  </span>1 (8538):929-30, 1987</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>59.<span style='mso-tab-count:1'>       </span>Zubieta
    JK, Alessi <span class=GramE>NE :</span> Acute and chronic administration
    of trazodone in the treatment of disruptive behavior disorders in
    children.<span style='mso-spacerun:yes'>  </span>J Clin
    Psychopharmacol<span style='mso-spacerun:yes'>  </span>12 (5):346-51, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>60.<span style='mso-tab-count:1'>       </span>Eison AS,
    Wright <span class=GramE>RN :</span> 5-HT1A and 5-HT2 receptors mediate
    discrete behaviors in the Mongolian gerbil.<span style='mso-spacerun:yes'> 
    </span>Pharmacol Biochem Behav<span style='mso-spacerun:yes'>  </span>43
    (1):131-7, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>61.<span style='mso-tab-count:1'>       </span>Pazos A,
    Probst A, Palacios <span class=GramE>JM :</span> Serotonin receptors in the
    human brain--III. <span class=GramE>Autoradiographic mapping of serotonin-1
    receptors.</span><span style='mso-spacerun:yes'>  </span>Neuroscience<span
    style='mso-spacerun:yes'>  </span>21 (1):97-122, 1987</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>62.<span style='mso-tab-count:1'>       </span>Wu PH,
    Gurevich N, Carlen <span class=GramE>PL :</span> Serotonin-1A receptor
    activation in hippocampal CA1 neurons by
    8-hydroxy-2-(di-n-propylamino)tetralin, 5-methoxytryptamine and
    5-hydroxytryptamine.<span style='mso-spacerun:yes'>  </span>Neurosci
    Lett<span style='mso-spacerun:yes'>  </span>86 (1):72-6, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>63.<span style='mso-tab-count:1'>       </span>Ieni JR,
    Meyerson <span class=GramE>LR :</span> The 5-HT1A receptor probe
    [3H]8-OH-DPAT labels the 5-HT transporter in human platelets.<span
    style='mso-spacerun:yes'>  </span>Life Sci<span style='mso-spacerun:yes'> 
    </span>42 (3):311-20, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>64.<span style='mso-tab-count:1'>       </span>Dumuis A,
    Sebben M, Bockaert <span class=GramE>J :</span> Pharmacology of
    5-hydroxytryptamine-1A receptors which inhibit cAMP production in
    hippocampal and cortical neurons in primary culture.<span
    style='mso-spacerun:yes'>  </span>Mol Pharmacol<span
    style='mso-spacerun:yes'>  </span>33 (2):178-86, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>65.<span style='mso-tab-count:1'>       </span>Gillis
    RA, Hill KJ, Kirby JS, et al<span class=GramE>. :</span> Effect of
    activation of central nervous system serotonin 1A receptors on
    cardiorespiratory function.<span style='mso-spacerun:yes'>  </span>J
    Pharmacol Exp Ther<span style='mso-spacerun:yes'>  </span>248 (2):851-7,
    1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>66.<span style='mso-tab-count:1'>       </span>Mandal
    AK, Kellar KJ, Friedman E, Pineo SV, Hamosh P, Gillis <span class=GramE>RA
    :</span> Importance of central nervous system serotonin-1A receptors for
    mediating the hypotensive effect of urapidil.<span
    style='mso-spacerun:yes'>  </span>J Pharmacol Exp Ther<span
    style='mso-spacerun:yes'>  </span>251 (2):563-70, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>67.<span style='mso-tab-count:1'>       </span>Lazosky
    AJ, Britton <span class=GramE>DR :</span> Effects of 5-HT-1A receptor
    agonists on CRF-induced behavior.<span style='mso-spacerun:yes'> 
    </span>Psychopharmacology (Berl)<span style='mso-spacerun:yes'>  </span>104
    (1):132-6, 1991</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>68.<span style='mso-tab-count:1'>       </span>Eison <span
    class=GramE>MS :</span> The new generation of serotonergic anxiolytics:
    possible clinical roles.<span style='mso-spacerun:yes'>  </span>Psychopathology<span
    style='mso-spacerun:yes'>  </span>1 (13):13-20, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>69.<span style='mso-tab-count:1'>       </span>Millan
    MJ, Bervoets K, Colpaert <span class=GramE>FC :</span> 5-hydroxytryptamine
    (5-HT)1A receptors and the tail-flick response. <span class=GramE>I.
    8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks
    in the rat as an in vivo model of 5-HT1A receptor-mediated activity.</span><span
    style='mso-spacerun:yes'>  </span>J Pharmacol Exp Ther<span
    style='mso-spacerun:yes'>  </span>256 (3):973-82, 1991</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>70.<span style='mso-tab-count:1'>       </span>Mittman
    SM, Geyer <span class=GramE>MA :</span> Effects of 5HT-1A agonists on
    locomotor and investigatory behaviors in rats differ from those of
    hallucinogens.<span style='mso-spacerun:yes'>  </span>Psychopharmacology
    (Berlin)<span style='mso-spacerun:yes'>  </span>98 (3):321-9, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>71.<span style='mso-tab-count:1'>       </span>Odagaki
    Y, Fuxe <span class=GramE>K :</span> Pharmacological characterization of
    the 5-hydroxytryptamine-1A receptor-mediated activation of high-affinity
    GTP hydrolysis in rat hippocampal membranes.<span
    style='mso-spacerun:yes'>  </span>J Pharmacol Exp Ther<span
    style='mso-spacerun:yes'>  </span>274 (1):337-44, 1995</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>72.<span style='mso-tab-count:1'>       </span>Eison AS,
    Eison <span class=GramE>MS :</span> Serotonergic mechanisms in
    anxiety.<span style='mso-spacerun:yes'>  </span>Prog Neuropsychopharmacol
    Biol Psychiatry<span style='mso-spacerun:yes'>  </span>18 (1):47-62, 1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>73.<span style='mso-tab-count:1'>       </span>Moss LE,
    Neppe VM, Drevets <span class=GramE>WC :</span> Buspirone in the treatment
    of tardive dyskinesia.<span style='mso-spacerun:yes'>  </span>J Clin
    Psychopharmacol<span style='mso-spacerun:yes'>  </span>13 (3):204-9, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>74.<span style='mso-tab-count:1'>       </span>Neppe <span
    class=GramE>VM :</span><span style='mso-spacerun:yes'>  </span>2
    (8677):High-dose buspirone in case of tardive dyskinesia. Lancet, 1989 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>75.<span style='mso-tab-count:1'>       </span>Neppe VM.
    <span class=GramE>The clinical neuropharmacology of buspirone.</span>
    In:<span style='mso-spacerun:yes'>  </span>Innovative
    Psychopharmacotherapy, <span class=GramE>Neppe<span
    style='mso-spacerun:yes'>  </span>VM</span> ed. New York: Raven<span
    style='mso-spacerun:yes'>  </span>Press,<span style='mso-spacerun:yes'>  
    </span>35-57 , Ch 2, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>76.<span style='mso-tab-count:1'>       </span>Hicks <span
    class=GramE>PB :</span> The effect of serotonergic agents on
    haloperidol-induced catalepsy.<span style='mso-spacerun:yes'>  </span>Life
    Sci<span style='mso-spacerun:yes'>  </span>47 (18):1609-15, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>77.<span style='mso-tab-count:1'>       </span>Alhaider
    AA, Wilcox <span class=GramE>GL :</span> Differential roles of
    5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptor subtypes in
    modulating spinal nociceptive transmission in mice.<span
    style='mso-spacerun:yes'>  </span>J Pharmacol Exp Ther<span
    style='mso-spacerun:yes'>  </span>265 (1):378-85, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>78.<span style='mso-tab-count:1'>       </span>Kharin
    NA, Dolzhenko AT, Titievskii AV, Naletov <span class=GramE>SV :</span> [The
    possible neurochemical mechanisms of the neuroleptic action of
    buspirone-like serotonin agonists].<span style='mso-spacerun:yes'> 
    </span>Eksp Klin Farmakol<span style='mso-spacerun:yes'>  </span>56
    (4):12-4, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>79.<span style='mso-tab-count:1'>       </span>Millan
    MJ, Colpaert <span class=GramE>FC :</span> 5-hydroxytryptamine (HT)1A
    receptors and the tail-flick response. III. Structurally diverse 5-HT1A
    partial agonists attenuate mu- but not kappa-opioid antinociception in mice
    and rats.<span style='mso-spacerun:yes'>  </span>J Pharmacol Exp Ther<span
    style='mso-spacerun:yes'>  </span>256 (3):993-1001, 1991</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>80.<span style='mso-tab-count:1'>       </span>Sijbesma
    H, Schipper J, De <span class=GramE>KER :</span> The anti-aggressive drug
    eltoprazine preferentially binds to 5-HT1A and 5-HT1B receptor subtypes in
    rat brain: sensitivity to guanine nucleotides.<span
    style='mso-spacerun:yes'>  </span>Eur J Pharmacol<span
    style='mso-spacerun:yes'>  </span>187 (2):209-23, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>81.<span style='mso-tab-count:1'>       </span>Schipper
    J, Tulp MT, Sijbesma <span class=GramE>H :</span> Neurochemical profile of
    eltoprazine.<span style='mso-spacerun:yes'>  </span>Drug Metabol Drug
    Interact<span style='mso-spacerun:yes'>  </span>8 (1-2):85-114, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>82.<span style='mso-tab-count:1'>       </span>Mizuta T,
    Segawa <span class=GramE>T :</span> Chronic effects of imipramine and
    lithium on postsynaptic 5-HT1A and 5-HT1B sites and on presynaptic 5-HT3
    sites in rat brain.<span style='mso-spacerun:yes'>  </span>Jpn J
    Pharmacol<span style='mso-spacerun:yes'>  </span>47 (2):107-13, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>83.<span style='mso-tab-count:1'>       </span>Goodwin
    GM, De Souza RJ, Wood AJ, Green <span class=GramE>AR :</span> The
    enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced
    by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism.<span
    style='mso-spacerun:yes'>  </span>Psychopharmacology (Berlin)<span
    style='mso-spacerun:yes'>  </span>90 (4):488-93, 1986</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>84.<span style='mso-tab-count:1'>       </span>Corrigan
    PW, Yudofsky SC, Silver <span class=GramE>JM :</span> Pharmacological and
    behavioral treatments for aggressive psychiatric inpatients.<span
    style='mso-spacerun:yes'>  </span>Hosp Community Psychiatry<span
    style='mso-spacerun:yes'>  </span>44 (2):125-33, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>85.<span style='mso-tab-count:1'>       </span>Wickham
    EA, Reed <span class=GramE>JV :</span> Lithium for the control of aggressive
    and self-mutilating behaviour.<span style='mso-spacerun:yes'>  </span>Int
    Clin Psychopharmacol<span style='mso-spacerun:yes'>  </span>2 (3):181-90,
    1987</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>86.<span style='mso-tab-count:1'>       </span>Neppe <span
    class=GramE>VM :</span><span style='mso-spacerun:yes'>  </span>4
    (3):Central effects of beta blockers: a critique. 169-70, J Clin
    Psychopharmacol, 1984 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>87.<span style='mso-tab-count:1'>       </span>Neppe VM.
    <span class=GramE>Beta-adrenergic blocking agents:<span
    style='mso-spacerun:yes'>  </span>perspectives in psychiatry.</span>
    In:<span style='mso-spacerun:yes'>  </span>Innovative
    Psychopharmacotherapy, <span class=GramE>Neppe<span
    style='mso-spacerun:yes'>  </span>VM</span> ed. New York: Raven Press,<span
    style='mso-spacerun:yes'>  </span>Ch 1, 1-34, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>88.<span style='mso-tab-count:1'>       </span>Sprouse
    JS, Aghajanian <span class=GramE>GK :</span> (-)-Propranolol blocks the
    inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective
    agonists.<span style='mso-spacerun:yes'>  </span>Eur J Pharmacol<span
    style='mso-spacerun:yes'>  </span>128 (3):295-8, 1986</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>89.<span style='mso-tab-count:1'>       </span>Lopez RC,
    Fernandez <span class=GramE>GA :</span> Noradrenaline-serotonin
    interactions in the anxiolytic effects of 5-HT-sub(1A ) agonists.<span
    style='mso-spacerun:yes'>  </span>Behavioural Pharmacology<span
    style='mso-spacerun:yes'>  </span>5 (1):42-51, 1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>90.<span style='mso-tab-count:1'>       </span>Ariani K,
    Hamblin MW, Tan GL, Stratford CA, Ciaranello <span class=GramE>RD :</span>
    G protein dependent alterations in [125I]iodocyanopindolol and +/-
    cyanopindolol binding at 5-HT1B binding sites in rat brain membranes
    [published erratum appears in Neurochem Res 1989 Dec;14(12):1245].<span
    style='mso-spacerun:yes'>  </span>Mol Pharmacol<span
    style='mso-spacerun:yes'>  </span>36 (6):903-11, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>91.<span style='mso-tab-count:1'>       </span>Fern'andez
    GA, L'opez <span class=GramE>RC :</span> Evidence for the involvement of
    the 5-HT1A receptor in the anxiolytic action of indorenate and
    ipsapirone.<span style='mso-spacerun:yes'>  </span>Psychopharmacology
    (Berl)<span style='mso-spacerun:yes'>  </span>101 (3):354-8, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>92.<span style='mso-tab-count:1'>       </span>Tsuchihashi
    H, Nagatomo T, Imai <span class=GramE>S :</span> Three binding sites of
    125I-iodocyanopindolol, i.e. beta 1, beta 2-adrenergic and
    5HT1B-serotonergic receptors in rat brain determined by the displacement
    and Scatchard analysis.<span style='mso-spacerun:yes'>  </span>Eur J
    Pharmacol<span style='mso-spacerun:yes'>  </span>173 (2-3):121-5, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>93.<span style='mso-tab-count:1'>       </span>Kalkman <span
    class=GramE>HO :</span> Beta-adrenoceptor blockade in rats enhances the
    ambulation induced by 5-HT1A receptor agonists.<span
    style='mso-spacerun:yes'>  </span>Eur J Pharmacol<span
    style='mso-spacerun:yes'>  </span>173 (2-3):121-5, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>94.<span style='mso-tab-count:1'>       </span>Middlemiss
    <span class=GramE>DN :</span> Blockade of the central 5-HT autoreceptor by
    beta-adrenoceptor antagonists.<span style='mso-spacerun:yes'>  </span>Eur J
    Pharmacol<span style='mso-spacerun:yes'>  </span>120 (1):51-6, 1986</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>95.<span style='mso-tab-count:1'>       </span>Nos<span
    class=GramE>:al</span> R, Pe:civov:a J, Dr:abikov:a K : On the interaction
    of beta-adrenoceptor-blocking drugs with isolated mast cells.<span
    style='mso-spacerun:yes'>  </span>Agents Actions<span
    style='mso-spacerun:yes'>  </span>16 (6):478-84, 1985</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>96.<span style='mso-tab-count:1'>       </span>Fargin A,
    <span class=GramE>Raymond<span style='mso-spacerun:yes'>  </span>JR</span>,
    Lohse<span style='mso-spacerun:yes'>  </span>MJ, Kobilka<span
    style='mso-spacerun:yes'>  </span>BK, Caron<span style='mso-spacerun:yes'> 
    </span>MG, Lefkowitz<span style='mso-spacerun:yes'>  </span>RJ : The
    genomic clone G-21 which resembles a beta - adrenergic receptor sequence
    encodes the 5 HT 1A receptor .<span style='mso-spacerun:yes'> 
    </span>Nature<span style='mso-spacerun:yes'>  </span>335 :358 -360, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>97.<span style='mso-tab-count:1'>       </span>Fujiwara
    Y, Nelson DL, Kashihara K, Varga E, Roeske WR, Yamamura HI : The cloning
    and sequence analysis of the rat serotonin-1A receptor gene.<span
    style='mso-spacerun:yes'>  </span>Life Sci<span style='mso-spacerun:yes'> 
    </span>47 (22):32, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>98.<span style='mso-tab-count:1'>       </span>Yoshimura
    H, Kihara Y, Ogawa <span class=GramE>N :</span> Psychotropic effects of
    adrenergic beta-blockers on agonistic behavior between resident and
    intruder mice.<span style='mso-spacerun:yes'>  </span>Psychopharmacology
    (Berl)<span style='mso-spacerun:yes'>  </span>91 (4):445-50, 1987</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>99.<span style='mso-tab-count:1'>       </span>Tsuchihashi
    H, Nagotomo T, Imai <span class=GramE>S :</span> Selectivity of bunitrolol
    for beta 1- and beta 2-adrenergic receptors and 5HT1B-receptors: assessment
    by biphasic Scatchard plots and biphasic displacement curve analysis with
    125I-iodocyanopindolol and 3H-CGP12177.<span style='mso-spacerun:yes'> 
    </span>J Pharmacol Exp Ther<span style='mso-spacerun:yes'>  </span>247
    (3):902-10, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>100.<span style='mso-tab-count:1'>     </span>Alexander
    BS, Wood <span class=GramE>MD :</span> Stereoselective blockade of central
    [3H]5-hydroxytryptamine binding to multiple sites (5-HT1A, 5-HT1B and
    5-HT1C) by mianserin and propranolol.<span style='mso-spacerun:yes'> 
    </span>J Pharm Pharmacol<span style='mso-spacerun:yes'>  </span>39
    (8):664-6, 1987</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>101.<span style='mso-tab-count:1'>     </span>Oksenberg
    D, Peroutka <span class=GramE>SJ :</span> Antagonism of 5-hydroxytryptamine1A
    (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by
    pindolol and propranolol isomers.<span style='mso-spacerun:yes'> 
    </span>Biochem Pharmacol<span style='mso-spacerun:yes'>  </span>37
    (18):3429-33, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>102.<span style='mso-tab-count:1'>     </span>Hamel E,
    Gr'egoire L, Lau <span class=GramE>B :</span> 5-HT1 receptors mediating
    contraction in bovine cerebral arteries: a model for human cerebrovascular
    '5-HT1D beta' receptors.<span style='mso-spacerun:yes'>  </span>Eur J
    Pharmacol<span style='mso-spacerun:yes'>  </span>242 (1):75-82, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>103.<span style='mso-tab-count:1'>     </span>Nagatomo
    T, Hokibara R, Tanaka Y, Nakamura T, Aono J, Tsuchihashi H : Effects of
    ketanserin and 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2,4(1H,3H)- quinazolinedione
    monohydrochloride (SGB-1534), anti-hypertensive agents, on 3H-serotonin and
    3H-ketanserin bindings to serotonergic (5HT1 and 5HT2) receptors in dog
    brain and aorta.<span style='mso-spacerun:yes'>  </span>J Med Chem<span
    style='mso-spacerun:yes'>  </span>32 (4):859-63, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>104.<span style='mso-tab-count:1'>     </span>Maura G,
    Ulivi M, Raiteri <span class=GramE>M :</span> (-)-Propranolol and
    (+/-)-cyanopindolol are mixed agonists-antagonists at serotonin
    autoreceptors in the hippocampus of the rat brain.<span
    style='mso-spacerun:yes'>  </span>Neuropharmacology<span
    style='mso-spacerun:yes'>  </span>26 (7A):713-7, 1987</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>105.<span style='mso-tab-count:1'>     </span>Galzin AM,
    Poirier MF, Lista A, et al<span class=GramE>. :</span> Characterization of
    the 5-hydroxytryptamine receptor modulating the release of
    5-[3H]hydroxytryptamine in slices of the human neocortex.<span
    style='mso-spacerun:yes'>  </span>J Neurochem<span
    style='mso-spacerun:yes'>  </span>59 (4):1293-301, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>106.<span style='mso-tab-count:1'>     </span>Murphy TJ,
    Bylund <span class=GramE>DB :</span> Characterization of serotonin-1B
    receptors negatively coupled to adenylate cyclase in OK cells, a renal
    epithelial cell line from the opossum.<span style='mso-spacerun:yes'> 
    </span>J Pharmacol Exp Ther<span style='mso-spacerun:yes'>  </span>249
    (2):535-43, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>107.<span style='mso-tab-count:1'>     </span>Murphy RM,
    Zemlan <span class=GramE>FP :</span> Selective serotonin1A/1B agonists
    differentially affect spinal nociceptive reflexes.<span
    style='mso-spacerun:yes'>  </span>Neuropharmacology<span
    style='mso-spacerun:yes'>  </span>29 (5):463-8, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>108.<span style='mso-tab-count:1'>     </span>Brizer <span
    class=GramE>DA :</span> Psychopharmacology and the management of violent
    patients.<span style='mso-spacerun:yes'>  </span>Psychiatric Clinics of
    North America<span style='mso-spacerun:yes'>  </span>11 (4):551-568, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>109.<span style='mso-tab-count:1'>     </span>Neppe <span
    class=GramE>VM :</span><span style='mso-spacerun:yes'>  </span>27 (5):Beta
    blockers - their pharmacological application to psychiatry. 634, Fourth
    SAfr Conference of Psychiatry, Durban, 1985 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>110.<span style='mso-tab-count:1'>     </span>Yudofsky
    SC, Silver JM, Hales <span class=GramE>RE :</span> Pharmacologic management
    of aggression in the elderly.<span style='mso-spacerun:yes'>  </span>J Clin
    Psychiatry<span style='mso-spacerun:yes'>  </span>1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>111.<span style='mso-tab-count:1'>     </span>Eimer <span
    class=GramE>M :</span> Management of the behavioral symptoms associated
    with dementia.<span style='mso-spacerun:yes'>  </span>Prim Care<span
    style='mso-spacerun:yes'>  </span>16 (2):431-50, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>112.<span style='mso-tab-count:1'>     </span>Weinstock
    M, Weiss <span class=GramE>C :</span> Antagonism by propranolol of
    isolation-induced aggression in mice: correlation with 5-hydroxytryptamine
    receptor blockade.<span style='mso-spacerun:yes'> 
    </span>Neuropharmacology<span style='mso-spacerun:yes'>  </span>19
    (7):653-6, 1980</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>113.<span style='mso-tab-count:1'>     </span>Bonson KR,
    Johnson RG, Fiorella D, Rabin RA, Winter JC : Serotonergic control of
    androgen-induced dominance.<span style='mso-spacerun:yes'> 
    </span>Pharmacol Biochem Behav<span style='mso-spacerun:yes'>  </span>49
    (2):313-22, 1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>114.<span style='mso-tab-count:1'>     </span>Zhu XO,
    McNaughton <span class=GramE>N :</span> Minimal changes with long-term
    administration of anxiolytics on septal driving of hippocampal rhythmical
    slow activity.<span style='mso-spacerun:yes'>  </span>Psychopharmacology
    Berl<span style='mso-spacerun:yes'>  </span>118 (1):93-100, 1995</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>115.<span style='mso-tab-count:1'>     </span>Riblet LA,
    Taylor DP, Eison MS, Stanton <span class=GramE>HC :</span> Pharmacology and
    neurochemistry of buspirone.<span style='mso-spacerun:yes'>  </span>J Clin
    Psychiatry<span style='mso-spacerun:yes'>  </span>43 (12):S2, 11-18, 1982</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>116.<span style='mso-tab-count:1'>     </span>Damaj MI,
    Glennon RA, Martin <span class=GramE>BR :</span> Involvement of the
    serotonergic system in the hypoactive and antinociceptive effects of
    nicotine in mice.<span style='mso-spacerun:yes'>  </span>Brain Res
    Bull<span style='mso-spacerun:yes'>  </span>33 (2):199-203, 1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>117.<span style='mso-tab-count:1'>     </span>Yocca FD,
    Wright RN, Margraf RR, Eison <span class=GramE>AS :</span> 8-OH-DPAT and
    buspirone analogs inhibit the ketanserin-sensitive quipazine-induced head
    shake response in rats.<span style='mso-spacerun:yes'>  </span>Pharmacol
    Biochem Behav<span style='mso-spacerun:yes'>  </span>35 (1):251-4, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>118.<span style='mso-tab-count:1'>     </span>Eison <span
    class=GramE>AS :</span> Azapirones: history of development.<span
    style='mso-spacerun:yes'>  </span>J Clin Psychopharmacol<span
    style='mso-spacerun:yes'>  </span>1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>119.<span style='mso-tab-count:1'>     </span>Jackson
    HC, Kitchen <span class=GramE>I :</span> Behavioural profiles of putative
    5-hydroxytryptamine receptor agonists and antagonists in developing
    rats.<span style='mso-spacerun:yes'>  </span>Neuropharmacology<span
    style='mso-spacerun:yes'>  </span>28 (6):635-42, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>120.<span style='mso-tab-count:1'>     </span>Pauwels
    PJ, Van GP, Leysen <span class=GramE>JE :</span> Activity of serotonin
    (5-HT) receptor agonists, partial agonists and antagonists at cloned human
    5-HT1A receptors that are negatively coupled to adenylate cyclase in
    permanently transfected HeLa cells.<span style='mso-spacerun:yes'> 
    </span>Biochem Pharmacol<span style='mso-spacerun:yes'>  </span>45
    (2):375-83, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>121.<span style='mso-tab-count:1'>     </span>Robinson
    DS, Rickels K, Feighner J, et al<span class=GramE>. :</span> Clinical
    effects of the 5-HT1A partial agonists in depression: a composite analysis
    of buspirone in the treatment of depression.<span
    style='mso-spacerun:yes'>  </span>J Clin Psychopharmacol<span
    style='mso-spacerun:yes'>  </span>1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>122.<span style='mso-tab-count:1'>     </span>Eison AS, <span
    class=GramE>Eison<span style='mso-spacerun:yes'>  </span>MS</span>,
    Stanley<span style='mso-spacerun:yes'>  </span>M, al e : Serotonergic
    mechanisms in the behavioral effects of buspirone and gepirone.<span
    style='mso-spacerun:yes'>  </span>Pharmacol Biochem Behav<span
    style='mso-spacerun:yes'>  </span>24 :701-707, 1986</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>123.<span style='mso-tab-count:1'>     </span>Eison AS, <span
    class=GramE>Yocca<span style='mso-spacerun:yes'>  </span>FD</span> :
    Reduction in cortical 5-HT2 receptor sensitivity after continuous gepirone
    treatment.<span style='mso-spacerun:yes'>  </span>Eur J Pharmacol<span
    style='mso-spacerun:yes'>  </span>111 :389-392, 1985</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>124.<span style='mso-tab-count:1'>     </span>Mauk MD,
    Peroutka SJ, Kocsis <span class=GramE>JD :</span> Buspirone attenuates
    synaptic activation of hippocampal pyramidal cells.<span
    style='mso-spacerun:yes'>  </span>J Neurosci<span
    style='mso-spacerun:yes'>  </span>8 (1):1-11, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>125.<span style='mso-tab-count:1'>     </span>Coccaro
    EF, Gabriel S, Siever <span class=GramE>LJ :</span> Buspirone challenge:
    preliminary evidence for a role for central 5-HT1a receptor function in
    impulsive aggressive behavior in humans.<span style='mso-spacerun:yes'> 
    </span>Psychopharmacol Bull<span style='mso-spacerun:yes'>  </span>26
    (3):393-405, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>126.<span style='mso-tab-count:1'>     </span>Cowen PJ, Anderson
    IM, Grahame <span class=GramE>SDG :</span> Neuroendocrine effects of
    azapirones.<span style='mso-spacerun:yes'>  </span>J Clin
    Psychopharmacol<span style='mso-spacerun:yes'>  </span>1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>127.<span style='mso-tab-count:1'>     </span>Gregory
    CA, Anderson IM, Cowen <span class=GramE>PJ :</span> Metergoline abolishes
    the prolactin response to buspirone.<span style='mso-spacerun:yes'> 
    </span>Psychopharmacology (Berl)<span style='mso-spacerun:yes'>  </span>100
    (2):283-4, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>128.<span style='mso-tab-count:1'>     </span>Sharp T,
    Bramwell SR, Hjorth S, Grahame <span class=GramE>SD :</span>
    Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat
    hippocampal 5-HT release in vivo as measured by microdialysis.<span
    style='mso-spacerun:yes'>  </span>Br J Pharmacol<span
    style='mso-spacerun:yes'>  </span>98 (3):989-97, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>129.<span style='mso-tab-count:1'>     </span>Kubo T,
    Taguchi K, Ozaki S, Amano M, Ishizuka T : 8-OH-DPAT-induced hypotensive
    action and sympathoexcitatory neurons in the rostral ventrolateral medulla
    of the rat.<span style='mso-spacerun:yes'>  </span>Brain Res Bull<span
    style='mso-spacerun:yes'>  </span>36 (4):405-11, 1995</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>130.<span style='mso-tab-count:1'>     </span>Young AH,
    McShane R, Park SB, Cowen <span class=GramE>PJ :</span> Buspirone-induced
    hypothermia in normal male volunteers.<span style='mso-spacerun:yes'> 
    </span>Biol Psychiatry<span style='mso-spacerun:yes'>  </span>34 (9):665-6,
    1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>131.<span style='mso-tab-count:1'>     </span>Komissarov
    IV, Dolzhenko AT, Obraztsova OG, Zin'kovskaia <span class=GramE>L :</span>
    [An analysis of the hypothermic action of
    8-hydroxy-2-(di-N-propylamino)tetralin, 1-(2-pyrimidinyl)piperazine and its
    derivatives].<span style='mso-spacerun:yes'>  </span>Biull Eksp Biol
    Med<span style='mso-spacerun:yes'>  </span>109 (3):275-7, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>132.<span style='mso-tab-count:1'>     </span>Pascual J,
    Berciano <span class=GramE>J :</span> An open trial of buspirone in
    migraine prophylaxis. <span class=GramE>Preliminary report.</span><span
    style='mso-spacerun:yes'>  </span>Clin Neuropharmacol<span
    style='mso-spacerun:yes'>  </span>14 (3):245-50, 1991</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>133.<span style='mso-tab-count:1'>     </span>Domantay
    AG, Napoliello <span class=GramE>MJ :</span> Buspirone for elderly anxious
    patients.<span style='mso-spacerun:yes'>  </span>Int. Med. Certif.<span
    style='mso-spacerun:yes'>  </span>3 (2) :1-7, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>134.<span style='mso-tab-count:1'>     </span>Robinson
    D, Napoliello MJ, Schenk <span class=GramE>J :</span> The safety and
    usefulness of buspirone as an anxiolytic drug in elderly versus young
    patients.<span style='mso-spacerun:yes'>  </span>Clin Ther<span
    style='mso-spacerun:yes'>  </span>10 (6):740-6, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>135.<span style='mso-tab-count:1'>     </span>Blier P,
    Curet O, Chaput Y, de <span class=GramE>MC :</span> Tandospirone and its
    metabolite, 1-(2-pyrimidinyl)-piperazine--II. <span class=GramE>Effects of
    acute administration of 1-PP and long-term administration of tandospirone
    on noradrenergic neurotransmission.</span><span style='mso-spacerun:yes'> 
    </span>Neuropharmacology<span style='mso-spacerun:yes'>  </span>30
    (7):691-701, 1991</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>136.<span style='mso-tab-count:1'>     </span>Caccia S,
    Vigano GL, Mingardi G, et al<span class=GramE>. :</span> Clinical
    pharmacokinetics of oral buspirone in patients with impaired renal
    function.<span style='mso-spacerun:yes'>  </span>Clin Pharmacokinet<span
    style='mso-spacerun:yes'>  </span>14 (3):171-7, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>137.<span style='mso-tab-count:1'>     </span>Cullen WK,
    Rowan <span class=GramE>MJ :</span> Gepirone and
    1-(2-pyrimidinyl)-piperazine-induced reduction of aversively evoked
    ultrasonic vocalisation in the rat.<span style='mso-spacerun:yes'> 
    </span>Pharmacol Biochem Behav<span style='mso-spacerun:yes'>  </span>48
    (1):301-6, 1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>138.<span style='mso-tab-count:1'>     </span>Fuller RW,
    Perry <span class=GramE>KW :</span> Effects of buspirone and its
    metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their
    metabolites in rats.<span style='mso-spacerun:yes'>  </span>J Pharmacol Exp
    Ther<span style='mso-spacerun:yes'>  </span>248 (1):50-6, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>139.<span style='mso-tab-count:1'>     </span>Grasby P,
    Sharp T, Moorman J, Grahame <span class=GramE>SD :</span> Comparison of the
    effect of buspirone and 1-(2-pyrimidinyl)-piperazine on cerebral glucose
    utilization in the rat.<span style='mso-spacerun:yes'>  </span>Eur J
    Pharmacol<span style='mso-spacerun:yes'>  </span>230 (1):41-6, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>140.<span style='mso-tab-count:1'>     </span>Engberg <span
    class=GramE>G :</span> A metabolite of buspirone increases locus coeruleus
    activity via alpha 2-receptor blockade.<span style='mso-spacerun:yes'> 
    </span>J Neural Transm<span style='mso-spacerun:yes'>  </span>76 (2):91-8,
    1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>141.<span style='mso-tab-count:1'>     </span>Cao BJ, Li
    <span class=GramE>WP :</span> Antagonism of clonidine antinociception by
    buspirone and 1-(2-pyrimidinyl)-piperazine.<span style='mso-spacerun:yes'> 
    </span>Eur J Pharmacol<span style='mso-spacerun:yes'>  </span>259 (1):75-8,
    1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>142.<span style='mso-tab-count:1'>     </span>McMillen
    BA, Chamberlain JK, DaVanzo <span class=GramE>JP :</span> Effects of
    housing and muricidal behavior on serotonergic receptors and interactions
    with novel anxiolytic drugs.<span style='mso-spacerun:yes'>  </span>J
    Neural Transm<span style='mso-spacerun:yes'>  </span>71 (2):123-32, 1988</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>143.<span style='mso-tab-count:1'>     </span>Tompkins
    EC, Clemento AJ, Taylor DP, al <span class=GramE>e :</span> Inhibition of
    aggressive behavior in rhesus monkeys by buspirone.<span
    style='mso-spacerun:yes'>  </span>Res Commun Psychol Psychiat Behav<span
    style='mso-spacerun:yes'>  </span>5 :337-352, 1980</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>144.<span style='mso-tab-count:1'>     </span>Olivier B,
    Mos <span class=GramE>J :</span> Rodent models of aggressive behavior and
    serotonergic drugs.<span style='mso-spacerun:yes'>  </span>Prog
    Neuropsychopharmacol Biol Psychiatry<span style='mso-spacerun:yes'> 
    </span>16 (6):847-70, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>145.<span style='mso-tab-count:1'>     </span>Coccaro
    EF, Gabriel S, Mahon T, Macaluso J, Siever <span class=GramE>LJ :</span>
    Preliminary evidence of a serotonin (5-HT-1-like) component to the
    prolactin response to buspirone challenge in humans.<span
    style='mso-spacerun:yes'>  </span>Arch Gen Psychiatry<span
    style='mso-spacerun:yes'>  </span>47 (6):594-5, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>146.<span style='mso-tab-count:1'>     </span>Uhlenhuth <span
    class=GramE>EH :</span> &quot;Buspirone: a clinical review of a new,
    non-benzodiazepine anxiolytic:.<span style='mso-spacerun:yes'>  </span>J
    Clin Psychiatry<span style='mso-spacerun:yes'>  </span>1982</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>147.<span style='mso-tab-count:1'>     </span>Riblet LA,
    Eison AS, Eison MS, Newton RE, Taylor DP, Temple <span class=GramE>DJ :</span>
    Buspirone: an anxioselective alternative for the management of anxiety
    disorders.<span style='mso-spacerun:yes'>  </span>Prog Neuropsychopharmacol
    Biol Psychiatry<span style='mso-spacerun:yes'>  </span>7 (4-6):663-8, 1983</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>148.<span style='mso-tab-count:1'>     </span>Ratey JJ,
    Sovner R, Mikkelsen E, Chmielinski <span class=GramE>HE :</span> Buspirone
    therapy for maladaptive behavior and anxiety in developmentally disabled
    persons.<span style='mso-spacerun:yes'>  </span>J Clin Psychiatry<span
    style='mso-spacerun:yes'>  </span>50 (10):382-4, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>149.<span style='mso-tab-count:1'>     </span>Ratey J,
    Sovner R, Parks A, Rogentine <span class=GramE>K :</span> Buspirone
    treatment of aggression and anxiety in mentally retarded patients: a
    multiple-baseline, placebo lead-in study.<span style='mso-spacerun:yes'> 
    </span>J Clin Psychiatry<span style='mso-spacerun:yes'>  </span>52
    (4):159-62, 1991</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>150.<span style='mso-tab-count:1'>     </span>Byrne AP,
    Martin W, Hnatko <span class=GramE>G :</span> Beneficial effects of
    buspirone therapy in Huntington's disease.<span style='mso-spacerun:yes'> 
    </span>American Journal of Psychiatry<span style='mso-spacerun:yes'> 
    </span>151 (7)1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>151.<span style='mso-tab-count:1'>     </span>Colella
    RF, Ratey JJ, Glaser <span class=GramE>AI :</span> Paramenstrual aggression
    in mentally retarded adult ameliorated by buspirone.<span
    style='mso-spacerun:yes'>  </span>Int J Psychiatry Med<span
    style='mso-spacerun:yes'>  </span>22 (4):351-6, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>152.<span style='mso-tab-count:1'>     </span>Findling <span
    class=GramE>RL :</span> Treatment of aggression in juvenile-onset
    Huntington's disease with buspirone.<span style='mso-spacerun:yes'> 
    </span>Psychosomatics<span style='mso-spacerun:yes'>  </span>34 (5):460-1,
    1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>153.<span style='mso-tab-count:1'>     </span>Quiason N,
    Ward D, Kitchen <span class=GramE>T :</span> Buspirone for aggression.<span
    style='mso-spacerun:yes'>  </span>J Am Acad Child Adolesc Psychiatry<span
    style='mso-spacerun:yes'>  </span>30 (6):1026, 1991</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>154.<span style='mso-tab-count:1'>     </span>Stanislav
    SW, Fabre T, Crismon ML, Childs <span class=GramE>A :</span> Buspirone's
    efficacy in organic-induced aggression.<span style='mso-spacerun:yes'> 
    </span>J Clin Psychopharmacol<span style='mso-spacerun:yes'>  </span>14
    (2):126-30, 1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>155.<span style='mso-tab-count:1'>     </span>Holzer JC,
    Gitelman DR, Price <span class=GramE>BH :</span> Efficacy of buspirone in
    the treatment of dementia with aggression.<span style='mso-spacerun:yes'> 
    </span>Am J Psychiatry<span style='mso-spacerun:yes'>  </span>152 (5):812,
    1995</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>156.<span style='mso-tab-count:1'>     </span>Holttum
    JR, Lubetsky MJ, Eastman <span class=GramE>LE :</span> Comprehensive
    management of trichotillomania in a young autistic girl.<span
    style='mso-spacerun:yes'>  </span>Journal of the American Academy of Child
    &amp; Adolescent Psychiatry<span style='mso-spacerun:yes'>  </span>33
    (4):577-581, 1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>157.<span style='mso-tab-count:1'>     </span>Herrmann
    N, Eryavec <span class=GramE>G :</span> Buspirone in the management of
    agitation and aggression associated with dementia.<span
    style='mso-spacerun:yes'>  </span>American Journal of Geriatric
    Psychiatry<span style='mso-spacerun:yes'>  </span>1 (3):249-253, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>158.<span style='mso-tab-count:1'>     </span>Yatham LM,
    Barry S, Dinan <span class=GramE>TG :</span> Serotonin receptors,
    buspirone, and premenstrual syndrome.<span style='mso-spacerun:yes'> 
    </span>Lancet<span style='mso-spacerun:yes'>  </span>1 (8652):1447-8, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>159.<span style='mso-tab-count:1'>     </span>Backerman <span
    class=GramE>IA :</span> Premenstrual syndrome update: 1991.<span
    style='mso-spacerun:yes'>  </span>Md Med J<span style='mso-spacerun:yes'> 
    </span>40 (11):1003-9, 1991</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>160.<span style='mso-tab-count:1'>     </span>Anderson <span
    class=GramE>IM :</span> Serotonin receptors, buspirone, and premenstrual
    syndrome.<span style='mso-spacerun:yes'>  </span>Lancet<span
    style='mso-spacerun:yes'>  </span>2 (8663)1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>161.<span style='mso-tab-count:1'>     </span>Rickels K,
    Freeman E, Sondheimer <span class=GramE>S :</span> Buspirone in treatment
    of premenstrual syndrome.<span style='mso-spacerun:yes'> 
    </span>Lancet<span style='mso-spacerun:yes'>  </span>1 (8641)1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>162.<span style='mso-tab-count:1'>     </span>Cohn JB,
    Rickels <span class=GramE>K :</span> A pooled, double-blind comparison of
    the effects of buspirone, diazepam and placebo in women with chronic
    anxiety.<span style='mso-spacerun:yes'>  </span>Curr Med Res Opin<span
    style='mso-spacerun:yes'>  </span>11 (5):304-20, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>163.<span style='mso-tab-count:1'>     </span>B<span
    class=GramE>:ohm</span> C, Robinson DS, Gammans RE : Buspirone therapy for
    elderly patients with anxiety or depressive neurosis.<span
    style='mso-spacerun:yes'>  </span>J Clin Psychiatry<span
    style='mso-spacerun:yes'>  </span>51 (7)1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>164.<span style='mso-tab-count:1'>     </span>Sakauye
    KM, Camp CJ, Ford <span class=GramE>PA :</span> Effects of buspirone on
    agitation associated with dementia.<span style='mso-spacerun:yes'> 
    </span>American Journal of Geriatric Psychiatry<span
    style='mso-spacerun:yes'>  </span>1 (1):82-84, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>165.<span style='mso-tab-count:1'>     </span>Schneider <span
    class=GramE>LS :</span> Efficacy of treatment for geropsychiatric patients
    with severe mental illness.<span style='mso-spacerun:yes'> 
    </span>Psychopharmacol Bull<span style='mso-spacerun:yes'>  </span>29
    (4):501-24, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>166.<span style='mso-tab-count:1'>     </span>Neppe VM,
    Young <span class=GramE>ZO :</span> Buspirone as a new treatment for
    attention deficit disorder and aggression in children and adolescents.<span
    style='mso-spacerun:yes'>  </span>Journal of Clinical Psychiatry<span
    style='mso-spacerun:yes'>  </span>(S)1996 in press</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>167.<span style='mso-tab-count:1'>     </span>Neppe <span
    class=GramE>VM :</span><span style='mso-spacerun:yes'>  </span>:
    Carbamazepine, limbic modulation and psychosis with dyscontrol. First Intl
    Conf on Recent Advances in Psychiatric Treatment, San Fransicso, CA, 1986 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>168.<span style='mso-tab-count:1'>     </span>Neppe VM.
    Carbamazepine in the non affective psychotic and non psychotic <span
    class=GramE>dyscontrol .</span> In:<span style='mso-spacerun:yes'> 
    </span>Carbamazepine and ox-carbazepine in <span class=GramE>psychiatry
    :International</span> Clinical Psychopharmacology, 5 ( Suppl 1 ). Emrich<span
    style='mso-spacerun:yes'>  </span>H, Schiwy<span style='mso-spacerun:yes'> 
    </span>W, Silverstone<span style='mso-spacerun:yes'>  </span>T ed. London:
    Clinical Neuroscience Publishers,<span style='mso-spacerun:yes'>  </span>43
    -54, 1990</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>169.<span style='mso-tab-count:1'>     </span>Tunks ER,
    Dermer <span class=GramE>SW :</span> Carbamazepine in the dyscontrol
    syndrome associated with limbic system dysfunction.<span
    style='mso-spacerun:yes'>  </span>J Nerv Ment Dis<span
    style='mso-spacerun:yes'>  </span>164 (1):56-63, 1977</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>170.<span style='mso-tab-count:1'>     </span>Sugarman <span
    class=GramE>P :</span> Carbamazepine and episodic dyscontrol.<span
    style='mso-spacerun:yes'>  </span>Br J Psychiatry<span
    style='mso-spacerun:yes'>  </span>161 :721, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>171.<span style='mso-tab-count:1'>     </span>Gardner
    DL, Cowdry <span class=GramE>RW :</span> Positive effects of carbamazepine
    on behavioral dyscontrol in borderline personality disorder.<span
    style='mso-spacerun:yes'>  </span>Am J Psychiatry<span
    style='mso-spacerun:yes'>  </span>143 (4):519-22, 1986</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>172.<span style='mso-tab-count:1'>     </span>Lewin J,
    Sumners <span class=GramE>D :</span> Successful treatment of episodic
    dyscontrol with carbamazepine [see comments].<span
    style='mso-spacerun:yes'>  </span>Br J Psychiatry<span
    style='mso-spacerun:yes'>  </span>161 :261-2, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>173.<span style='mso-tab-count:1'>     </span>Neppe VM,
    Ellegala D, Baker <span class=GramE>C :</span><span
    style='mso-spacerun:yes'>  </span>32 (5):The Inventory of Neppe of Symptoms
    of Epilepsy and the Temporal Lobe ( INSET) : A new rating scale. 4,
    Epilepsia, 1991 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>174.<span style='mso-tab-count:1'>     </span>Neppe V,
    Chen A, Davis JT, Sawchuk K, Geist <span class=GramE>M :</span><span
    style='mso-spacerun:yes'>  </span>4 (1):The application of the Screening
    Cerebral Assessment of Neppe (BROCAS SCAN) to a neuropsychiatric
    population. 85-94, J Neuropsychiatry Clin Neurosci, 1992 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>175.<span style='mso-tab-count:1'>     </span>Weilburg
    JB, Schachter S, Sachs GS, et al<span class=GramE>. :</span> Focal
    paroxysmal EEG changes during atypical panic attacks.<span
    style='mso-spacerun:yes'>  </span>J Neuropsychiatry Clin Neurosci<span
    style='mso-spacerun:yes'>  </span>5 (1):50-5, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>176.<span style='mso-tab-count:1'>     </span>Weilburg
    JB, Schachter S, Worth J, et al<span class=GramE>. :</span> EEG
    abnormalities in patients with atypical panic attacks.<span
    style='mso-spacerun:yes'>  </span>J Clin Psychiatry<span
    style='mso-spacerun:yes'>  </span>56 (8):358-62, 1995</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>177.<span style='mso-tab-count:1'>     </span>Morris
    GLr, Galezowska J, Leroy R, North <span class=GramE>R :</span> The results
    of computer-assisted ambulatory 16-channel EEG.<span
    style='mso-spacerun:yes'>  </span>Electroencephalogr Clin Neurophysiol<span
    style='mso-spacerun:yes'>  </span>91 (3):229-31, 1994</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>178.<span style='mso-tab-count:1'>     </span>Varney NR,
    Hines ME, Bailey C, Roberts <span class=GramE>RJ :</span> Neuropsychiatric
    correlates of theta bursts in patients with closed head injury [see
    comments].<span style='mso-spacerun:yes'>  </span>Brain Inj<span
    style='mso-spacerun:yes'>  </span>6 (6):499-508, 1992</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>179.<span style='mso-tab-count:1'>     </span>Beauregard
    LA, Fabiszewski R, Black CH, et al<span class=GramE>. :</span> Combined
    ambulatory electroencephalographic and electrocardiographic recordings for
    evaluation of syncope.<span style='mso-spacerun:yes'>  </span>Am J
    Cardiol<span style='mso-spacerun:yes'>  </span>68 (10):1067-72, 1991</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>180.<span style='mso-tab-count:1'>     </span>Neppe <span
    class=GramE>VM :</span><span style='mso-spacerun:yes'> 
    </span>:Carbamazepine Use in Neuropsychiatry. 1-64, J Clin Psychiatry
    Supplement 4, 1988 </p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>181.<span style='mso-tab-count:1'>     </span>Neppe VM. <span
    class=GramE>Carbamazepine, limbic kindling and non-responsive psychosis.</span>
    In:<span style='mso-spacerun:yes'>  </span>Innovative
    Psychopharmacotherapy, <span class=GramE>Neppe<span
    style='mso-spacerun:yes'>  </span>VM</span> ed. New York: Raven Press,<span
    style='mso-spacerun:yes'>   </span>123-151 , Ch 5, 1989</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>182.<span style='mso-tab-count:1'>     </span>Neppe VM. <span
    class=GramE>Perspectives on the pharmacologic management of agitation and
    irritability in the geriatric patient.</span> In:<span
    style='mso-spacerun:yes'>  </span>Psychiatric Disorders in the Elderly:
    Current Treatment Practices, Conference ed. San Francisco: Mt Zion
    Institute on Aging,<span style='mso-spacerun:yes'>  </span>56-62, 1993</p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal>183.<span style='mso-tab-count:1'>     </span>Neppe <span
    class=GramE>VM :</span><span style='mso-spacerun:yes'>  </span>41
    (39):Management of irritability and aggressive behavior. October 18, 1993
    pp 2-3 plus audiotape, Audio Digest Family Practice, 1993 <!--[if gte mso 9]><xml>
     <w:data>8520A8FE0023A3685610000832CF656E626200ACD91AD0001540680200007E85B346BAEF0000000000</w:data>
    </xml><![endif]--><!--[if supportFields]><span style='mso-element:field-end'></span><![endif]--></p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
    0in;margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify'><u><span
    style='font-size:11.0pt;mso-bidi-font-size:10.0pt'><o:p><span
     style='text-decoration:none'>&nbsp;</span></o:p></span></u></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:7.1pt;margin-bottom:
    0in;margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify'><u><span
    style='font-size:11.0pt;mso-bidi-font-size:10.0pt'>Professor <st1:City
    w:st="on"><st1:place w:st="on">Vernon</st1:place></st1:City> M. Neppe<o:p></o:p></span></u></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:7.1pt;margin-bottom:
    0in;margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify'><span
    style='font-size:11.0pt;mso-bidi-font-size:10.0pt'>Director, Pacific
    Neuropsychiatric Institute, Seattle, WA, USA; Adjunct Professor of
    Psychiatry and Human Behaviour, St Louis University School of Medicine, St
    Louis, MO, USA.<o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:7.1pt;margin-bottom:
    0in;margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify'><span
    style='font-size:11.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:7.1pt;margin-bottom:
    0in;margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify'><span
    style='font-size:11.0pt;mso-bidi-font-size:10.0pt'>Correspondence:<o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:7.1pt;margin-bottom:
    0in;margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify'><st1:City
    w:st="on"><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt'>Vernon</span></st1:City><span
    style='font-size:11.0pt;mso-bidi-font-size:10.0pt'> M. Neppe, MD, PhD,
    FFPsych, MMed, FRCPC, <st1:place w:st="on"><st1:City w:st="on">DPM</st1:City>,
     <st1:State w:st="on">MB</st1:State></st1:place>, BCh, Dip ABPN<o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:7.1pt;margin-bottom:
    0in;margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify'><span
    style='font-size:11.0pt;mso-bidi-font-size:10.0pt'>Director<o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:7.1pt;margin-bottom:
    0in;margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify'><span
    style='font-size:11.0pt;mso-bidi-font-size:10.0pt'>Pacific Neuropsychiatric
    Institute<o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:7.1pt;margin-bottom:
    0in;margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify'><st1:Street
    w:st="on"><st1:address w:st="on">Seattle Healing Arts Center, Suite 353<br>
      6300 Ninth Ave NE<br>
      Seattle, WA 98115</st1:address></st1:Street>
      
      <st1:place
    w:st="on">
        <st1:country-region w:st="on"></st1:country-region>
      </st1:place>
      <o:p></o:p>
      </p>
    <p class=MsoNormal style1 style='text-indent:14.2pt'><span style='mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>
    <p class=Affiliations style='line-height:150%'><span style='font-size:12.0pt;
    mso-bidi-font-size:10.0pt;line-height:150%;font-family:Times;mso-bidi-font-family:
    "Times New Roman"'><span style='mso-tab-count:1'>    </span>The assistance
    of John A. Walenta in the data analysis for Cohorts 3 and 4 <span
    class=GramE>is gratefully acknowledged</span>.<o:p></o:p></span></p>
    <p>See Also: <a
    href="http://www.pni.org/neuropsychiatry/attention_deficit/buspirone/index.html">BUSPIRONE
    AS A NEW TREATMENT FOR ATTENTION DEFICIT DISORDER AND AGGRESSION IN
    CHILDREN AND ADOLESCENTS</a> </p>
    <p class=MsoNormal style='text-indent:14.2pt'><span style='font-size:11.0pt;
    mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal style='text-indent:14.2pt'><span style='font-size:11.0pt;
    mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal style='text-indent:14.2pt'><o:p>&nbsp;</o:p></p>
    <p align=center style='text-align:center'><br>
    Copyright ©1997-2003 Pacific Neuropsychiatric Institute</p>
    <p>&nbsp;</p>
    <p>&nbsp;</p>    </td>
   </tr>
  </table>
  <p class=MsoNormal><span style='font-size:10.0pt;font-family:Arial'><o:p></o:p></span></p>  </td>
 </tr>
</table>
</div>

<p class=MsoNormal><span style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman";
color:windowtext'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>
</div>
</body>

</html>
